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Abstract of this thesis 
 
Signaling through the Jak-STAT pathway is initiated when an extracellular signaling 
protein binds to its corresponding transmembrane receptor. This leads to activation 
of the Jaks. The Jaks mediate phosphorylation at the specific receptor tyrosine 
residues, which then serve as docking sites for the STATs. Once recruited to the 
receptors, the STATs become phosphorylated by the Jaks. Activated STATs will 
dimerize, translocate to the nucleus and target gene promoters. STAT proteins 
display a wide range of functions in many biological aspects. Consequently they are 
involved in or mediating pathological processes.  
This thesis describes and discusses our research, performed to understand in more 
detail the role of Jak-STAT signaling in liver pathophysiology. 
Hepatitis C virus (HCV) is a major cause of chronic liver disease. It is believed that 
HCV proteins interfere with interferon alpha induced Jak-STAT signaling in order to 
escape the interferons induced antiviral state. We therefore analyzed interferon alpha 
induced Jak-STAT signaling in the presence of HCV viral proteins in in vivo and in 
vitro models to gain more insight in this interference, as well as to identify the viral 
protein(s) responsible for this interference. In chapter 2 we show inhibition of Jak-
STAT signaling in transgenic mice that express HCV proteins in their liver cells. The 
inhibition occurred in the nucleus and blocked binding of STATs to the promoters of 
interferon stimulated genes. This inhibition of interferon induced signaling resulted 
in an enhanced susceptibility of the HCV transgenic mice to LCMV infection and the 
development of severe hepatitis. The results described in chapter 3, show that the 
combined HCV structural proteins and the core protein alone partly inhibit interferon 
alpha induced Jak-STAT signaling, using a panel of tetracycline-regulated cell lines 
inducibly expressing individual HCV proteins or in different combinations. In cells 
expressing HCV nonstructural proteins, interferon alpha induced Jak-STAT signaling 
was not impaired.  
The last chapters of this thesis describe the generation of conditional active gain-
of-function models to study STAT signaling independent of natural ligands. Fusion 
proteins were constructed between STAT1, STAT3 or STAT5a and the modified ligand 
binding domain of the estrogen receptor (ER) and subsequently expressed in mouse 
embryonic fibroblasts. In addition several mutants of the fusion proteins were 
generated. The fusion protein between wild-type STAT3 and the ER (mSTAT3wt-ER) 
was shown to bind DNA and mimic STAT3 signaling upon activation by 4-
hydroxytamoxifen (synthetic steroid ligand) only (chapter 4). mSTAT3wt-ER and 
mSTAT5aR618K-rER (SH-2 domain mutant) fusion protein constructs were used to 
generate liver-specific conditional active gain-of-function mouse models. 
Chapter 5 describes the multistep cloning approach to prepare the constructs for 
injection and the analysis of the transgenic mice designated albSTAT3wt-ER and 
albSTAT5R618K-rER. The transgenic mice were designed to express the fusion 
proteins under control of the albumin promoter allowing liver-specific expression. 
Transgenic founders have been identified, as well as a transgenic F1 offspring. The 
transgenic mice appeared to be healthy and show a normal phenotype. Further 
characterization has to be completed. In chapter 6 possibilities for future use of the in 
chapter 5 described transgenic mice are discussed. The mice could be used to study 
STAT3 and STAT5a signaling in processes as liver cell regeneration, cellular 
transformation, bacterial infection, gluconeogenesis and cell survival.
  
 
  
 
Chapter 1   General Introduction 
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1.1 Jak-STAT signaling 
 
The Janus kinase (Jak)-signal transducer and activator of transcription 
(STAT) pathway is an intracellular signal transduction pathway that transmits 
information received from extracellular signaling proteins (cytokines, growth 
factors and hormones) through transmembrane receptors to target gene 
promoters in the nucleus 1.  Binding of the ligand to its corresponding receptor 
leads to conformational changes in the cytoplasmic part of the receptor, 
allowing homo- or heterodimerization of the receptor subunits and initiating 
signaling through tyrosine phosphorylation of the receptor associated 
members of the Jak family of protein tyrosine kinases. The activated Jaks 
mediate phosphorylation at the specific receptor tyrosine residues, which will 
then serve as docking sites for the STATs. STAT proteins comprise a family of 
transcription factors latent in the cytoplasm that consists of seven different 
members in mammals; i.e. STAT1, 2, 3, 4, 5a, 5b and 6.  The STATs bind to the 
receptors’ docking sites through their src-homology 2 (SH2) domain and are 
phosphorylated by the Jaks at single tyrosine residues. STATs dimerize by 
reciprocal phosphotyrosine-SH2 domain interactions and translocate to the 
nucleus. Activated STATs initiate transcription by binding as dimers to 
response elements in the promoters of target genes. Different ligands 
specifically activate different members of the Jak and STAT families. The Jak-
STAT pathway is modulated by a range of regulatory proteins, which 
contribute to the specificity and diversity of cellular responses 2-6. 
 
1.1.1 Ligands and their receptors 
The extracellular signaling proteins that signal through the Jak-STAT pathway 
bind members of various receptor families: single transmembrane receptors 
with an intrinsic protein tyrosine kinase domain (PTK receptors), single 
transmembrane receptors without kinase domain (non-PTK receptors) and 
seven transmembrane receptors (G-protein coupled receptors). 
 
PTK receptors 
To this group of receptors belong receptors for epidermal growth factor (EGF), 
platelet derived growth factor (PDGF), colony stimulating factor 1 (CSF-1), 
hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), c-Kit 
and insulin. These receptors may activate STATs indirectly through Jak 
kinases or directly, as was described for STAT1 activation in vitro by PDGF or 
EGF receptor 7, 8. STAT1 can bind directly to tyrosine residues on the EGF-R 
and CSF-1-R, STAT3 to EGF-R and HGF-R, and STAT5 to PDGF-R and 
insulin-R. Additionally STAT1, 3, 5 and/or 6 can be activated through these 
receptors 5, 9. 
 
Non-PTK receptors 
This group of receptors lacks an intrinsic protein kinase tyrosine domain, but 
they signal through associated Jaks. They are also are referred to as cytokine 
receptors, and divided into four subtypes (class I-IV) based on similarities in 
their extracellular binding domains. Class I cytokine receptors include the 
following four families; i.e. gp130 family, IL-2 family, IL-3/ IL-5/GM-CSF 
family (gp140 family) and growth hormone (GH) family. All of the receptors 
belonging to class I contain four conserved cysteine residues, extracellular a 
tryptophan-serine-X-tryptophan-serine (WSXWS) motive and variable 
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intracellular domains. Class II cytokine receptors only contains the interferon 
(IFN) family. Receptors within one family share two or more subunits that are 
brought together upon ligand binding 5, 10, 11. 
gp130 family. Receptors for interleukins-6 (IL-6) and IL-11, oncostatinM, 
LIF, cardiotrophin-1, G-CSF, IL-12, IL-23, leptin and ciliary neurotrophic 
factor (CNTF) all signal through a common β-chain called gp130. The IL-6 
receptor (IL-6R) complex consists of a non-signal-transducing ligand binding 
IgG-like α-chain and two gp130 chains 12. The LIF receptor is composed out of 
a signal transducing LIFRβ chain and a gp130. The CNTF receptor α chain 
associates with gp130 and the LIFβ chain. The IL-11 receptor α chain requires 
gp130 for high affinity binding and signal transduction. The receptors 
associate with either Jak1, Jak2 or Tyk2 and activate STAT3 using the motif 
YXXQ as STAT3 docking site. 
IL-2 receptor family. IL-2 and IL-15 signal both through the IL-2 receptor, 
which consists of a non transducing α chain (IL-2Rα) and two signal 
transducing chains, IL-2Rβ or IL-2Rγ. The receptor for IL-4, IL-7 and IL-9 
consists of individual α chains, and share the IL-2Rγ chain. The IL-4Rα chain 
can also combine with the IL-13Rα chain to form a functional high affinity 
receptor for both IL-4 and IL-13. The IL-2Rγ chain associates with Jak3, and 
IL-2Rβ, IL-7Rα and IL-9Rα chains with Jak1. IL-4Rα and IL-13Rα bind Jak1, 
Jak3 or Tyk2. They mainly activate STAT5 and STAT6.  
gp140 family. Receptors for IL-3, -5 and GM-CSF have individual α chains 
and share the gp140 component, which associates with Jak2. They all signal 
through STAT5.  
GH family. Receptors for GH, prolactin, erythropoietin (EPO) and 
thrombopoietin (TPO) form homodimers after ligand binding and do not 
share any receptor components. All members of the GH receptor family 
associate with Jak2 and bind to or activate STAT5 9.   
IFN family. The receptors contain four cysteine residues, but lack 
extracellular domains and bind IFN α,β,ω, limitin, IFNγ  and IL-10 5, 13. Type I 
interferons; i.e. IFNα/β/ω and limitin signal through an interferon alpha 
receptor (IFNAR) complex, which consists of two subunits IFNAR-1 and 
IFNAR-2. Human IFNAR-1 is a 557-aa glycoprotein with a 21-aa 
transmembrane segment and a 100-aa cytoplasmic domain. IFNAR-2 exists in 
three forms; IFNAR-2a (short form), IFNAR-2b (soluble form) and IFNAR-2c 
(long form). IFNAR-2c is composed of 515 aa and acts as a functional receptor 
for IFNα/β signaling. The tyrosine kinases Tyk2 and Jak1 are associated with 
IFNAR-1 and IFNAR-2 respectively 14, 15. IFNAR-2 can bind additionally 
STAT2 through tyrosine residues Y466 and Y481 on the receptor 16. Type II 
IFN, IFNγ binds to IFNγ receptor complex IFNGR, containing a chain 1 (α) 
and 2 (β). IFNGR-1 and -2 bind Jak1 and Jak2 respectively 17. Type I IFNs 
activate mainly STAT1, 2 and 3, type II IFN STAT1 18. 
 
G-protein coupled receptors  
These receptors span the cell membrane seven times and they activate GTP-
binding proteins. Only angiotensin has been shown to signal through the Jak-
STAT pathway. Angiotensin II receptor (AT1) associates with Jak2 and 
activates STAT1 and STAT2 19. 
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1.1.2 Janus kinases (Jaks) 
Jaks are a family of cytoplasmic receptor associated protein tyrosine kinases 
required for cytokine signaling. In mammals the family consists of four 
members; Jak1, Jak2, Jak3 and Tyk2, which are activated by cytokine induced 
receptor dimerization. Once they are activated they cause the phosphorylation 
of tyrosine residues on the receptor cytoplasmic tails to provide docking sites 
for the recruitment of STATs recognizing these phosphotyrosines via their src-
homology-2 (SH-2) domains, and thus mediating signaling of the activated 
STATs 13. Jak1, Jak2 and Tyk2 are expressed ubiquitously, whereas the 
expression of Jak3 is only expressed by myeloid and lymphoid cells 20. The 
Jaks contain seven regions of homology, JH1-JH7. JH1 encodes for a kinase 
and is located at the C-terminal. The catalytic activity of JH1 is stimulated by 
phosphorylation of two tyrosine residues (Y1038/Y1039 in Jak1, Y1007/Y1008 
in Jak2, Y980/Y981 in Jak3, and Y1054/Y1055 in Tyk2) in the domain. JH2 
represents a pseudokinase domain; it has no catalytic function, however a 
Jak2 mutant lacking the domain was able to mediate GH signaling 21. A single 
glutamic acid to lysine substitution in the JH2 domain resulted in 
hyperphosphorylated and hyperactivated STAT when overexpressed in cells 22. 
The other Jak homology domains (JH7-JH3) are located at the N-terminal 
end and thought to be involved in receptor association and in determining the 
specificity of the Jak-receptor binding. The Jaks have clear functions in vivo as 
has been shown by knockout studies in mice 23. 
 
The Jak1 knockout mouse exhibited an early post-natal lethal phenotype, 
probably caused by a neurological defect due to loss of LIF function, which 
express itself in the inability to suckle 24. Decreased responses to IL-7 resulted 
in impaired lymphopoiesis. Also responses to IFNs and IL-10 were 
diminished. Jak2 null mice die at embryonic day 12.5 caused by failure of 
erythropoiesis and immunological impairments 13. Mice lacking Jak3 suffer 
from defects in B-cell maturation (IL-7 mediated) and T-cell negative selection 
because of loss of gamma receptor chain (γC) (in IL-2R, IL-4R, IL-7R, IL-9R, 
IL-15R and IL21R) signaling.  Also humans suffering from SCID were found to 
have mutations in the Jak3 gene 9.  Tyk2 deficient mice were shown to be 
more susceptible to pathogens caused by defective responses to IL-12 and in 
less degree to IFN type I 25. 
 
1.1.3 STATs: structure and functional domains 
The STAT genes have been identified in three chromosomal clusters. The 
genes encoding STATs 1 and 4 map to a region of mouse chromosome 1 
(equivalent to human chromosome 2, q12-q33), STATs 3, 5a and 5b map to a 
region of mouse chromosome 11 (human chromosome 12, q13-14.1), STATs 2 
and 6 map to a region of mouse chromosome 10 (human chromosome 17, 
q11.1-q22). STATs 1, 3, 4,5a and 5b are between 750 and 795 aa long, whereas 
STATs 2 and 6 are approximately 850 aa long 26, 27. Despite functional 
differences of the individual STAT proteins, crystallography studies (an 
example of the crystal structure of activated STAT1 bound to DNA is shown in 
Figure 2) and protein sequence comparisons of STAT1, STAT3 and STAT4 
display common STAT structural domains (an overview is depicted in Figure 
1) 28, 29.  
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Figure 1. Domain structure of STAT proteins. Defined structural and functional 
regions of the STAT proteins: N, N-terminal domain; C-C, coiled-coil domain; DNA, DNA 
binding domain; LD, linker domain; SH2, SH2 domain with the arginine (R) conserved in all 
STATs depicted; P, phosphorylated tail segment with the tyrosine (Y) on which all STATs are 
activated; T, transactivation domain with the serine (S) on which STAT1, 3, 4 and 5a/b can be 
phosphorylated. Colors of the domains do correspond to the domain colors in the three-
dimensional STAT picture (Figure 4). 
 
 
The N-terminal domain is highly conserved and is required for the dimer-
dimer interactions to form tetramers or oligomers of STATs. It has been 
shown for STAT1, 4 and 5 that they are able to form tetrameric complexes on 
tandemly linked GAS (gamma interferon activated sequence) motifs. The 
tetramerization of STATs contributes to the stabilization of the STAT-DNA 
binding and allows STAT proteins to bind with higher affinity, and therefore 
increases the transcriptional activity. The formation of this complex is thought 
to be mediated through protein-protein interactions involving tryptophan 37 
(W37). Studies have demonstrated that a STAT1 W37F mutant was still able to 
form a dimer, however lost the ability to form tetrameric complexes on 
tandem sites on DNA, which resulted in loss of transcriptional activity 30-32. 
Furthermore, STAT1 mutations of phenylalanine (F) 77 and leucine (L) 78 
were shown to interfere with dimer formation 33. The N-domain in STAT1 also 
enhances transcription by interaction with histone transacetylases (CBP/p300 
proteins) 34.  
Arginine (R) 31 in the N-terminal domain of STAT1 is required for 
dephosphorylation of tyrosine 701 of STAT1. Methylation of R31 has shown to 
prevent STAT1 from binding to PIAS1. PIAS1 binding prevent STAT1 from 
binding DNA 35. The deletion of the STAT1 N-terminal domain resulted in a 
mutant STAT1 protein which was constitutively phosphorylated on Tyr-701 36. 
STAT3 proteins lacking the N-terminal domain did show that the domain is 
not required for Y705 phosphorylation of STAT3 stimulated by IL-6 37.  
The N-terminal domain is also involved in nuclear translocation. Activated 
STAT1 molecules lacking the entire N-terminal domain were not able to 
translocate to the nucleus 38. 
The coiled-coil domain is located between residues 136 and 315 and 
consists of four α-helices 28. The coiled-coil domain of STAT1 (in particular 
lysine (K) 161) for example interacts with IRF9/p48, which makes part of the 
interferon stimulated gene factor 3 complex 39. This domain of STAT3 
interacts with transcription factor c-jun 40 and STAT5a and 5b with the 
silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) 41. 
Single mutations of STAT3’ aspartic acid (D) residue 170 or, to a lesser extent 
K177 diminishes receptor binding and tyrosine phosphorylation, and 
consequently dimer formation, nuclear translocation and transcriptional 
activation. Further mutation experiments with STAT3 showed that all four 
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coiled-coil domain helices are required for recruitment of STAT3 to the IL-6 
receptor and for Y705 phosphorylation 37. Furthermore, mutation studies of 
coiled-coil domain of STAT3 have revealed that only residues R214/R215 in 
the domain (but not R152/K153/R154, K161/K163, K177/K180, R197/R199 
and K244/R245/R246) have influence on nuclear import 42.  
The DNA-binding domain (approx. aa 320-480) is structurally similar to 
the immunoglobin-like DNA-binding domain and shows similarities to the 
DNA-binding domains of NFκB and p53 29. The domain determines the DNA 
binding specificity. The analysis of the crystal structure of phosphorylated 
STAT1 bound to DNA (Figure 2) suggested that there are few direct contacts 
between the DNA-binding domain of the DNA bases, i.e. K336, E421 and 
N460 are essential for the binding of the DNA bases, whereas R378, K410, 
E411, K413, T427 and T459 make contacts with phosphate backbone of DNA 
29. The activated STAT3 dimer requires residues K340 and N466 for the 
binding to the bases in the response elements, aa M331, H332, V343, Q344, 
R382, R417, I431, V432, S465, I467 and Q469 make contacts to the DNA 
sugar-phosphate backbone 28.  
The domain is also important for nuclear translocation of the STAT dimers 42.  
 
 
 
 
Figure 2. Crystal structure of tyrosine phosphorylated STAT1 dimer bound to 
DNA. Ribbon presentation of the STAT1 core dimer (aa 136-710) on DNA. The coiled-coil 
domain is shown in green, the DNA-binding domain in red, the linker domain in orange and 
the SH2 domain is shown in blue. The phosphorylated tail segment is colored purple and the 
DNA backbone in grey. ‘N’ and ‘C’ indicate the location of the lacking N- and C-termini in this 
STAT1 dimer. Reprint from a publication by Chen et al. 29. 
 
 
The α-helical linker domain (approx. aa 485-575) separates the DNA 
domain from the SH2 domain 29. For STAT1 it was reported that its linker 
domain may play a role in transcriptional responses. Mutations (W539A, 
K544A and E545A, but not F506A and R512A) resulted in the lack of ability to 
induce transcriptional responses to IFNγ, but not to IFNα, although STAT1 
phosphorylation, dimerization, nuclear translocation and DNA binding were 
normal in response to IFNγ 43. Additional analyses of this STAT1 
(K544A/E545A) mutant have suggested that the primary defect in this mutant 
is its abnormal DNA binding kinetics (it binds and dissociates from DNA more 
rapidly than wild type STAT1 protein) and inability to accumulate on DNA 
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response elements, rather then a defective co-activator recruitment 
mechanism 44. 
The SH2 (src homology domain 2) domain is located between aa 575 and 
680. It is required for the recruitment of STATs to phosphorylated receptors 
and for the reciprocal SH2-phosphotyrosine interactions between monomeric 
STATs to form dimers 45. The binding of the STATs to the receptors occurs 
through the interaction of the conserved arginine in the SH2 domain (R602 
for STAT1, R609 for STAT3 and R618 for STAT5) with the phosphorylated 
tyrosine residues located in the intracellular domains of the receptors. This 
interaction is highly specific and determines the STAT binding to the different 
cytokine receptors 28, 46. This conserved arginine residue is also essential for 
the recognition of the single phosphate group of the phosphotyrosine to 
initiate dimerization of the STAT proteins required for STAT transcriptional 
activity 47. Additional contacts between A641 and V642 in the SH2 domain 
and L706 C-terminal of the phosphotyrosine are essential in the dimer 
formation in STAT1. For STAT3 are these N641, M642 in the SH2 domain and 
F706 29.  
The phosphorylated tail segment harbours the tyrosine residue (Y701 for 
STAT1, Y690 for STAT2, Y705 for STAT3, Y693 for STAT4, Y694 for STAT5 
and Y641 for STAT6), which phosphorylation is essential for STAT 
dimerization through SH2 domain binding and DNA binding activity 48. The 
four to five aa C-terminal of the phosphorylated tyrosine (for STAT1 
Y701IKTEL, for STAT3 Y705LKTKF and for STAT5a Y694VKPQI) make the 
contacts with other aa of the SH2 domain and are therefore essential in 
dimerization 28, 29, 49.  
The transcriptional activation domain (TAD) at the C-terminal region 
between approximately aa 700 and 851, is involved in the communication with 
transcriptional complexes. A conserved serine in STAT1 (S727), 3 (S727), 4 
(S722) and 5 (S726/731) can be phosphorylated and regulates STAT 
transcription. Several studies showed an reduced transcriptional activity when 
this serine is replaced by alanine 50-52. Alternative splicing at the 3’end of the 
gene transcripts generates shorter isoforms of STAT1, 3, 4, 5a and 5b. The 
isoforms lack the functional transcriptional activation domain, but are still 
able to bind to the response elements of target genes. When the isoforms are 
overexpressed, they can act as dominant negative regulators of transcription, 
by competing with full length STATs for the DNA binding sites 53. 
 
 
1.2  Mechanisms and regulation of Jak-STAT signaling 
 
1.2.1 IFN signaling 
Type I interferons are produced by leukocytes and fibroblasts upon virus 
infection and type II IFN is produced by activated Thelper (Th)1-cells and 
natural killer (NK) cells 54, 55. IFNα/β (type I) gene transcription in virus 
infected cells is an important early event in the host response to infections. 
IFNα/β is produced by virus-infected cells within hours and plays an 
important role in preventing virus spread. Production of IFN-gamma on the 
other hand needs activation of the immune system 56. The induction of 
transcription of IFNα/β genes is mediated through the binding of interferon 
regulatory factors (IRF) to virus-inducible enhancers in their promoter 
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regions 17. IRF3 and IRF7 are the key regulators of the induction of IFNα/β 
genes. IRF3 is phosphorylated and translocated to the nucleus upon viral 
infection. It associates with the co-activator p300/CBP, and activates IFNβ 
and IFNα1 genes. IFNα and β are produced, bind to their receptors, signal 
through the Jak-STAT pathway and activate a number of target genes, 
collectively called interferon stimulated genes (ISGs). One of them is IRF7. In 
the presence of viral infection IRF7 is also phosphorylated, translocates to the 
nucleus, forms a dimer with IRF3 and transcriptionally stimulates additional 
IFNα genes 57, 58. 
Signals of both types IFN are transmitted through the Jak-STAT pathway, 
as illustrated in Figure 3. Binding of the IFNs to their receptors links the two 
components of the receptors and results in the activation of Jak1 and Tyk2 for 
IFNα/β, and Jak1 and Jak2 for IFNγ. The two kinases (Jak1/Tyk2 and 
Jak1/Jak2) transactivate each other by transphosphorylation. The activated 
kinases then phosphorylate tyrosine residues on the receptors: Y440 on 
IFNGR-1 and Y466 on IFNAR-2, which are then able to bind STAT1 and 
STAT2 respectively through their SH2 domains on these sites. As a result 
STAT1 is phosphorylated by the Jaks on its tyrosine 701, STAT2 on Y690 and 
STAT3, which is also activated by IFNα/β, on Y705.  
 
 
 
 
 
 
Figure 3. Schematic overview of IFNα/β and γ induced signal transduction 
through the Jak-STAT pathway. The Jak1 and Tyk2 kinases are activated by IFNα/β, 
which leads to phosphorylation,  dimerization and nuclear translocation of STATs. IFN type I 
activates two classes of STAT complexes. STAT1 (p91) and STAT2 (p113) heterodimer 
combine with IRF9 (p48) to form ISGF3, which activate transcription of ISGs through ISRE 
and STAT1 and STAT3 homodimers, which bind to GAS elements. Upon IFNγ binding are 
STAT1 homodimers formed, which induces transcription by binding to GAS element 60. 
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Through reciprocal phosphotyrosine-SH2 domain interactions STAT1 forms 
homodimers (IFNα/β/γ), STAT3 forms homodimers and heterodimers with 
STAT1 (IFNα/β) and additionally upon IFNα/β signaling STAT1 and STAT2 
are able to form a heterotrimeric complex with IRF-9 (p48) , designed 
interferon stimulated gene factor 3 (ISGF3). The STAT dimers will translocate 
to the nucleus and to the specific response elements (STAT1 and 3 homo and 
heterodimers to GAS elements, and ISGF3 to ISRE) in promoters of target 
genes and stimulate transcription 59.  
 
IFNs have antiproliferative, immunomodulatory and antiviral activity. Mice 
lacking IFNAR1 have increased susceptibility to vesicular stomatitis virus 
(VSV), Semliki Forest virus SFV), vaccinia virus or lymphocytic 
choriomeningitis (LCMV). In contrast mice deficient for IFNGR1 were able to 
overcome a VSV and SFV infection, died from vaccinia virus infection and 
were increased susceptible, however less than the IFNAR KO mice, to LCMV. 
Furthermore IFNAR KO mice were resistant against the pathogen Listeria 
monocytogenes, whereas the IFNGR deficient mice were highly susceptible. 
This points out that IFN type I and II have partially overlapping but distinct 
antiviral effects 61, 62. Differences in the induction of target genes by IFN type I 
and II are responsible for the differences in antiviral effects. Especially the use 
of oligonucleotide arrays to study the differential expression of mRNA in 
response to IFNs have identified many new and confirmed known interferon-
stimulated genes and provided insights into the mechanisms of IFN action 63, 
64. IFNα/β induced genes (i.e. ISG) include ISG-56K, MxA, 6-16, IRF1, 2’-5’-
oligoadenylate synthetase (OAS), double stranded RNA activated protein 
kinase (PKR), eIF-2α, MHC-class I,  IL-12, IL-15, ICE and IFNα/β. Antiviral 
activity requires induction of OAS, PKR and Mx proteins 65,15. Direct antiviral 
effects of IFNγ  are mediated through its upregulation of PKR, OAS and 
dsRNA specific adenosine deaminase (dsRAD) 55. IFNγ has direct antibacterial 
activity through the activation of monocytes, lymphocytes, neutrophils and 
macrophages by the enhancement of expression of chemokines, inducible 
nitric oxide synthase (iNOS) and natural  resistance-associated macrophage 
protein1 (NRAMP1) 55, 65. 
IFNs are also modulators of the immune system and do influence cell growth 
and differentiation. IFNα/β suppress the antigen-specific- or mitogen-induced 
proliferation of T helper cells and cytotoxic T cells on one hand, while at the 
other hand they induce IL-15 production in macrophages, which enhances T-
cell growth and proliferation of NK-cells. IFNα/β also induce expression of 
MHC classI, thereby stimulating antigen presentation 15, 61.  
IFNγ is a strong inducer of both MHC class I and II molecules. 55. IFNγ can 
also regulate the isotypes of immunoglobulins secreted during humoral 
immune responses 63 and induces cell death of T-cells 54. 
IFN signaling is also involved in apoptosis and in the regulation of cell cycle. 
IFN induced growth inhibiting and proapoptotic genes included IRF1, tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL), XIAP-associated 
factor 1 (XAF1), galectin 9, a cyclin E binding protein, amphiphysin 1, MyD88, 
and several ubiquitin pathway genes  15, 55, 64. 
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1.2.2 IL-6 signaling 
IL-6 is a cytokine that exhibits a wide range of biological effects. It is induced 
by proinflammatory stimuli like IL-1 and TNFα, which are expressed at most 
inflammatory sites. 11 TNFα activation leads to activation of NFκB, which is 
the transcription factor for the induction of IL-6 gene expression. In liver, 
TNFα activates IL-6 expression mainly in Kupffer cells, but also in endothelial 
cells and hepatic stellate cells, resulting in Jak-STAT/ SHP2/MAPK activation 
in hepatocytes 66-68.  
Signaling through the Jak-STAT pathway is illustrated in Figure 4. IL-6 
binds specifically to the IL-6R α-chain, which allows recruitment of the two 
signaling gp130 receptor subunits. The receptor subunit gp130 is ubiquitously 
expressed, but the number of cells responding to IL-6 is limited because of the 
restricted availability of the α-chain. The soluble form of IL-6Rα (sIL-6Rα) 
can as well be used to initiate IL-6 signaling when bound to IL-6. In addition 
to sIL-6Rα, also soluble gp130 (sgp130) is present in serum. Soluble gp130 is 
probably translated from an alternative spliced mRNA and can neutralize IL-
6/sIL-6Rα complexes, thereby acting as an antagonist. IL-6 alone is not able 
to interact or cause homodimerization of gp130 12, 69-71.  
 
 
 
 
Figure 4. Schematic diagram of IL-6 induced signaling. IL-6 activates the Jak-STAT 
pathway and the MAPK cascade.  IL-6 binding to the IL-6 receptor causes aggregation of the 
three receptor chains and consequently activation of Jak1, Jak2 or Tyk2. The receptor chain 
gp130 is phosphorylated on four tyrosine residues (Y767, Y814, Y905 and Y915) to allow 
binding of STAT3. Activated STAT3 forms homodimers, which are binding to GAS-like 
response elements. Through activation of SHP2 is IL-6 also coupled to MAPK signaling (TF, 
transcription factor) 70. 
 
 
As result of the receptor-IL-6 binding, gp130 associated kinases Jak1, Jak2 
and Tyk2 become phosphorylated and will in return phosphorylate six 
tyrosine residues on the cytoplasmic tail of the gp130 receptor chains. Four of 
these tyrosine residues serve as docking sites for the SH2 domains of STAT3 
(Y767, Y814, Y905 and Y915) and of STAT1 (Y905 and Y915) 70, which will 
subsequent be phosphorylated on their single tyrosine residues (Y705, 
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respectively Y701). The phosphorylated STAT1 and 3 will form homo and 
heterodimers and translocate to the nucleus to bind to GAS-like response 
elements. 
Activation of the IL-6R complex does not only lead to signaling through the 
Jak-STAT pathway, but also to activation of the SHP2/MAPK signaling 
pathway. One of the six tyrosine residues (Y759) on gp130 cytoplasmic tail, is 
bound by SHP2 (SH2 domain containing tyrosine phosphatase). Upon Jak-
SHP2 interaction, SHP2 will be phosphorylated by Jak1 on its tyrosine 
residues 304 and 327. Subsequently Grb2 (growth-factor-receptor-bound 
protein), which is linked to SOS (son of Sevenless), can bind to the pY304 of 
SHP2. Recruitment of SOS to the receptor complex at the membrane allows 
Ras activation. This leads to signaling through the Ras-Raf-MAPK cascade 12, 
70. Activated MAPK activates the transcription factors NF (nuclear factor)-IL6, 
and CAAT/enhancer binding protein (C/EBP) β and δ, which bind to the 
promoters of acute phase proteins to induce transcription 11, 72.  Through 
association of SHP2 with Gab1 (a scaffolding adaptor protein) ERK2 is 
activated. This interaction links IL-6 signaling to the activation of the PI3K 
/Akt pathway which mediates anti-apoptotic effects and cell growth 12, 70. 
SHP2 not only links IL-6R complex activation to the MAPK pathway, it also 
has an inhibitory role. Through its activation and association with Y759 on the 
receptor, it counteracts receptor and STAT activation by tyrosine 
dephosphorylation of receptor kinase sites, resulting in inhibition of IL-6 
induced gene expression. Furthermore, IL-6 signaling is negatively regulated 
by SHP1, which can dephosphorylate Jak2 and Tyk2, and by SOCS3, which 
competes with SHP2 for binding of Y759 on the IL-6R complex and inhibits 
Jak activity 71, 73, 74. 
 
Il-6 acts on various cells. In addition to its important role in inflammation, Il-
6 induces differentiation and development of haematopoietic cells, 
osteoclasts, neural cells and hepatocytes. It also acts as growth factor for renal 
cell carcinoma and Karposi’s sarcoma, and promotes growth of 
haematopoietic stem cells 67.  
IL-6 deficient mice develop normally, probably because other members of the 
gp-130 cytokine family do compensate for the lack of IL-6. However they fail 
to control efficiently infection with vaccinia virus or Listeria monocytogenes 
and have an impaired T-cell dependent antibody response against vesicular 
stomatitis virus. Most important, the inflammatory acute-phase response after 
minor tissue damage or infection with bacterial lipopolysaccharide (LPS), was 
severely impaired 75, 76. Furthermore do they show a decreased IL-10 
production and increased IL-12 production in macrophages.  
IL-6 target genes involved in anti-inflammatory responses include IL-1R 
antagonist, soluble TNFα-R, IL-10, acute phase proteins, glucocorticoids, 
tissue inhibitor of metalloproteinase-1 (TIMP-1) and SOCS3 66, 77. 
 
1.2.3 Nucleocytoplasmic transport 
In unstimulated cells STATs predominantly localize to the cytoplasm, and 
upon stimulation rapidly translocate to the nucleus and induce gene 
expression. Nuclear translocation is mediated by the nuclear pore complex 
(NPC).  
Active nuclear import is directed by a nuclear localization signal (NLS), which 
is recognized and bound by members of the importin family. Importin-α5 
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recognizes the NLS and functions as an adaptor for the binding of importin-β. 
Importin-β interacts with the NPC and mediates the transport of the STAT 
dimer into the nucleus. Hydrolysis of GTP by Ran, a Ras-like small GTPase, 
provides the energy that is required to translocate the STATs through the 
central gated channel of the NPC. NLS elements include a short stretch 
arginine and lysine residues. Mutagenesis studies of possible NLS motifs have 
indicated that K410-R418 in STAT1 and R409-K415 in STAT2 are required for 
IFN-induced nuclear import 78. Also a single mutation in STAT1 leucine 407 
(L407A), or double mutations in lysines 410 and 413 (K410A/K413A), were 
shown to block nuclear import due to abolishment of the importin-α5 binding 
to these mutated STAT1 molecules. The L407 mutant can still bind DNA, 
whereas the K410A/K413A mutant can not 79. Mutations of R414/417 in 
STAT3, corresponding to K410/413 in STAT1, also caused loss of nuclear 
import ability of STAT3 42. 
Nuclear export is specified by nuclear export signal (NES) elements. Three 
nuclear export signal (NES) elements have described for STAT3; i.e. aa306-
318, aa404-414 and aa524-535, and for STAT1; aa302-314, aa399-410 and 
aa534-53380, 81. The NES element is recognized by an exportin CRM1 
(chromosome region maintenance 1), which is bound as well to Ran-GTP in 
the nucleus. The CRM1-STAT-Ran/GTP complex is exported through the NPC 
and dissociates in the cytoplasm after the hydrolysis of Ran-GTP 13, 81. 
 
1.2.4 STAT DNA binding and transcriptional activation 
Activated STATs can bind to two classes of DNA response elements in 
promoters of target genes. The STAT dimers, STAT1, 3, 4, 5 and 6 
homodimers and STAT1 and 3 heterodimer bind to variations of GAS (gamma 
activated sequence)-like motifs, palindromic response elements 
TTCNNNGAA, except for STAT6 which prefers TTCNNNNGAA 82. GAS-like 
elements have been identified in promoters of many different genes, like for 
cFos, M67, FcγR1, IRF1 and β-casein. The other class of response elements 
where STATs bind to are interferon stimulated response elements (ISRE); i.e. 
AGTTTNNNTTTCC. ISRE elements are bound by ISGF3 (interferon 
stimulated gene factor 3); i.e. the complex of STAT1 and STAT2 together with 
IRF9/p48 (interferon regulatory factor 9) 83. These elements can be found in 
ISG like ISG54, ISG15, 6-16 and OAS 4. 
Once the activated STAT dimer binds to its target promoter, the 
transcription rate from this promoter is increased. The STATs have the ability 
through their TAD to recruit nuclear co-activators that mediate chromatin 
modifications and communication with the promoter. The TAD of STAT1 can 
directly interact with the CREB-binding protein (CBP)/p300 family of 
transcriptional coactivators to contribute to transcriptional activation. 
Recently was shown that both tyrosine-phosphorylated STAT1α (full-length 
wild-type protein) and STAT1β (lacking the TAD) stimulate in vitro 
transcription on a naked DNA template. Using a system with purified proteins 
and naked DNA, it was shown that STAT1α- and STAT1β-dependent 
transcription is stimulated by the TRAP/Mediator co-activator complex. 
Although both STAT1α and STAT1β bind to known STAT sites within in vitro 
assembled chromatin templates, only STAT1α, and not STAT1β, in 
cooperation with p300 and acetyl-CoA, stimulated in vitro transcription from 
chromatin. After IFNγ treatment, it was shown that cells recruit STAT1α or -β 
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to the chromosomal interferon-1 gene, but only STAT1α-containing cells 
recruit p300 and stimulate transcription. The results indicate that the 
recruitment of p300 to the chromatin is required to make TRAP/Mediator 
effective in stimulating transcription 34, 84. 
Furthermore, transcriptional activity can be positively regulated by 
phosphorylation of the conserved serine residue in the TAD. Serine 
phosphorylation is independent of tyrosine phosphorylation 85 and is not 
required for DNA binding of the activated STATs86. It has been described that 
an activated JAK2 is the kinase responsible for serine phosphorylation 85; 
other candidates include p38, ERK and JNK 83. Expression of a dominant-
negative p38 led to defective STAT1 serine 727 phosphorylation and 
diminished IFNγ mediated protection against viral killing 87. In contrast have 
Zhu et al. showed that ERK, JNK and p38 do not exhibit kinase activity under 
IFNγ stimulation 85.  
 
1.2.5 Negative regulation 
Inactivation or inhibition of Jak-STAT activation is important in the 
regulation of their biological signaling effects. As result of actions of negative 
regulators at several points in the signaling pathway, the duration of STAT 
activation is temporary. After STATs are phosphorylated, dimerized, 
translocated to the nucleus and have induced transcription, they are exported 
back to the cytoplasm in dephosphorylated state.  
Factors involved in negative regulation are members of the SOCS (suppressors 
of cytokine signaling) family, of the PIAS (protein inhibitor of activated 
STATs) family, PTPs (protein tyrosine phosphatases) and enzymes that 
mediate modifications of STATs proteins, like ubiquitination and SUMO-
ylation13, 23. At the receptor level the pathway is negatively regulated through 
receptor internalization to endocytic vesicles 88.  
 
SOCS  
They comprise a family of eight members who share a similar structure, with a 
central SH2 domain, a region of homology called the SOCS box at the C-
terminal and a kinase inhibitory region located at the N-terminal. Members 
are CIS-1 (cytokine-inducible SH2 containing protein) and SOCS1-7 89. SOCS 
are target genes of the STATs and do thus generate a negative feedback loop. 
They inhibit STAT signaling by binding to the phosphorylated tyrosine 
residues on the receptors to physically block binding of STATs, by binding of 
Jaks or to the receptors to inhibit Jak kinase activity or by interacting with the 
elongin BC complex and cullin 2 to induce ubiquitination of the Jaks 6, 89. 
Ubiquitination of the Jaks prepares them for proteasomal degradation 5. The 
essential negative regulatory function of SOCS1 was revealed by the fatal, 
immune-mediated inflammatory disease which is present in SOCS 1 deficient 
mice 23.  
 
PIAS  
This family contains five members, PIAS1, PIAS3, PIASγ, PIASxα and PIASxβ. 
PIAS1, PIAS3 and PIASx can specifically interact with STAT1, STAT3 and 
STAT4, respectively. PIAS-STAT interaction is cytokine dependent. PIAS 
family members have a central Zn-binding RING-finger domain, a well 
conserved domain at the N-terminus and a less-well conserved C-terminal 
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domain. PIAS bind to phosphorylated STAT dimers and prevent them from 
binding DNA 90. Inhibition of R31 methylation of STAT1 proteins, by 
methylthioadenosine (MTA), a methyl-transferase inhibitor promotes PIAS1 
binding and thus inhibits STAT1 signaling. With other words, arginine 
methylation protects the STATs from binding to PIAS1 and deactivation. The 
methylation of the highly conserved R31 residue in STAT1 by the protein 
arginine methyl-transferase PRMT1 was found to be required for IFN type I 
induced transcription 35. PIAS 1 binding of STAT1 seems to protect STAT1 
from dephosphorylation by TC-PTP/TC45. So arginine methylation of STAT1 
regulates STAT1’ dephosphorylation 91. In addition to PIAS1, PIASy also 
interacts with STAT1 and seems to function as corepressor of STAT1. 
Very recently the PIAS1 KO mouse has been reported by Liu et al. Tyrosine 
phosphorylation of STAT1 induced by IFNα or IFNγ and likewise of STAT2 by 
IFNβ, was not altered in PIAS1-/- cells. Gene activation analysis showed that 
PIAS1 selectively regulates a subset of IFNγ or IFNβ target genes. Due to 
PIAS1 inhibitorial function, the immune response to viral and bacterial 
infections was enhanced in these PIAS1 deficient mice 92. 
It has been reported that PIAS proteins have E3 ligase activity for SUMO-
ylation mediated by the RING finger domain. However in the PIAS1 -/- 
thymocytes no defect was obeserved in SUMO3 or SUMO1 protein 
modification 92. SUMO (small ubiquitin-related modifier) has been found 
added to target proteins by special protein-protein interactions. This is 
regulated by SUMO E3 ligases 93. How SUMO-ylation of STAT inhibits its 
activation is not yet understood. 
 
Protein tyrosine phosphatases  
PTPs are active both in the cytoplasm and the nucleus. SHP1 and SHP2 are 
cytoplasmic PTPs, which can dephosphorylate Jaks and receptors. SHP1 has 
been shown to directly bind and dephosphorylate Jak2 89. Also SHP2 seems to 
be a regulator of Jak2 activity. Dephosphorylation of Jak2 by SHP2 protects 
Jak2 from SOCS1 mediated ubiquitination and degradation 94. PTP1b 
specifically inhibits JAK2 and Tyk2 23. Although TC-PTP/TC45 (T-cell protein 
tyrosine phosphatase 45 kDa isoform) is known as a nuclear PTP, there is also 
evidence that it is involved in the dephosphorylation of Jak1 and Jak3. It was 
shown that it can bind to Jak1 and Jak3. Furthermore cells from mice 
deficient for TC-PTP/TC45 show increased phosphorylation of Jak1, STAT1 
and STAT5 depending on the stimulation. Jak2 phosphorylation was not 
affected 95. Nuclear tyrosine phosphatases TC-PTP/TC45 was identified to 
dephosphorylate specifically phosphorylated STAT1 in the nucleus. In TC-PTP 
null mouse embryonic fibroblasts (MEFs) the dephosphorylation of STAT1 is 
defective, as well as the dephosphorylation of STAT3, but not of STAT5 and 6. 
Reconstitution with TC-PTP/TC45, but not with TC48, the other TC-PTP 
isoform, could repair this defect 96. 
 
1.2.6 Specificity and diversity in signaling 
Diversity and specificity are decisive factors in the determination of the 
outcome response in the complexity of intercellular signaling. The different 
cytokines induce specific and distinct biological responses in different types of 
cells by activating different members of the Jak and STAT families. However, 
even in the same type of cell, the responses to a certain cytokine can vary 
depending on the location of the cell and the condition of its 
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microenvironment. The cell specificity of cytokine action through the Jak-
STAT pathway is determined at several levels, which are obviously influenced 
by one another 97. 
To start with, specificity is reached through the selective activation of the 
different STATs by specific ligands. This is achieved through the selective 
binding of different STAT family members to phosphotyrosine docking sites 
on receptors 46, 98. This was shown by domain swapping experiments the 
docking sites 98 and with the STAT SH2 domains 46. STAT2 constructed with 
the SH2 domain of STAT1 could be activated by IFNγ, whereas the STAT1 
constructed molecule including the STAT2’ SH2 domain could not. When the 
tyrosine residues which phosphorylation is required for dimerization and 
nuclear translocation of the STATs, with surrounded sequence of STAT1 
(Y701) and STAT2 (Y690) were swapped, the STAT1’SH2 domain was 
required to induce phosphorylation of the STAT protein by IFNγ 46. Using a 
phosphopeptide library to determine the sequence specificity of the receptor 
binding sites (i.e. peptides) for the SH2 domains of STAT1 and STAT3, did 
show by Wiederkehr-Adam et al. that STAT1 preferentially binds peptides 
with a motif phosphotyrosine-(aspartic acid/glutamic acid)-
(proline/arginine)-(arginine/proline/glutamine), whereby a negatively 
charged aa at +1 excludes a proline at+2 and vice versa. STAT3 preferentially 
binds peptides with a motif phosphotyrosine-(basic or hydrophobic)-(proline 
or basic)-glutamine 99. 
Another level of specificity is determined by the specific binding of 
activated STAT dimers to slightly different response elements. Variations of 
the inner nucleotides between the different palindromic GAS-like motifs, have 
been shown to influence the binding affinity towards specific STAT dimers. 
For example STAT1 homodimer binds to the GAS element in the promoter of 
the FcγR1 gene, whereas the STAT3 homodimer does not 100. Furthermore, it 
seems that the ability of STATs to bind cooperatively to tandem GAS elements 
(which are 6-10 bp apart) also contributes to DNA binding specificity 82, 101. 
 
 
1.3 Biological functions of STAT proteins 
 
The biological role of each individual STAT protein has been examined 
through the study of knockout mice.  
 
STAT1 
STAT1 KO mice are highly susceptible to microbial and viral infections and 
tumor formation due to defective IFN responses. These mice failed to induce 
transcription of STAT1 target genes in response to both IFNα/β and IFNγ. 
They also failed to induce ISGs in response to IFNα 102. It is also demonstrated 
that STAT1-deficient mice exhibit a higher incidence of spontaneous and 
chemically induced tumors. This can be explained through STAT1 roles in 
upregulation of proapoptotic genes (caspases103) and its role in the regulation 
of expression of proteins involved in antigen presentation (MHC class II) and 
thus affecting the immunogenicity of the tumor 104. Furthermore, it is shown 
that STAT1 interacts with p53 to enhance DNA damage-induced apoptosis. In 
addition, STAT1 could suppress Mdm2 protein in STAT1-deficient cells. 
Mdm2 protein interacts with p53 to induce its degradation 105. 
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STAT2 
STAT2 is the only member that does not bind to GAS elements. Its biological 
function is not well understood sofar, however since it is activated by IFNα/β 
it is clear that it plays a critical role in promoting antiviral immune response. 
STAT2 knockout mice are, like STAT1 KO susceptible to viral infections. 
Studies in these mice suggested that STAT2 regulates the basal levels of STAT1 
expression in MEFs, since upregulation of STAT1 in response to IFNα is 
impaired. This was not the case in macrophages 106. STAT1/STAT2 double 
knockouts are completely unresponsive to all IFNs and show more 
susceptibility to infection than either of the single knockouts.  
 
STAT3 
STAT3 is activated by many cytokines. STAT3 KOs are embryonically lethal at 
day 7.5. However the generation of tissue-specific knockouts using the Cre-lox 
method has revealed STAT3’ role in a wide variety of tissues 107. The lack of 
STAT3 in skin showed that it is important in the migration of keratinocytes 
and is essential during the hair cycle and wound healing 108. STAT3 deficient 
T-cells exhibit loss of proliferative response to IL-6, which has previously been 
shown to suppress apoptosis in these cells 109. Furthermore do STAT3-
deficient T-cells show an impaired IL-2-mediated IL-2 receptor (IL-2R) alpha 
chain expression 110. The lack of STAT3 in liver results in an impaired acute 
phase response, caused by a defective STAT3 induced expression of 
fibrinogen, haptoglobin, serum amyloid (SAP), serum amyloid A1 (SAA) and 
proteinase inhibitor α2-macroglobulin 72. STAT3 does also play an essential 
role in the normal glucose homeostasis by downregulation of the expression of 
gluconeogenic genes like phosphoenolpyruvate carboxykinase-1 (PCK-1) and 
glucose 6-phosphatase (G6PC). Mice with liver-specific STAT3 deficiency 
showed insulin resistancy associated with increased hepatic expression of 
PCK-1 and G6PC genes 111. Liver partial hepatectomy in STAT3 liver-specific 
KO mice showed that STAT3 promotes cell cycle progression and cell 
proliferation during liver regeneration. Activation of MAPK signaling was 
normal in these livers 112. In thymus, it impairs the postnatal maintenance of 
thymic architecture and thymocyte survival 113. Mice deficient for STAT3 in 
macrophages and neutrophils are more susceptible to endotoxin shock with an 
increased production of inflammatory cytokines such as TNF alpha, IL-1, IFN 
gamma, and IL-6 by the macrophages and neutrophils probably due to 
impaired IL-10 suppressive effects on this production in these mice 114. 
Deletion of STAT3 in mammary glands results in delayed apoptosis that 
occurs during cyclical mammary gland involution 115. Selective targeting of the 
full length STAT3α and truncated STAT3β splice variants showed specific 
functions for both isoforms. Mice lacking STAT3β are hypersensitive to 
endotoxin-induced inflammation 116. In liver-specific STAT3 isoform KO mice 
it was reported that STAT3β is not a dominant negative factor, since its 
expression can rescue the embryonic lethality of a complete STAT3 deletion. 
Both isoforms can induce acute phase proteins. STAT3α however is 
responsible for regulation of the IL-6 response and of the IL-10 anti-
inflammatory function in macrophages 117. 
 
 
 
Chapter 1 
  27
STAT4 
Since Il-12 activates STAT4, the STAT4 knockout mouse does display defective 
IL-12 responses; i.e. impaired T-helper-cell type I (Th1) differentiation and 
therefore impaired IFNγ production and cell-mediated immunity 118. Because 
of the defective Th1 response these animals are resistant to Th1 mediated 
autoimmune diseases like arthritis and diabetes 119.  
 
STAT5 
The two STAT5a and STAT5b proteins are approximately 95% identical in aa 
sequence.  Mice deficient for only STAT5a 120 or STAT5b 121 have revealed 
specific and limited functions for the two STAT5 proteins individually 122. 
Through analyses of these single knockouts has been revealed that STAT5a is 
important in prolactin, GM-CSF and IL-2 signaling. STAT5a KO mice show no 
effect on body growth or serum IGF-1 (mediator of the somatic effects of GH) 
levels 122. In liver is STAT5a, together with STAT5b the most important 
mediator activated by GH 123. STAT5b is important in controlling somatic 
growth in mice. It is as well regulating sexually dimorphic gene patterns, 
which exhibits itself in STAT5b KOs by GH mediated loss of male-
characteristic body growth rates and male specific liver gene expression of 
cytochrome P450 (CYP) steroid hydroxylases. Levels of male specific CYP2D9 
and testosterone 16α-hydroxylase were decreased in these knockouts and 
levels of female liver specific CYP3a, CYP2B and testosterone 6β-hydroxylase 
were increased. In female mice are both STAT5a and STAT5b required for the 
constitutive expression of hepatic female specific GH-regulated, CYP2B, as 
well as several CYP-catalyzed testosterone hydroxylase activities 124, 125.  
STAT5a is furthermore required for mediating prolactin signaling and 
mammary gland development and lactogenesis 120. STAT5a/5b double 
knockout females are infertile, caused by an altered corpus luteum 
development. This is in contrast to single STAT5a or 5b deficient mice, which 
are fertile, suggesting that the function of the STAT5 proteins may be 
redundant 122. 
 
STAT6 
STAT6 is required for the induction of IL-4 dependent gene expression 
leading to type II T-helper-cell (Th2) differentiation and IL-4 dependent B-
cell proliferation. In addition, has it been demonstrated that STAT6 is 
important for the functions mediated by IL13, which is related to IL4. IL4 and 
IL13 have been shown to induce the production of IgE, which is a major 
mediator in an allergic response. STAT6 activation might therefore be 
involved in IL4- and IL13-mediated disorders such as allergy 126 127. This was 
proven in STAT6 deficient mice, which display a reduced pathology in asthma. 
Furthermore is it described that STAT6 deficiency is associated with enhanced 
tumor immunity, since natural killer T-cells (NKT-cells) and IL-13, produced 
by NKT-cells and signaling through the IL-4R-STAT6 pathway, are necessary 
for down-regulation of tumor immunosurveillance 128. 
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1.3.1 Impact of STATs in disease 
Since STAT proteins display a wide range of functions in many biological 
aspects, they are consequently involved in or mediating pathological 
processes.  
Many viruses have developed mechanisms to inhibit the anti-viral immunity 
actions of IFNs through disruption of IFN induced Jak-STAT signaling. 
Hepatitis C virus (HCV) inhibits IFN signaling downstream of STAT 
phosphorylation 129. Duong et al. showed that acceleration of the negative 
feedback loop of Jak-STAT signaling, through an increased upregulation of 
PP2Ac, is responsible for decreased binding of activated STAT1 to the DNA 
and inhibition of signaling 130. In vitro and in vivo studies to demonstrate HCV 
interference with IFNα induced Jak-STAT signaling are described in chapter 2 
and 3.  Interference with IFN induced Jak-STAT signaling in many different 
ways as mechanism of viral persistence, is also reported for other viruses as 
simian virus 5 131, herpes simplex virus type 1 (HSV-1) 132, hepatitis B virus 
(HBV) 133,  Sendai virus 134, human parainfluenza virus type 2 135, adenovirus 
136, 137, human papilloma virus (HPV) 138, 139, Epstein-Barr virus (EBV) 140, 
cytomegalovirus (CMV) 141 and paramyxoviruses like mumps virus 142, 143, 
measles virus 144 and Nipah virus 145. 
Other examples of diseases caused by a defective signal transduction 
through the Jak-STAT pathway are X-linked combined immunodeficiency 
(XCID) and X-linked severe combined immunodeficiency (XSCID). In both 
diseases Jak3 activation is impaired due to mutations of the IL-2Rγ chain. C-
terminal truncations of this receptor chain completely prevent Jak3 binding 
and results in development of XSCID. In XCID the Jak3 association with the 
receptor is only reduced due to a point mutation in IL-2Rγ chain. Mutational 
Jak3 deficiency has also been detected in patients with the less severe form 
SCID 9 146.  
STAT3 might be involved in the pathogenesis of Crohn’s disease. Mice with 
tissue-specific deletion of STAT3 during haematopoiesis showed Crohn’s 
disease-like pathogenesis and intestinal T-cells from patients with Crohn’s 
disease express constitutively activated STAT3 147, 148. 
Dysregulation of STAT signaling pathways has been demonstrated to 
contribute malignant cellular transformations by promoting cell cycle 
progression and/or cell survival. Constitutive activation of Jak and STAT 
proteins has been reported in a large and growing number of malignant cell 
lines and human cancers 5, 149. Constitutive activation of STATs is often 
associated with malignant transformation induced by oncogenes coding for 
oncogenic tyrosine kineses like members of the Src, Abl or Ras family. Also a 
constitutive active STAT3 (STAT3-C; substitution of two cysteine residues in 
the SH2 domain) could function as oncogene independently of a tyrosine 
kinase oncogene. This molecule is capable of driving transcription and induces 
cell transformation 150. Constitutative activated STAT3 and STAT5 participate 
in oncogenesis through upregulation of genes encoding apoptosis inhibitors 
like Mcl-1, Bcl-XL and Bcl-2 to promote cell survival 151, 152 and cell cycle 
regulators like cyclins D1, 2, 3 and A, c-myc, cdc25A to promote cell cycle G1 
to S phase transition 153, 154 and inducers of angiogenesis like VEGF 155. 
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1.4 Hepatitis C virus (HCV) 
 
Hepatitis C virus is a small, enveloped, positive single-stranded RNA virus 
that belongs to the Flaviviridae Family and the genus Hepacivirus.  Based on 
sequence similarities the different HCV strains are divided into 6 different 
genotypes (nr 1-6) and a large group of subtypes (a, b, ect.). The most 
important way of transmission is by direct blood contact. The initial infection 
is usually asymptomatic. Between 40-85% of infected patients do not clear the 
virus and develop chronic HCV 156, 157. More than 170 million people 
worldwide are chronically infected 157, 158. Chronic HCV patients can develop 
progressive liver fibrosis, cirrhosis with as result portal hypertension and liver 
failure (approx. 10-20% of cases after 10-20 years) and finally hepatocellular 
carcinoma (HCC) (75% of cirrhosis cases after 20-30 years, incidence of 1-4% 
per year) 156, 157, 159. 
HCV infected patients are treated with a combination therapy of pegylated 
IFNα-2a or 2b and ribavirin. Pegylation of IFNα increases the half life of IFNα 
from 5-6 hours to several days. The virological response is defined by a 
reduction of HCV RNA in serum and ideally by the absence of detectable HCV 
RNA by qualitative RT-PCR. HCV genotypes 1 and 4 show a 40-60% response 
rate after 48 weeks of combined antiviral treatment whereas genotype 2 and 3 
show a 75-85% response rate 156. 
 
Although a HCV-specific immune response is generated, there is not enough 
control over viral replication to terminate persistent infection or to resolve 
chronic infection. There is evidence that both CD4+ and CD8+ T-cell 
responses are crucial for the clearance of viral load. In chronic infection, T-cell 
responses are to HCV significantly impaired 160. It has been hypothesized that 
HCV avoids the induction of a strong innate or adaptive immune response 
during early infection. It was believed that the vigor and quality of the 
antiviral CD8+ T-cell response determines the outcome of acute HCV 
infection. However, studies in chimpanzee have shown that the clearance of 
HCV, derived from an infectious full-length HCV genotype 1b cDNA, was not 
correlated with T-cell responses. Two of four infected chimpanzees cleared the 
infection to undetectable levels for more than 12 months, but all four 
displayed weak and transient Thelper-cell responses during acute infection 161.  
The production of a protecting antibody response to HCV following acute 
infection is delayed. Crossreactive neutralizing antibodies against 
heterologous HCV viruses seem to appear only between 33 and 111 weeks of 
infection. Before this period only strain-specific neutralizing antibodies are 
thought to be generated 162.  
 
1.4.1 Genomic organization of HCV and functions of viral proteins 
The HCV genome (approximately 9.6 kb) contains a single long open reading 
frame encoding a polyprotein precursor of approximately 3100 aa that is post-
translationally cleaved by both host and viral proteases to produce 10 
structural and nonstructural proteins (Figure 5) 163-165. The structural proteins 
which are coding at the N-terminal of the polyprotein include the 
nucleocapsid core protein, envelope glycoproteins E1 and E2 and p7. The 
nonstructural region encodes for NS2, NS3, NS4a, NS4b, NS5a and NS5b 166.  
The nucleocapsid core protein forms together with the HCV RNA the HCV 
nucleocapsid. In addition has experimentally been suggested that HCV core 
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protein plays a role in gene transcription, cell proliferation, cell death, cell 
signaling, lipid metabolism and host immune responses 167. The E1 and E2 
envelope glycoproteins are believed to be essential for host-cell entry by 
binding to receptors and inducing fusion with a host-cell membrane. The p7 
protein belongs to the viroporin family and can form an ion channel and might 
therefore play a role in viral particle release and maturation 168. The 
nonstructural proteins are involved in polyprotein processing and viral 
replication. The junction between NS2 and NS3 encodes for a NS2-NS3 zinc-
dependent metalloproteinase. The N-terminal of NS3 encodes for a serine 
proteinase, and the C-terminal region of NS3 includes RNA helicase and 
NTPase activities. NS4b is an integral membrane protein that appears to play 
a role in the formation of the replication complex 169. 
 
 
 
 
 
Figure 5. Schematic organization of the Hepatitis C virus (HCV) genome. The 
genome is depicted with the 5’ containing the IRES and the 3’ non-translated region (NTR or 
NC, non-coding in this picture).  The open reading frame of the polyprotein is depicted as 
rectangle showing the process of translation and positions of post-translational cleavage sites 
by arrows.  The individual functional HCV proteins and their functions are listed at the 
bottom. Picture is taken from a publication by JM Pawlotsky 157. 
 
 
NS5a is a polyphosphorylated protein of unknown function. NS5a has been 
reported to be involved in the inhibition of the antiviral actions of IFN by 
interacting with PKR, in transcriptional activation and in regulation of cell 
growth and cellular signaling pathways. Recent structural analyses of NS5a 
revealed that NS5a contains a membrane anchor domain that is likely 
involved in specific interactions essential for the assembly of the HCV 
replication complex 170. NS5b is the RNA-dependent RNA polymerase and 
belongs to the family of tail-anchored proteins. NS5b C-terminal membrane 
Chapter 1 
  31
insertion sequence traverses the phospholipid bilayer as a transmembrane 
segment and believed to be a target for specific inhibitors 171.  
 
1.4.2 HCV polyprotein processing and replication 
The HCV replication system is only partly understood, however based on its 
similarity to other Flaviviridae has the following model been proposed. The 
envelope glycoprotein complex E1-E2 is expressed on the surface of the HCV 
particle. Because the HCV particles have been shown to associate with low 
density lipoproteins (LDL) in serum, it has been suggested that HCV infection 
may occur through binding of LDL with the LDL receptor. Furthermore has 
the LDL receptor been shown to mediate HCV internalization by binding to 
virion-associated LDL particles 172. However they did not show that these 
interactions lead to productive infection.  
Sequences in the 5' and 3' termini of plus-strand RNA viruses harbor cis-
acting elements important for efficient translation and replication. After 
entering the cell the viral protein translation is initiated by the ribosome 
binding to the internal ribosomal entry site (IRES) in the 341-nucleotide-long 
5’ non-translated region (NTR). The IRES is located downstream of an about 
40-nucleotide-long sequence of unknown function. This 40-nucleotide long 
sequence was characterized to be required for RNA replication, deletions 
introduced into the 5' terminal 40 nucleotides abolished RNA replication but 
only moderately affected translation 173. The 5’ and 3’ NTRs are highly 
conserved in all genotypes and an interesting subject for investigations 
concerning the development of antiviral therapies against HCV infection 174.  
The polyprotein is subsequently synthesized and co- and posttranslational 
cleaved by cellular and viral proteases at the level of the endoplasmic 
reticulum.  
 
 
 
 
 
 
Figure 6. Schematic representation of the polyprotein processing and the 
location of the HCV proteins relative to the endoplasmic reticulum membrane. 
The structural proteins (C, core protein; E1 and E2, envelope glycoproteins and p7) and the 
nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) are shown. Picture is taken 
from a publication by JM Pawlotsky 157. 
 
 
The structural proteins are cleaved by host-cell signal peptidases. The 
nonstructural proteins are produced by cleavage by NS2-NS3 zinc-dependent 
metalloproteinase, located at the NS2-NS3 junction, which separates NS2 
from NS3. The NS3 serine proteinase, located at the N-terminal of NS3, is in 
association with NS4a, responsible for the cleavage of the remaining NS 
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proteins 175. A schematically representation of the anchor regions of the HCV 
proteins within the endoplasmic reticulum membrane is shown in Figure 6.  
 
In tetracycline-regulated cell lines inducibly expressing the entire HCV 
polyprotein has been demonstrated that intracellular membrane changes, 
called membranous web, were induced by the expression of all structural and 
nonstructural proteins in context of the entire HCV polyprotein. All HCV 
proteins were found to be associated with a membranous web, which consists 
of small vesicles embedded in a membranous matrix. Formation of the 
membranous web seems to be induced by the NS4b protein. A similar 
structure has also been found in the infected livers of chimpanzees 176. 
Fluorescence in situ hybridization (FISH), EM-in situ hybridization and 
metabolic labeling with 5’-bromouridine 5’-triphosphate in presence of 
actinomycin D showed that the membranous web is the site of viral RNA 
synthesis and therefore represents the replication complex of HCV 177. The 
HCV positive strand RNA is used as template for the synthesis of a negative 
strand RNA, which will serve as a template for the synthesis of positive strand 
RNA molecules that are through interaction with core proteins encapsidated 
in newly formed virions or serve as mRNA to generate viral proteins. The 
immature viral nucleocapsid particles are released to the ER lumen and are 
then transported to the Golgi apparatus where the envelope glycoproteins 
mature (glycosylation) and the final viral particles are formed. Subsequently 
are the viral proteins released from the cell through the ER membrane and 
cytoplasm 157, 167, 178. 
 
1.4.3 Models to study HCV escape of immune response 
HCV has a replication rate of about 1010-1012 new virions per day 179. The high 
replication rate, in combination with the absence of any HCV polymerase 
proofreading ability, gives rise to viral quasispecies, which provide a 
mechanism for escaping host immune responses. The genetic instability of 
HCV also makes it difficult to develop vaccines. Furthermore it is probably 
that HCV viral proteins interfere with the host cellular functions by down-
regulating processes unfavorable and up-regulating processes favorable for 
virus replication and persistence. Since a high percentage of infected patients 
do not respond to combined treatment of pegylated IFNα and ribavirin, it is 
necessary to investigate host-virus interaction and the mechanisms behind 
resistance against antiviral response and treatment by IFNα 157, 165.  
Since cells and small animals can not be infected with HCV, serving as model 
for replicating HCV, several models has been developed to study HCV viral 
proteins interference with IFN response and HCV viral structure and life cycle 
180. Continuous human osteosarcoma cell lines allowing tetracycline-regulated 
expression of the full length HCV open reading frame have been developed by 
Moradpour et al. 181. A replicon system to study HCV replication was 
developed by Lohmann et al. 182. They developed subgenomic and full-length 
replicons consisting of the 5’ end of HCV including the IRES and 12 codons of 
the core protein, which is fused in frame with a neomycin resistance gene, the 
EMCV IRES to drive translation of the HCV structural and/or nonstructural 
proteins and the 3’NTR of HCV. The chimpanzee is the only animal model for 
HCV infection. However they have a very high viral clearance rate, thus are 
this not useful models to study persistent infection 183. HCV transgenic mice 
have been raised expressing single HCV viral proteins 184, 185 or in 
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combinations 186, 187. Also mouse models expressing all HCV viral proteins 
have been developed (see Chapter 2) 129 and HCV infected mice with human 
livers 188. 
Novel therapies for HCV include use of specific immunoglobulins against HCV 
189, DNA vaccines on its own or in combination with cytokines 190 and 
targeting of IRES mediated translation to block HCV replication 191. 
 
 
1.5 Liver cell regeneration 
 
1.5.1 Liver  
The liver is the largest organ of the human body. Its weight makes about 2.5% 
of the body weight in a human adult. The human liver consists of a main left 
and right lobe and two accessory lobes. The mouse liver contains three lobes, a 
middle, left and right lobe, from which the middle lobe is divided in two parts. 
Two-third of the liver cells are hepatocytes, they are responsible for glucose 
metabolism and uptake of lipids, amino acids and vitamins. Other cells 
include biliary epithelial cells, hepatic stellate cells and Kupffer cells, which 
are liver specific macrophages. The functional unit of the liver is the acinus, 
consisting of hepatic cells in between two terminal venules. The blood is 
supplied into the terminal portal venule and released into the sinusoids; from 
there the blood is collected in the central venule of the acinus and transported 
out of the liver via the hepatic veins. 
 
1.5.2 Regulation of liver regeneration 
Under normal physiological circumstances only a small percentage (0.0012% 
to 0.01%) of the hepatocytes proliferate, however after toxic injury or surgical 
resection the proliferative ability of the remaining hepatocytes is enormous. 
Within two weeks (after a loss of up to two thirds) the liver mass will grow 
back to its original size without losing its specific functions. The liver has the 
unique capacity to regulate its growth and mass. Studies with hepatic 
resections in larger animals and humans have shown that the regenerative 
response is proportional to the amount of liver removed and even 
proportional to the body size of where the liver mass is placed in, in case of a 
transplantation. So the size of the liver mass can be regulated positively as well 
as negatively 192, 193. The experimental model to study liver regeneration is 
partial hepatectomy (PH), developed by Higgins and Anderson 194, in which 
two-thirds of the liver of mouse or rat is removed. The excised lobes do not 
regrow; instead do the remaining lobes enlarge, undergoing compensatory 
hyperplasia 195.  Regeneration is induced by extrahepatic signals, which are 
probably a combination of interacting hormones (e.g. insulin, glucagon, 
growth hormone and glucocorticoids), growth factors (epidermal growth 
factor (EGF), transforming growth factorα and β (TGFα andβ), hepatocyte 
growth factor (HGF)) and cytokines (IL-1, IL-6, TNFα,) 195. When primed 
hepatocytes progress from the G0 phase of the cell cycle to G1, move to the S 
phase and undergo mitosis. The first peak of DNA synthesis occurs in mice 
and rat at 24 to 40 hours after PH and at 180 to 200 hours in human 193. The 
following priming model has been proposed for the factors involved in the 
response to PH to induce regeneration. Directly after PH are TNFα and IL-6 
secreted in response to gut-derived lipopolysaccharide. They induce 
hepatocyte to respond to growth factors (G0 to G1). The growth factors (HGF, 
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TGFα and EGF) allow hepatocytes to progress through the cell cycle (G1 to S). 
Insulin and epinephrine are growth promoting hormones and support the 
activity of the growth factors. Growth inhibitory factors activin A and TGFβ 
are down regulated during liver cell regeneration by suppressors of growth 
inhibitors LAP (latency associated peptide), inhibitor of TGFβ and follistatin, 
inhibitor of activin 192. 
Within 30 min after PH immediate early genes (like transcription factors c-
myc, c-fos, c-jun and C/EBPβ) are induced, several of these are target genes of 
STAT3 and NFκB 196. STAT3 is activated by IL-6, and NFκB by TNFα. Liver 
regeneration studies in IL-6 and TNFR1 deficient mice showed high mortality 
after PH and impaired DNA synthesis in hepatocytes. The regeneration was 
delayed but in the surviving animals did the liver mass recover completely 197. 
Mice overexpressing human IL-6 from Chinese hamster ovary cells showed 
massive hepatocyte proliferation and hepatomegaly 198. Blindenbacher et al. 
showed that IL-6 was not required for liver cell proliferation since some KO 
animals did regenerate normally without IL-6 substitution. STAT3 target 
genes cyclin D1 and c-myc were not induced in these animals, and cell cycle 
progression was thought to take place with help of compensatory cyclin D3-
CDK6 activation. The more important role of IL-6 in liver cell regeneration is 
induction of acute phase response. By acute phase protein activation induces 
IL-6 protective, i.e. anti-apoptotic pathways in hepatocytes 199. Il-6 can induce 
expression of acute phase proteins through two kind of responsive elements, 
type I and type II. Type I IL-6 responsive elements are binding sites for 
CAAT/enhancer binding protein (C/EBP) transcription factor and have been 
identified on the class I genes for haptoglobin, α1-acid glycoprotein (AGP), 
hemopexin (Hpx), complement component 3 (C3), C-reactive protein (CRP), 
serum amyloid A (SAA), serum amyloid P (SAP). Class II genes, like α2-
macroglobulin (α2M), fibrinogen, haptoglobin and α1-antitrypsin are 
regulated by type II IL-6 response elements (i.e. GAS-like response elements), 
which can be bound by STAT3. GAS-like motifs have also been identified on 
class I gene promoters 72, 200. 
 
New models to study liver regeneration make use of hematopoietic stem cells 
(HPCs) or bone marrow mesenchymal stem cells, of which has been proven 
that they are capable of generating many different types of cells, including 
hepatocytes. Production of hepatocytes from these stem cells, injected in mice 
with injured livers should lead to liver repopulation 201. Bone marrow stem 
cells have however a very low capacity to generate hepatocytes in injured livers 
202-204. The most successful examples of hepatocyte generation from bone 
marrow stem cells are the production of hepatocytes in cultures of multipotent 
adult progenitor cells (MAPCs) 205, 206 and the repopulation of livers in 
fumarylacetoacetate hydrolase (FAH)-deficient mice by transplanted HSCs 207. 
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1.6 Aim of this thesis 
 
In general, the aim of this thesis was to understand in more detail the 
interference of HCV with Jak-STAT signaling and to develop new gain-of-
function models to study the role of STAT signaling in liver pathophysiology.  
 
Previous studies have suggested that interference of HCV proteins with IFNα 
induced signaling through the Jak-STAT pathway could contribute to 
resistance to IFNα treatment and enable HCV to escape the IFNα induced 
antiviral defense and so establish chronic infection. Such interference was 
shown in human osteosarcoma-derived cell lines expressing the entire HCV 
genotype 1a open reading frame under control of a tetracycline dependent 
promoter. When viral proteins were expressed in these cells, IFN induced 
DNA binding of STATs was inhibited and led to an impaired upregulation of 
IFNα target genes 217. Here, we analyzed interferon induced signal 
transduction through the Jak-STAT pathway in transgenic mice that express 
HCV proteins (genotype 1b) in their liver cells, to confirm and get further 
insight in these previous in vitro found observations. Virus challenge 
experiments with LCMV were used to demonstrate the functional importance 
of Jak-STAT inhibition. Footpad swelling assays and vesicular stomatitis virus 
challenge experiments were used to exclude a defect immune response in the 
HCV transgenic mice (chapter 2). On the other hand we aimed to identify the 
HCV gene product(s) responsible for the observed inhibition of Jak-STAT 
signaling. For this purpose, we established a comprehensive panel of the 
osteosarcoma-derived and tetracycline-regulated cell lines allowing the 
expression of HCV genotype 1a or 1b structural and genotype 1a nonstructural 
proteins either alone or in different combinations. IFNα induced STAT 
activation was analyzed and compared in the diverse cell lines with EMSAs 
and Western blots (chapter 3). 
 
We aimed to develop conditional gain-of-function mouse models to study the 
function of STAT1, STAT3 or STAT5a in various pathophysiological conditions, 
like HCV infection, cell regeneration or oncogenesis in liver. Therefore we have 
generated conditionally active forms of these STAT proteins, designed to be 
activated independently of their natural ligands and to mimic STAT signaling 
(i.e. fusion proteins between STAT proteins and the modified ligand binding 
domain of the estrogen receptor). In addition, for each STAT fusion protein 
three mutants were generated to study its functionality and ability to be 
activated. First, the wild-type and mutant fusion proteins for STAT1 and 
STAT3 were expressed in mouse embryonic fibroblasts in order to compare 
and analyze their ability to be activated and to mimic STAT signaling (chapter 
4). Next, the transgenic mice were generated, designed to express wild-type 
STAT3 or SH2 domain mutant STAT5a fusion proteins under control of the 
liver-specific albumin promoter. The transgenic founders and F1 offspring 
were identified by PCR (chapter 5).  
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Abstract 
 
Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis and 
hepatocellular carcinoma worldwide. The majority of patients treated with 
interferon alpha do not have a sustained response with clearance of the virus. 
The molecular mechanisms underlying interferon resistance are poorly 
understood. Interferon induced activation of the Jak-STAT signal 
transduction pathway is essential for the induction of an antiviral state. 
Interference of viral proteins with the Jak-STAT pathway could be responsible 
for interferon resistance in patients with chronic HCV. 
We have analyzed interferon induced signal transduction through the Jak-
STAT pathway in transgenic mice that express HCV proteins in their liver 
cells. STAT activation was investigated with Western blots, 
immunofluoresence and electrophoretic mobility shift assays (EMSA). Virus 
challenge experiments with LCMV were used to demonstrate the functional 
importance of Jak-STAT inhibition. 
STAT signaling was found to be strongly inhibited in liver cells of HCV 
transgenic mice. The inhibition occurred in the nucleus and blocked binding 
of STAT transcription factors to the promoters of interferon stimulated genes. 
Tyrosine phosphorylation of STAT proteins by Janus kinases at the interferon 
receptor was not inhibited. This lack in interferon response resulted in an 
enhanced susceptibility of the transgenic mice to infection with a hepatotropic 
strain of LCMV. 
Interferon induced intracellular signaling is impaired in HCV transgenic mice. 
Interference of HCV proteins with interferon induced intracellular signaling 
could be an important mechanism of viral persistence and treatment 
resistance. 
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Introduction 
 
The majority of patients infected with HCV develop chronic liver disease that 
may progress to cirrhosis and hepatocellular carcinoma 208-210. The 
mechanisms by which the virus evades clearance by the host immune system 
despite a polyclonal and multispecific T-cell response and the presence of 
antibodies against all viral proteins are poorly understood 211. There is good 
evidence in hepatitis B virus and lymphocytic choriomeningitis virus infection 
that noncytolytic, cytokine-mediated antiviral mechanisms play a key role in 
viral clearance from liver cells 212, 213. Interferons (IFNs) induce an antiviral 
state in hepatocytes through the transcriptional induction of several dozens of 
target genes in the cell nucleus. After binding to their cognate receptors on the 
cell membrane, IFNs activate the Jak-STAT signal transduction pathway 18, 65. 
Type I IFNs (IFNα and β) bind to heterodimeric receptors consisting of IFNα 
receptor 1 and 2 (IFNAR1, IFNAR2). Ligand binding results in activation of 
two receptor-associated protein tyrosine kinases, Jak1 and Tyk2. The activated 
receptor kinase complex then recruits and activates signal transducer and 
activator of transcription 1 (STAT1), STAT2 and STAT3 2, 214. STAT1 and 
STAT2 combine with a third transcription factor, p48 or interferon response 
factor 9 (IRF9), to form interferon stimulated gene factor 3 (ISGF3) 18. ISGF3 
binds to interferon stimulated response elements (ISREs) in the promoters of 
IFN stimulated genes (ISGs). Alternatively, the IFN activated STAT1 and 
STAT3 can form homodimers or STAT1-STAT3 heterodimers. These STAT 
dimers bind a different class of response elements, the gamma activated 
sequence (GAS) elements. Once bound to the promoters of ISGs, STATs 
induce the transcription of genes involved in the generation of an antiviral 
state 1, 65. Signaling through the Jak-STAT pathway is of critical importance, 
since most IFN induced cellular effects are lost upon deletion of STAT1 in 
mice 102, 215 or in cell lines 51. Therefore, interference with Jak and STATs could 
be a mechanism of viral persistence, and indeed, viruses such as adenovirus, 
cytomegalovirus, mumps virus and HBV have been shown to interfere with 
Jak-STAT signaling 133, 137, 216. We hypothesized that interference with IFN 
signaling could enable HCV to escape the innate immune system. In previous 
work we have found evidence for such an interference with Jak-STAT 
signaling in human osteosarcoma cell lines with an inducible transgene 
comprising the complete open reading frame (ORF) of a HCV genotype 1a 
isolate 181, 217. When viral proteins are expressed in these cells, IFN induced 
activation of ISGF3 is blocked and the activation of the STAT1/3 dimers is 
inhibited. Here, we report our analysis of IFN induced Jak-STAT signaling in 
liver cells of mice that express HCV proteins from a transgene with a liver 
specific promoter. We have found a strong inhibition of ISGF3 activation in 
these mice. When infected with lymphocytic choriomeningitis virus strain WE 
(LCMV-WE), the transgenic mice could not control the viral replication and 
suffered from a severe hepatitis. An inhibition of the interferon induced 
antiviral defenses in hepatocytes might enable HCV to establish a chronic 
infection in the majority of patients, and could contribute to resistance to 
treatment with IFNα. 
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Materials and Methods 
 
Animals 
A 9.0 kb cDNA fragment derived from plasmid pCD(38-9.4) 218 that covers the 
HCV ORF (aa 3 to 3010) was used for the generation of the transgenic mice. 
The HCV cDNA was inserted into a A1AT minigene by homologous 
recombination in bacterial cells 219. Donor plasmid p(PucII-V ex A1AT) was 
first generated. This construct carries exons II, IV and V and intron IV of the 
A1AT gene, and it contains a multiple cloning site between exon II and exon 
IV. The HCV cDNA, spanning from nt 339 to 9416, flanked by two Pac I sites 
was then inserted into the Pac I site of plasmid p(PucII-V ex A1AT) such that 
the transgene ORF starts from the ATG of A1AT (in exon II), coding a fusion 
protein formed by 32 additional aa at the N-terminus of the  HCV polyprotein. 
DH1 cells were used for the homologous recombination using as acceptor the 
recombinant cosmid containing the entire A1AT gene as described 220. 
Transgenic C57BL/6 were generated by pronuclear microinjection in one-cell 
stage embryos of inbred C57BL/6 by BRL (BRL, Füllinsdorf, Switzerland) as 
described 221. Genotype analysis was performed by Southern blot analysis on 
10 µg of total genomic DNA extracted from tail specimens using a HCV cDNA 
fragment as probe (spanning E2-NS3). A full description of the mice will be 
published elsewhere. The inbred C57BL/6 control mice were purchased from 
the same provider that generated the transgenic mice (BRL; Füllinsdorf, 
Switzerland). Mice were bred in a specific pathogen free environment under 
standard conditions. For all experiments described in this manuscript, 7 to 14 
week old animals were used, and controls and transgenic mice were age and 
sex matched. The study was approved by the animal care committee of the 
Kanton Basel. 
 
Northern blot 
RNA was isolated from frozen tissues using Trizol reagent (Life Technologies) 
according to the manufacturer’s instructions. Total RNA (20µg) was used in 
Northern blot analysis. HCV cDNA fragment including regions E2-NS3 and a 
28S ribosomal RNA fragment were used as probe and labeled by random 
priming. 
 
Western blots 
For the Western blot analysis whole cell extracts were prepared from the 
middle lobe of the mouse liver. The lobe was homogenized in lysis buffer ( 50 
mM Tris pH 8, 280 mM NaCl, 0.5% NP40, 0.2 mM EDTA, 2 mM EGTA, 10% 
glycerol, 100 µM NaVO4, 1 mM PMSF, and proteinase inhibitors), incubated 
30 minutes on a rotating wheel at 4 °C, and centrifuged at 14’000 x g for 5 
minutes. To analyze the liver extracts for the presence of HCV core protein, 75 
µg of total protein per sample was loaded onto a 12 % SDS-PAGE gel. The 
membranes were probed with the murine monoclonal antibody C7-50 directed 
against a conserved, linear epitope in the aminoterminal region of the HCV 
core protein 222. For Western blot analysis of STAT phosphorylation, 100 µM 
NaVO4 was added to the lysis buffer. Tyrosine phosphorylation of STAT1 and 
STAT3 was tested using the phospho-STAT1 specific antibody 9171S and the 
phospho-STAT3 specific antibody 9173S (New England BioLabs, Inc., Beverly, 
Massachusetts). Total amounts of STAT1 and STAT3 were determined with 
polyclonal antibodies sc346 and sc482, respectively (both from Santa Cruz 
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Biotechnology, Inc., Santa Cruz, California). For cytoplasmic/nuclear extracts, 
mouse livers were homogenized in 200 µl of Buffer A containing 20 mM 
Hepes pH 7.6, 10 mM NaCl, 3 mM MgCl2, 0.1% NP-40, 10% glycerol, 0.2 mM 
EDTA and 1 mM DTT. After centrifugation at 2000 rpm for 5 min, 
supernatant (cytoplasmic extracts) was removed and the pellet was washed 
with 200 µl of Buffer B containing 20 mM Hepes pH 7.6, 0.2 mM EDTA, 20% 
glycerol and 1 mM DTT, and then centrifuged at 3000 rpm for 5 min. The 
pellet was then resuspended in 150 µl of Buffer C containing 20 mM Hepes pH 
7.6, 400 mM NaCl, 0.2% EDTA, 20% glycerol and 1mM DTT. This nuclear 
extract was cleared by centrifugation and used for Western blot analysis. 
 
Immunostaining of liver sections 
Cryosections were prepared at a thickness of 7 µm and fixed in 4% 
paraformaldehyde. They were then permeabilized with 0.1% Triton X-100, 
blocked with 3% BSA, and incubated overnight at 37°C with phospho-STAT1 
specific antibody 9173S (New England Biolabs, Inc., Beverly, Massachusetts) 
or anti-core monoclonal antibody C7-50 222. After several washes, sections 
were incubated with secondary antibodies labeled with Cy3 or with FITC for 
90 min at RT (Molecular Probes, Inc., Eugene, Oregon). Nuclei were stained 
with Hoechst stain diluted to 1/200 and sections were mounted with 
Fluorsave Reagent (Calbiochem, La Jolla, California). 
 
Electrophoretic mobility shift assays (EMSA) 
Mice were injected with the indicated doses of murine IFNα (Calbiochem, La 
Jolla, California) or TNFα (Sigma, Buchs, Switzerland) into the tail vein. The 
animals were euthanized 20 minutes later. Nuclear extracts and EMSA were 
done as described previously 223. The oligonucleotides used have the following 
sequences: ISRE = 5’-GAAAGGGAAACCGAAACTGAAGC-3’, m67 = 5’-CATT 
TCCCGTAAATCAT-3’, NFkB consensus site = AGTTGAGGGGACTTTCCCA 
GGC-3’. The experiments were repeated several times, using also murine IFNα 
from a different provider (Sigma, Buchs, Switzerland). 
 
LCMV infections 
LCMV-WE was originally obtained from Dr. F. Lehmann-Grube (Hamburg, 
Germany) and was propagated on L929 cells. C57BL/6 and B6 HCV 
transgenic mice were infected i.v. with LCMV strain WE with the indicated 
dose. Virus titers in the liver were determined in an LCMV infectious focus 
assay as previously described 224. For the LCMV footpad swelling reaction, 
mice were infected with 200 PFU LCMV-WE into the hind footpad and the 
swelling was measured daily with a spring-loaded caliper. Assays for serum 
concentration of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were performed at the Department of Clinical 
Chemistry, University Hospital Zurich, using photometric assays on a Hitachi 
747 autoanalyzer (Tokyo, Japan). 
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Results 
 
HCV transgenic mice 
To assess the effects of HCV proteins on IFN induced intracellular signaling in 
liver cells in vivo, we have generated a transgenic C57BL/6 mouse line 
carrying the entire ORF of a HCV genotype 1b isolate 163 under the control of 
an α1-antitrypsin promoter. The transgenic mice were designated B6HCV. 
B6HCV mice are healthy. With advanced age, more than 70% of the mice 
develop fatty liver, and, interestingly, a diffuse T-cell infiltration is observed in 
more than half of the mice. These observations are the subject of a separate 
manuscript. Since both liver steatosis and lymphocyte infiltrates could 
potentially influence signaling through the Jak-STAT pathway, we used for all 
our experiments 7 to 14 week old animals. In these younger mice, analysis of 
formalin fixed liver sections showed no inflammatory infiltrates or liver 
steatosis (Figure 1A). Controls were age and sex matched. In liver cell extracts 
of B6HCV mice a single full length mRNA transcript of the transgene of 
approximately 10kb can be detected by Northern blot (Figure 1B), and strong 
expression of HCV core protein was found by Western blot (Figure 1C). The 
core protein is fused on its N-terminus to 32 aa of α1-antitrypsin, and has a 
calculated molecular weight of 24 kDa. We could not detect additional HCV 
proteins by Western blot. Immunostaining of liver sections showed HCV core 
expression in hepatocytes (Figure 1D).  
 
Similar to findings in other transgenic mice, the expression level of the 
transgene is not uniform. In some hepatocytes, no core protein can be 
detected, while others show strong signals. Core protein is found both in the 
cytoplasm and the nucleus of hepatocytes. The number of hepatocyte nuclei 
that stained positive was counted in liver sections from three mice. The mean 
percentage of nuclei containing core protein was 29% (with a standard error of 
the mean of 6%). Nuclear localization of the HCV core protein is a debated 
issue. While some authors have found core protein only in the cytoplasm 225 
others have found an additional nuclear localization of the protein in vitro 226 
and in transgenic mice in vivo 184. In our transgenic mouse model, the high 
expression level of core protein in a subgroup of hepatocytes might allow the 
detection of core protein in the nucleus. Alternatively, the fusion of the first 32 
aa from α1-antitrypsin to the N-terminus of core protein might have changed 
the subcellular distribution of core. 
 
 
Figure 1. Expression of HCV core protein in liver cells of B6HCV mice. (A) 
Formalin fixed liver sections of C57BL/6 and of B6HCV mice were stained with hematoxilin-
eosin according to standard procedures. Neither inflammatory infiltrates nor liver steatosis is 
present in these 14-week-old animals. The yellow size bars indicate 100 µm. (B) Liver specific 
expression of the A1AT-HCV transgene. Northern blot analysis was performed using RNA 
extracted from 1 month old transgenic mouse tissues probed with a HCV specific probe. 20 µg 
of total RNA were loaded per lane. A probe for the 28S ribosomal RNA was used as an 
internal control. Sg, salivary glands; M, muscle; Sk, skin; H, heart; K, kidney; Sp, spleen; L, 
liver of transgenic mice; C, control = liver of wild type mouse. (C) Liver cell extract from a 
C57BL/6 (lane 1) and a B6HCV mouse (lane 2) were analyzed for the presence of HCV core 
protein by Western blot. The asterisk indicates the core protein. The positions of the 
molecular weight markers are indicated to the left. (D) HCV core protein can be detected by 
immunostaining in liver cells of B6HCV mice. Core protein is present both in the cytoplasm 
and in the nucleus (arrows). The size bars indicate 20 µm. 
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IFN induced Jak-STAT signaling 
In a first set of experiments B6HCV and control C57BL/6 mice were injected 
with murine IFNα (mIFNα) into the tail vein (Figure 2A). The animals were 
euthanized 20 minutes later. Nuclear extracts were prepared from liver cells 
and tested for ISGF3 induction by electrophoretic mobility shift assays 
(EMSA) using an ISRE oligonucleotide probe. A total of 12 control mice and 16 
B6HCV mice were used 4 independent experiments with 5 to 10 mice each. In 
C57BL/6 mice a strong ISGF3 shift was detected after treatment with 1000 IU 
mIFNα /g body weight, whereas the same dose was ineffective in B6HCV mice 
(Figure 2A, lanes 6, 7 and 8, respectively). This inhibition of STAT signaling 
could be overcome by higher doses of mIFNα. The intravenous (i.v.) injection 
of 4000 IU mIFNα/g body weight induces a strong STAT activation as shown 
by EMSA with the m67 probe (Figure 2B). The inhibition of STAT signaling is 
not due to non specific toxic effects of the viral proteins, since signaling of 
tumor necrosis factor α (TNFα) through NFκB was not inhibited (Figure 2C). 
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Figure 2. Activation of STATs after intravenous cytokine injections in B6HCV 
and C57BL/6 mice. (A) Nuclear extracts from liver cells were tested by EMSA with the 
ISRE oligonucleotide. An ISGF3 shift (arrow) is readily detected in C57BL/6 mice injected 
with 1000 IU mIFNα/g body weight, but not in B6HCV mice. C57BL/6 and B6HCV mice were 
injected with PBS, 100 IU mIFNα/g body weight, or 1000 IU mIFNα/g body weight as 
indicated. (B) EMSA with the m67 oligonucleotide. The positions of gel shift complexes 
containing STAT3 homodimers, STAT1-STAT3 heterodimers, and STAT1 homodimers are 
indicated. No induction of STAT gel shift complexes can be detected in both C57BL/6 and 
B6HCV mice after injection with 250 IU mIFNα/g body weight (lanes 1 and 2, respectively). 
Injection of 1000 IU mIFNα/g body weight induces STAT dimers in a C57BL/6 mouse (lane 
3) but not in a B6HCV mouse (lane 4). In both the C57BL/6 (lane 5) and the B6HCV mouse 
(lane 6), STAT gel shifts are induced by 4000 IU mIFNα/g body weight. (C) TNFα induced 
NFκB activation is not impaired in B6HCV mice. EMSA with NFκB consensus 
oligonucleotide. Injection of 5 ng TNFα/g body weight results in NFκB shifts (arrow) in both a 
C57BL/6 mouse (lane 1) and in two B6HCV mice (lanes 2 and 3). PBS controls are shown in 
lane 4 (C57BL/6) and lane 5 (B6HCV). 
 
 
The absence of ISGF3 and STAT1 and STAT3 homodimer gel shift complexes 
could result from a lack of activation of STATs through tyrosine 
phosphorylation at the IFNα receptor kinase complex. The phosphorylation of 
STATs on a single tyrosine residue carboxy-terminal of their SH2 domain is 
required for dimerization and nuclear translocation 48. In HCV protein 
containing liver cells of B6HCV mice this decisive STAT activation event could 
be impaired through a downregulation of IFNAR1, IFNAR2, Jak1, Tyk2 or the 
STATs, or through the induction of suppressor of cytokine signaling 1 or 3 
(SOCS1 or SOCS3)227. However, tyrosine phosphorylation of STAT1 and 
STAT3 after injection of 1000 IU mIFNα/g body weight is not impaired in the 
liver of B6HCV mice compared to C57BL/6 control mice (Figure 3A). This 
observation is in accordance with our previous findings in inducible cell lines 
in vitro 217. 
 
 
Figure 3. Tyrosine phosphorylation and nuclear translocation of STATs. (A) 
Tyrosine phosphorylation of STATs is not impaired in B6HCV mice compared to C57BL/6 
mice. Mice were injected i.v. with PBS or with 1000 IU mIFNα/g body weight and euthanized 
20 minutes later. The arrows indicate STAT1 and STAT3, respectively. The position of the 116 
kDa and 85 kDa size markers is shown.  
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(B) Nuclear import of phospho-STAT1 is not inhibited in B6HCV mice. Cytoplasmic as well as 
nuclear extracts were prepared from livers of control mice and HCV transgenic mice 20 min 
after injection with PBS or 1000 IU mIFNα/g body weight as indicated. Tyrosine 
phosphorylated STAT1 was detected by Western blot with phospho-STAT1 specific antibodies. 
(C) Phospho-STAT1 nuclear translocation is impaired in B6HCV mice. The scale bar 
represents 50 µm. Hepatocytes with phospho-STAT1 nuclear localization were counted under 
a fluorescent microscope. Five C57BL/6 mice and four B6HCV mice were analyzed. For each 
animal, ten areas were randomly chosen for counting. About 2000 cells were counted per 
animal. The histogram shows the average percentage of cell nuclei that stain positive with the 
phospho-STAT1 specific antibody 9171S in C57BL/6 and B6HCV mice, respectively. The error 
bars represent the 95% confidence interval for the mean values. 
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Viral proteins could also impair the nuclear translocation of phosphorylated 
STATs. Such a block in nuclear import in the presence of a normal STAT1 
tyrosine phosphorylation at the receptor-kinase complex would result in an 
accumulation of phospho-STAT1 in the cytosol and a relative lack phospho-
STAT1 in the nucleus. However, in both controls and B6HCV mice, most 
phosphorylated STAT1 molecules were found in nuclear extracts and not in 
cytoplasmic extracts (Figure 3B). We conclude that nuclear translocation is 
not significantly impaired in liver cells of HCV transgenic mice. Alternatively, 
viral proteins could stimulate the dephosphorylation of STATs in the nucleus 
through the upregulation of one or more as yet unidentified phosphatases. To 
address this issue with a more quantitative method than western blot 
detection of phospho-STAT1 in cytoplasmic and nuclear extracts, we stained 
cryosections from livers of five C57BL/6 and four B6HCV mice, respectively, 
with a phosphospecific STAT1 antibody (Figure 3C), and counted the number 
of cells that showed nuclear localization of phosphorylated STAT1. All mice 
have been injected i.v. with 1000 IU mIFNα/g body weight and euthanized 20 
minutes later. About 2000 cells were counted for each mouse. The average 
percentage of phospho-STAT1 positive nuclei was 48.0% in C57BL/6 mice 
(standard deviation = 8.3, standard error of the mean = 3.7), but only 31.3% in 
B6HCV mice (standard deviation = 7.9, standard error of the mean = 2.3) 
(Figure 3C). The absence of detectable STAT gel shifts in nuclear extracts from 
B6HCV mice could be explained by this reduction of nuclear phospho-STAT1, 
since the sensitivity and detection limit of the EMSA with liver cell nuclear 
extracts is not known. Alternatively, the DNA binding of phosphorylated 
STAT1 complexes could be inhibited by viral proteins or by endogenous 
inhibitors such as protein inhibitor of activated STAT1 (PIAS1) that would be 
upregulated in the liver cells of B6HCV mice. By Western blots with PIAS1 
antibodies we could not detect increased expression of PIAS1 in liver cells of 
B6HCV mice (data not shown). However, yet unknown inhibitors of STAT 
DNA binding could be involved in the observed inhibition of STAT gel shifts. 
 
Impaired antiviral response in vivo 
We next tested the consequences of impaired IFN signaling for host resistance 
to a viral infection. Susceptibility to LCMV has been shown to be greatly 
increased in mice that lack IFNAR1 61. The hepatotropic strain LCMV-WE is a 
non-cytopathic RNA virus that causes a dose-dependent immunpathology. 
The liver damage is mediated by a cytotoxic T cell response 228. We 
hypothesized that the inhibition of IFN signaling by HCV proteins in liver cells 
of B6HCV transgenic mice would increase the viral replication, and 
consequently result in an increased immunopathological liver inflammation. 
Therefore, transgenic and control mice were injected i.v. with various doses of 
the hepatotropic lymphocytic choriomeningitis virus strain WE (LCMV-WE). 
LCMV-WE infects hepatocytes, Kupffer and sinusoidal endothelial cells 229. In 
support of our hypothesis, B6HCV mice suffered a more severe hepatitis 
(Figure 4). 
 
After injection of 2 x 104 pfu LCMV or 2 x 105 pfu LCMV C57BL/6 controls had 
only a slight increase of serum amino transferase levels at day 8 after infection 
with a return to normal values at day 12 (Figure 4A). The liver histology of 
C57BL/6 mice showed a minimal mononuclear infiltrate in liver sinusoids at 
day 8, and a normal liver at day 12 (Figure 4B). On the contrary, B6HCV mice 
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had very high amino transferase values and liver histology showed a more 
severe hepatitis with diffuse hydropic swelling and ballooning of hepatocytes, 
diffuse intrasinusoidal mononuclear infiltrates and apoptotic hepatocytes 
(Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Increased susceptibility of B6HCV mice to LCMV-WE infection. (A) 
B6HCV (red circles) and C57BL/6 (blue rectangles) mice were injected i.v. with the indicated 
doses of LCMV-WE. Serum alanine amino transferase (ALT) values (U/L) were determined at 
day 0, 4, 8 and 12. Three mice each were used per group and per LCMV-WE dose. The 
rectangles and circles represent mean values; the bars show the standard error of the mean. 
(B) All C57BL/6 and B6HCV mice were euthanized 12 days after i.v. injection of 2 x 105 pfu of 
LCMV. Formalin fixed liver sections were stained with hematoxilin-eosin according to 
standard procedures. Representative samples are shown. Whereas C57BL/6 mice show no 
signs of hepatitis, a moderately severe hepatitis with slight lobular disarray, diffuse 
intrasinusoidal mononuclear infiltrates and apoptotic hepatocytes (arrow) are seen in B6HCV 
mice. The yellow size bars indicate 100 µm. (C) Virus titers were measured 12 days after 
infection with the indicated doses. Results from B6HCV mice are shown in red, controls in 
blue. Two mice each were used per group and LCMV-WE dose. The bars are standard error of 
the means. The assay has a limit of detection at 4.2 log 10 pfu (shown as yellow bar). After 
injection of 2 x 103 pfu in both groups and after injection of 2 x 104 pfu in controls, the values 
were below the limit of detection. 
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A likely explanation for the observed difference between controls and HCV 
transgenic mice is our finding of an increased LCMV replication in livers of 
B6HCV mice (Figure 4C). When measured 12 days after i.v. infection of 2 x 105 
pfu LCMV, the difference in viral replication was up to one hundred fold. This 
increased viral replication is most probably a consequence of the inhibition of 
the IFN induced antiviral defense caused by the interference of HCV proteins 
with the Jak-STAT pathway. Alternatively, the transgene insertion could have 
incidentally resulted in an ineffective CTL response against LCMV, causing an 
insufficient CTL mediated control of LCMV replication. However, local 
infection with LCMV resulted in a normal CTL mediated immunopathology in 
HCV transgenic mice, as shown by footpad-swelling after injection of 200 pfu 
LCMV-WE in the foot of B6HCV and control mice. Both groups showed a 
similar increase of 150-170% 8 days after infection (data not shown). Further 
evidence for an unimpaired immune response in B6HCV mice was obtained 
with VSV challenge experiments. Infection of mice with vesicular stomatitis 
virus (VSV), a neurotropic rhabdovirus with a high mortality rate in mice 
lacking the IFNα receptor 61, was controlled by an equally efficient immune 
response in both C57BL/6 and B6HCV mice. Of three B6HCV and three 
control mice infected with 2 x 106 pfu VSV, all survived (data not shown).  
In an observational study with 12 B6HCV and 12 control mice infected with 
various dosis of LCMV-WE, 6 of 12 B6HCV mice and 2 of 12 controls died 
between 10 and 12 days after infection. The death of the controls is in the 
range of the CTL mediated immunopathology usually observed in wild-type 
mice (around 10-15% mortality). In the case of the B6HCV mice we believe 
that the liver disease contributed to the excess mortality. 
 
Interference of viral proteins with nuclear localization of STATs 
Our observation of a nuclear localization of the HCV core protein in about 
30% of the hepatocytes (Figure 1C) and the 35% reduction of phospho-STAT1 
localized in the nucleus after IFNα treatment in B6HCV mice as compared to 
C57BL/6 mice (Figure 3C) suggested that the two phenomena might be 
interdependent. We therefore performed double staining experiments of liver 
sections from C57BL/6 and B6HCV mice after mIFNα treatment. 
Interestingly, most cells that were strongly stained with antibodies to HCV 
core protein had no detectable phospho-STAT1 in the nucleus (Figure 5B, D 
and F). 
 
 
 
 
 
 
Figure 5. Double immunostaining for HCV core protein and phospho-STAT1 in 
C57BL/6 and B6HCV after injection of mIFNα. (A) Hoechst stain of C57BL/6 mouse 
liver section. (B) Hoechst stain of B6HCV mouse liver section. (C) phospho-STAT1 staining, 
C57BL/6, (D) phospho-STAT1 staining, B6HCV. (E) HCV core protein staining, C57BL/6, 
(F) HCV core protein staining, B6HCV. As expected, no HCV core protein could be detected 
in C57BL/6 mice. In B6HCV mice, approximately 30% of hepatocytes show HCV core protein 
nuclear localization and its presence in the nucleus is negatively correlated with the presence 
of activated STAT1. The white arrows show nuclei of hepatocytes that stain positive for HCV 
core but negative for phospho-STAT1. The blue arrows show hepatocytes with nuclear 
staining for phospho-STAT1 but without nuclear staining for HCV core. The yellow size bar 
indicates 20µm. 
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Discussion 
 
In order to establish a persistent infection in humans, HCV must, at least to a 
degree, evade the antiviral cellular defense mechanisms induced by IFNs. The 
very same defense strategies could also contribute to the observed resistance 
to IFN based treatments in the majority of patients with chronic hepatitis C. 
Over the last years, several groups have reported that HCV proteins NS5A or 
E2 can interfere with the IFN induced antiviral effector protein PKR 230-232. 
These results have been obtained by biochemical methods using purified 
proteins or by analyses of transfected mammalian or yeast cells, and the 
significance of these findings for chronic hepatitis C in patients remains to be 
determined. As an alternative to the inhibition of antiviral effector systems the 
virus could already interfere with IFN induced signaling and thereby prevent 
the induction of these systems. Since Jak-STAT signaling is required for IFN 
induction of an antiviral state, such an inhibition could be a very efficient 
defense strategy for HCV. We report here that HCV proteins expressed from a 
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transgene in mouse liver cells indeed inhibit signaling through the Jak-STAT 
pathway. 
Since HCV can not be propagated in cultured cells and small animal models 
for chronic hepatitis C are still not available, we have generated a transgenic 
mouse that constitutively expresses the entire ORF of a genotype 1b HCV 
isolate. These mice provide an opportunity to study interference of HCV 
proteins with IFN induced signaling or with IFN induced effector systems in 
liver cells in vivo. They have some properties that should be kept in mind. 
First, the expression level of the HCV transgene in hepatocytes is 
heterogeneous. We do not have an explanation for the patchy staining of 
hepatocytes, but similar staining patterns have been reported in other 
transgenic mouse lines 186, 187. We detect strong signals with core specific 
antibodies in about 30% of hepatocytes. However, it is likely that viral 
proteins are expressed in more than 30% of hepatocytes, but at a lower level 
not detectable by immunofluorescence. Second, the core protein contains 32 
additional amino acids from the N-terminus of α1-antitrypsin. It is unlikely 
that the observed inhibition of Jak-STAT signaling is caused by novel 
properties specific to the fusion protein, since we have observed an inhibition 
of Jak-STAT signaling in cell lines that express the core protein in its regular 
form 217. Third, we have little information on the other viral proteins. We can 
not detect them by Western blot, and can therefore not know if they are 
correctly cleaved from the HCV polyprotein precursor and present in 
undetectably low concentrations, or if they are completely absent. This is an 
important caveat, because even a low amount of viral proteins could still have 
a major impact on cellular processes such as signaling. In fact it is known that 
HCV protein expression levels in human liver samples from patients with 
chronic hepatitis C are generally low, often not detectable by Western blots. 
The functional importance of impaired IFN induced signaling through the 
Jak-STAT pathway is demonstrated in the virus challenge experiments with 
LCMV-WE. We show here for the first time that expression of HCV proteins in 
hepatocytes has an influence on the course of a viral infection in an animal. 
B6HCV mice are clearly more susceptible to LCMV induced hepatitis than the 
controls. The most likely explanation for the more severe hepatitis and the 
increased mortality in B6HCV mice is the increased viral replication in liver 
cells and thereby the increased CTL mediated lysis of infected hepatocytes. We 
believe that hepatocytes that express HCV proteins do not mount an effective 
antiviral defense against LCMV, because the endogenous IFN that binds to its 
receptors on the surface of hepatocytes can not signal to the nucleus.  
In a recent report, expression of HCV core protein in liver cells after infection 
with a replication defective recombinant adenovirus coding for core was found 
to induce normal immune response against adenovirus 233. In the same report, 
HCV core transgenic mice were shown to mount a normal CTL response 
against adenovirus. The authors concluded that core protein has no 
immunomodulatory effect on virus-induced cellular immunity. Experiments 
performed by another group using core-E1-E2 transgenic mice that were 
infected with replication defective adenovirus found also an intact cellular and 
humoral immune response against adenovirus 234. The authors concluded that 
HCV core and envelope proteins do not inhibit the hepatic antiviral 
mechanism in general. In agreement with these reports we also find a normal 
immune response against LCMV in our HCV transgenic mice. B6HCV mice 
have a normal footpad-swelling assay after local injection of 200 pfu LCMV-
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WE in the foot as well as an unimpaired immune response against the 
neurotropic rhabdovirus VSV. However, when challenged with the replication 
competent hepatotropic LCMV-WE virus, B6HCV mice show a profound 
defect in the control of viral replication because of the defect of the IFN 
stimulated antiviral intracellular defense. Because the immune response is 
intact, B6HCV mice suffer a stronger and often fulminant hepatitis. In 
patients with chronic hepatitis C, liver histology usually does not show a 
similar degree of necroinflammatory changes. Indeed, for the host response 
against HCV, clearance of the virus without destruction of liver cells has been 
suggested to be an important mechanism 179. It depends on IFNα induced 
non-cytopathic clearance through the induction of intracellular antiviral 
defense mechanisms in hepatocytes 212, 213. An inhibition of IFN induced 
intracellular signaling by viral proteins would prevent the induction of an 
antiviral state and allow an active viral replication despite the presence of a 
strong cellular immune response. 
Our data provide evidence that the inhibition of STAT signaling occurs at the 
level of DNA binding of the activated STAT transcription factors. We found an 
intact tyrosine phosphorylation of STAT1 and STAT3 (Figure 3A), indicating a 
functional IFN receptor and a normal activity of the receptor associated 
kinases Jak1 and Tyk2. For this reason, an upregulation of the well-known 
pathway inhibitor SOCS1 and SOCS3 is unlikely, and indeed, we found no 
such induction of SOCS1 or SOCS3 (data not shown). Next, nuclear import of 
STATs could be inhibited by viral proteins. A block in nuclear import in the 
presence of normal STAT activation at the receptor kinase complex could lead 
to an accumulation of phosphorylated STAT1 in the cytoplasm. However, we 
could not detect such an accumulation in cytoplasmic extracts of B6HCV mice. 
In the nucleus, STAT dephosphorylation is an important mechanism for the 
termination of STAT signaling. Viral proteins could induce nuclear 
phosphatases. The phospho-STAT1 immunostaining experiments (Figure 3C) 
provide evidence for such an increased dephosphorylation of STATs, since the 
number of nuclei with a positive phospho-STAT1 signal is reduced. Finally, 
STAT signaling can be blocked at the level of DNA binding. So far, the only 
protein known to interfere with DNA binding of activated STATs is PIAS1, and 
we could not detect an upregulation of PIAS1 by Western blot (data not 
shown). However, the strong inhibition of DNA binding found in the gel shift 
assays (Figure 2) indicates, that a direct or indirect interference of viral 
proteins with DNA binding is an important mechanism HCV induced 
inhibition of Jak-STAT signaling. 
As outlined above, we can not unequivocally identify the specific viral 
protein(s) that is (are) responsible for the observed inhibition of the Jak-STAT 
pathway. Our immunofluorescence results suggest a role of core protein in the 
inhibition of the Jak-STAT pathway in our transgenic mice. We found core 
protein expression in the nucleus of about 30% of the hepatocytes, and, 
interestingly, most of those very same hepatocytes did not have the active, 
tyrosine phosphorylated form of STAT1 in the nucleus. The core protein itself 
could stimulate a rapid dephosphorylation of STATs in the nucleus. 
Alternatively, high expression levels of core might just be an indicator of an 
above average expression of the entire viral transgene. In this case, the 
inhibition of Jak-STAT signaling could be caused by any other viral protein(s). 
Whatever the mechanism, hepatocytes with detectable core protein in the 
nucleus show a lack of phosphorylated STAT1 in the nucleus. 
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The same mechanism of interference with the Jak-STAT pathway could take 
place in chronic viral hepatitis. IFN would then be actively inducing an 
antiviral state only in hepatocytes that are not infected by HCV or have very 
low cellular viral loads with concomitant low expression levels of viral 
proteins. It is a matter of an ongoing debate what percentage of hepatocytes is 
actually infected by HCV in chronic hepatitis C. Published data indicate that 
viral replication and gene expression takes place in less than 20 percent of 
hepatocytes 235. In view of these data one may speculate that IFN treatment in 
patients with chronic hepatitis C actually induces an antiviral state in 
uninfected hepatocytes only, while the patient’s own HCV specific CD8 
positive cytotoxic T lymphocytes would have to clear the virus by attacking 
infected hepatocytes. On the other hand, high doses of IFN can overcome the 
block of IFNα induced Jak-STAT signaling in our mouse model (Figure 2B). 
Interestingly, a similar observation has been made in patients infected with 
HCV. It has been shown that treatment with higher IFNα doses results in a 
higher response rate in patients with chronic hepatitis C 236. Higher doses 
apparently could overcome the resistance against IFNα treatment in about 
15% of patients 236. Adverse effects of IFNα, however, limit the dose that can 
be administered to about 100 IU/g body weight three times per week. In this 
context, a more promising strategy to overcome viral interference with IFN 
signaling would be to search for compounds that counteract the effects of viral 
proteins on Jak-STAT signaling. 
In summary, we have found a functionally important inhibition of IFNα 
induced signaling through the Jak-STAT pathway in liver cells of HCV 
transgenic mice in vivo. Interference with this intracellular signaling pathway 
reduces the amount of phosphorylated STAT1 in the nucleus of cells 
expressing viral proteins and results in a loss of binding of STAT transcription 
factor complexes to their cognate response elements in the promoters of ISGs. 
This mechanism could contribute to escape from the antiviral effects of 
endogenous IFNs and thereby to HCV persistence in infected individuals. 
Moreover, it might contribute to the poor response to IFN based therapies in 
the majority of HCV infected patients. Strategies aimed at restoring IFN 
signaling in infected liver cells might allow to more successfully treating 
patients in the future. 
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Abstract 
 
The mechanisms of hepatitis C virus (HCV) persistence and resistance to 
interferonα (IFNα) are poorly understood. We have shown previously that 
expression of the HCV polyprotein inhibits IFNα induced signal transduction 
through the Jak-STAT pathway. The aim of this study was to identify the HCV 
protein(s) responsible for this inhibition. Using a comprehensive panel of 
tetracycline-regulated cell lines inducibly expressing individual HCV proteins 
alone or in different combinations, we found that the combined structural 
proteins strongly and the core protein alone partly inhibited Jak-STAT 
signaling. As previously observed in cell lines inducibly expressing the entire 
HCV polyprotein, inhibition occurred downstream of STAT tyrosine 
phosphorylation and resulted in an impaired upregulation of IFNα target 
genes. Interference with IFNα induced signaling through the Jak-STAT 
pathway may represent an escape strategy of HCV contributing to viral 
persistence and resistance to IFNα. Ultimately, elucidation of the molecular 
mechanism involved may open possibilities to design more effective therapies 
for chronic hepatitis C. 
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Introduction 
 
Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, liver 
cirrhosis, and hepatocellular carcinoma worldwide. A protective vaccine does 
not exist to date and therapeutic options are still limited 237. At present, 
pegylated interferon alpha (IFNα) in combination with ribavirin is the 
treatment of choice for chronic hepatitis C. However, only about 40% of 
patients infected with HCV genotype 1 experience a sustained response 238. 
The mechanisms underlying viral persistence and resistance to IFNα therapy 
are poorly understood 211, 239, 240. In general, the IFN-induced cellular antiviral 
response is the first line of innate defense against viral infections. In order to 
establish a productive infection, therefore, viruses must first overcome the 
IFN-induced mechanisms blocking viral replication 241, 242. 
The complete signal transduction pathway from the IFN receptors to the 
nucleus has been identified over the past several years (reviewed in9), and 
viral interference with IFN-induced signaling can now be studied in detail. 
Type I IFNs (IFNα and β) bind to heterodimeric type I IFN receptors 
consisting of IFNα receptor I (IFNARI) and IFNARII. Ligand binding results 
in activation of two cytoplasmic protein tyrosine kinases associated with 
IFNARI and IFNARII, Tyk2 and Jak1. The activated kinases then 
phosphorylate tyrosine residues of the receptors. These phosphotyrosines are 
consecutively bound by the Src homology 2 (SH2) domains of signal 
transducer and activator of transcription 1 (STAT1), STAT2 and STAT3. The 
STATs are then tyrosine phosphorylated, and form hetero- or homo-dimers 
through mutual SH2 domain-phosphotyrosine interactions. STAT3 and STAT1 
form homodimers, designated serum inducible factor A (SIF-A) and SIF-C, 
respectively, and a STAT1-STAT3 heterodimer, SIF-B. STAT1 can also 
dimerize with STAT2, and this STAT1-STAT2 heterodimer associates with a 
third DNA binding protein, ISGF3γ-p48 (IRF-9), to form interferon-
stimulated gene factor 3 (ISGF3). Binding of these STAT factors to their 
cognate sequences in the promoter regions of target genes results in enhanced 
gene transcription. Among others, STAT1, STAT2, and ISGF3γ-p48 (IRF-9) 
have been identified as IFNα induced target genes. A number of regulatory 
mechanisms of the Jak-STAT signal transduction pathway have recently been 
identified. The activity of the Jak kinases is controlled by receptor associated 
phosphatases and by the family of suppressors of cytokine signaling (SOCS). 
Binding of STAT dimers to DNA can be inhibited by protein inhibitors of 
activated STATs (PIAS). STATs are deactivated by an as yet unknown nuclear 
phosphatase and by protein degradation through the ubiquitin-proteasome 
pathway. At any of the steps outlined above, viral proteins could interfere with 
the Jak-STAT pathway and inhibit induction of antiviral effector proteins. 
We have shown previously that expression of the entire HCV polyprotein in 
tetracycline-regulated cell lines inhibits IFNα induced signal transduction 
through the Jak-STAT pathway 217. Inhibition occurred downstream of STAT 
tyrosine phosphorylation, led to an impaired upregulation of IFNα target 
genes 217, and resulted in an inhibition of antiviral IFN effector functions 243. 
More recently, these observations were confirmed and extended in HCV-
transgenic mice in vivo 129. 
The aim of this study was to identify the HCV gene product(s) responsible for 
the inhibition of Jak-STAT signaling. For this purpose, we established a 
comprehensive panel of cell lines allowing the regulated expression of HCV 
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structural and nonstructural proteins either alone or in different 
combinations. Using this well-characterized cell culture system, we 
demonstrate that expression of the HCV structural proteins inhibits IFNα 
induced signaling through the Jak-STAT pathway. 
 
 
Materials and Methods 
 
Expression constructs  
Fragments comprising the core protein (aa 1-191) or the entire structural 
region (core-E1-E2-p7; aa 1-809) of a functional HCV H strain consensus 
cDNA were amplified by PCR from pBRTM/HCV1-3011con 244; generously 
provided by Dr. Charles M. Rice, Center for the Study of Hepatitis C, 
Rockefeller University, New York, NY) using forward primer GAG36 (5'- 
GAGAATTCCGTGCACCATGAGCACGAATCCTAAACC-3'; EcoRI site 
underlined, HCV translation initiation codon boldface; 181 and reverse primers 
Crev (5'-GCTGTCTAGATTAGGCTGAAGCGGGCACGGTCAGGC-3'; XbaI site 
underlined, engineered stop codon boldface) or 809-rev (5'-GCTGTC 
TAGATTATGCGTATGCCCGCTGAGGCAACGCCAG-3'; XbaI site underlined, 
engineered stop codon boldface), respectively. The amplification products 
were digested with EcoRI and XbaI and cloned into the EcoRI-XbaI sites of 
pUHD10-3 245 to yield plasmids pUHDCcon and pUHDCp7con, respectively. 
These constructs allow expression of the core protein or of the entire 
structural region of HCV genotype 1a under the transcriptional control of a 
tTA-dependent promoter. 
The HinDIII-XbaI fragment of pcDNA5-9-1 222, comprising the core coding 
region (aa 1-191) of a genotype 1b isolate, designated TH 246 247, was ligated 
into the EcoRI-XbaI sites of pUHD10-3 after fill-in with Klenow polymerase 
of the 3' recessed termini resulting from HinDIII and EcoRI digestion to yield 
plasmid pUHDTHC. 
Fragments comprising the NS3-NS4B and NS4B-NS5B region of the HCV H 
consensus cDNA were amplified by PCR from pBRTM/HCV1-3011con using 
primer pairs GCA45 (5'-GCACGAATTCACCATGGCGCCCATCACGGCGTACG 
CCCAGCAGAC-3'; EcoRI site underlined, engineered translation initiation 
codon boldface; 175 - 4Brev (5'-GCTGTCTAGATTAGCATGGAGTGGTACACT 
CCGAGCTTATCC-3'; XbaI site underlined, engineered stop codon boldface; 
169 and 4Bfwd (5'-GAGAATTCACCATGTCTCAGCACTTACCGTACATCGA 
GCAAGGG-3'; EcoRI site underlined, engineered translation initiation codon 
boldface; 169 - NS5Brev (5‘-GCTGTCTAGATCATCGGTTGGGGAGGAGGTAGA 
TGCCTACC-3‘; XbaI site underlined, HCV stop codon boldface; 248, 
respectively, followed by digestion of the amplification products with EcoRI-
Bsu36I and Bsu36I-XbaI, respectively, and ligation of both fragments into the 
EcoRI-XbaI sites of pUHD10-3 245 to yield plasmid pUHDNS3-5Bcon. This 
construct allows expression of the nonstructural proteins 3-5B derived from a 
functional genotype 1a cDNA under the transcriptional control of a tTA-
dependent promoter. 
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Tetracycline-regulated cell lines  
Tetracycline-regulated cell lines were generated as previously described 249 169 
222 181 246 248 175. In brief, the constitutively tTA-expressing, U-2 OS human 
osteosarcoma (ATCC HTB-96)-derived founder cell line UTA-6 250; 
(generously provided by Dr. Christoph Englert, University of Würzburg, 
Germany) was cotransfected by a modified calcium phosphate precipitation 
protocol 251 with pUHDTHC, pUHDCcon, pUHDCp7con, or pUHDNS3-5Bcon, 
respectively, and pBabepuro 252, followed by selection with G418 and 
puromycin. Double-resistant clones were isolated and screened for tightly 
regulated HCV protein expression by immunofluorescence microscopy and 
immunoblot analyses. 
The following previously described cell lines were also used in this study: 
UTHCNS3-43 cells allow the inducible expression of the entire structural 
region including a functional NS2-3 autoprotease derived from the genotype 
1b TH cDNA 246. UNS3-4A-24 cells 175 allow the inducible expression of the 
NS3-4A complex derived from a prototype HCV H strain cDNA 164. UHCVcon-
57 248, UNS4Acon-27 (Moradpour et al., unpublished data), UNS4Bcon-4 and 
-52 169, UNS5Acon-26, -29, -37 and -46 249, and UNS5Bcon-8 cells 248 allow the 
inducible expression of the entire polyprotein, NS4A, NS4B, NS5A, or NS5B, 
respectively, derived from a functional HCV H consensus cDNA 244 (Fig. 1A). 
Cells were cultured in DMEM supplemented with 10% fetal bovine serum, 50 
U/ml penicillin G, 50 µg/ml streptomycin, 500 µg/ml G418, 1 µg/ml 
puromycin, and 1 µg/ml tetracycline. For induction of viral protein expression, 
cells were cultured in the absence of tetracycline for 24 h before IFNα 
stimulation. 
 
Reagents and antibodies  
Human IFN-alpha2b (Intron A Essex Chemie AG, Lucerne, Switzerland) was 
a gift of Essex Chemie AG. Antibodies against STAT1 (S21120) and ISGF3γ-
p48 (IRF-9) (I29320) were from Transduction Laboratories (Lexington, KY). 
A polyclonal antiserum against Tyr701-phosphorylated STAT1 (9171S) was from 
Cell Signaling Technologies (New Englands Biolabs, Beverly, MA). The HCV 
core protein-specific mAb C7-50 has been described 222. MAb 384 against E1 
was kindly provided by Dr. Michinori Kohara, The Tokyo Metropolitan 
Institute of Medical Science, Tokyo, Japan. MAbs A4 and A11 against E1 and 
E2, respectively, were generous gifts of Dr. Jean Dubuisson, Institut Pasteur 
de Lille, Lille, France and Dr. Harry Greenberg, Stanford University, Stanford, 
CA. MAb 11H against NS5A 249 was kindly provided by Dr. Jan Albert Hellings, 
Organon Teknika BV, Boxtel, The Netherlands. 
 
Indirect immunofluorescence microscopy  
Indirect immunofluorescence microscopy was performed as described 
previously 222 181. In brief, cells grown as monolayers on glass cover slips were 
fixed with 2% paraformaldehyde, permeabilized with 0.05% saponin, and 
incubated with primary antibodies in phosphate-buffered saline containing 
3% bovine serum albumin and 0.05% saponin. Bound primary antibody was 
revealed with fluorescein isothiocyanate-conjugated goat F(ab')2 fragment to 
mouse IgG F(ab')2 (Cappel, Durham, NC). Cover slips were mounted in 
SlowFade (Molecular Probes, Eugene, OR) and examined with a Zeiss 
Axiovert photomicroscope equipped with an epifluorescence attachment. 
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EMSA 
After treatment with IFNα, cells were lysed in low salt buffer (20 mM Hepes 
pH 7.9, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.2% NP-40, 10% glycerol, 0.1 
mM Na3VO4, 1 mM PMSF, 1 mM dithiothreitol, 2 µg/ml aprotinin, 1 µg/ml 
leupeptin, and 1 µg/ml pepstatin) at 4 °C for 10 min. After centrifugation for 
30 s at 12,000 x g, supernatants (= cytoplasmic extracts) were immediately 
frozen on dry ice, and pellets were extracted with high salt buffer (same as low 
salt, except for 420 mM NaCl and 20% glycerol) for 30 min at 4 °C. Samples 
were cleared by centrifugation at 12,000 x g at 4 °C. Supernatants were 
aliquoted, frozen on dry ice and stored at –70 °C. For EMSA, nuclear extracts 
(2 µl) were incubated for 20 min at RT in 20 mM HEPES, pH 7.9, 4% Ficoll, 1 
mM MgCl2, 40 mM KCl, 0.1 mM EGTA, 0.5 mM dithiothreitol, and 160 µg/ml 
poly[dI-dC]-poly[dI-dC] with 1 ng of 32P-labeled oligonucleotides. Samples 
were separated on a 5% non-denaturing polyacrylamide gel at 400 V for 4 h at 
4 °C. Gels were then dried and exposed for 10-20 h to a storage phosphor 
screen. Quantitation was performed using NIH Image 1.62 software, and the 
sum of arbitrary density values of STAT1:3 heterodimer and STAT1 and 
STAT3 homodimers was normalized to the nonspecific bands ran on the same 
gel. The following oligonucleotides corresponding to STAT response element 
sequences were used: ISRE (interferon stimulated response element) = 5'-
GAAAGGGAAACCGAAACTGAAGC-3'; SIE-m67 (mutated serum inducible 
element) = 5'-CATTTCCCGTAAATCAT-3'. 
 
Protein extraction and Western blotting 
For the preparation of whole cell extracts, cells were lysed in a buffer 
containing 50 mM Tris-HCl, pH 8.0, 280 mM NaCl, 0.5% NP-40, 0.2 mM 
EDTA, 2 mM EGTA, 10% glycerol, 0.1 mM Na3VO4, 1 mM PMSF, 2 µg/ml 
aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin A. SDS-polyacrylamide gel 
electrophoresis and Western blot were performed according to standard 
protocols 253. Quantitation was performed using NIH Image 1.62 software and 
arbitrary density values were normalized to the nonspecific bands run on the 
same gel. 
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Results 
 
Tetracycline-regulated cell lines  
A tetracycline-regulated gene expression system was used to establish U-2 OS 
human osteosarcoma-derived cell lines inducibly expressing the core protein 
derived from HCV genotype 1a and 1b cDNAs as well as the entire structural 
or nonstructural region derived from genotype 1a. Screening of G418- and 
puromycin-resistant clones resulting from transfection of the tetracycline-
controlled transactivator (tTA)-expressing founder cell line UTA-6 with the 
constructs pUHDTHC, pUHDCcon, pUHDCp7con, or pUHDNS3-5Bcon 
allowed the isolation of several tightly regulated UTHC, UCcon, UCp7con, and 
UNS3-5Bcon cell lines, respectively (Figure 1A). In general, the suffix "con" 
denotes cell lines harboring segments of an infectious HCV H consensus 
cDNA 244 and the numbers following cell line designations indicate 
independent clones. Cell lines UTHC-10 and -17 (both medium expression), 
UCcon-18 (low-medium expression) and -39 (high expression, regulation by 
tetracycline slightly leaky), UCp7con-9 (high expression), -10, and -23 (both 
medium expression), as well as UNS3-5Bcon-27 (medium expression), -33 
(high expression), and -35 (medium expression) were used in this study. 
These cell lines were maintained in continuous culture for more than 12 
months and over 50 passages with stable characteristics. Additional 
previously characterized cell lines used in this study are specified in Figure 1A 
and in the Materials and Methods section. 
Indirect immunofluorescence analyses of UTHC, UCcon, and UCp7con cells 
with the HCV core-specific monoclonal antibody (mAb) C7-50 revealed the 
typical cytosolic reticular and granular staining pattern 222 (Figure 1B). In 
addition, core protein was found on the surface of round cytoplasmic 
structures corresponding to lipid droplets 176 222 and, somewhat surprisingly, 
in the nucleus of UCp7con cells (Figure 1B). An estimated 2-5% of the total 
core protein expressed in these cells was found in the nucleus where it 
accumulated in the nucleoli. Interestingly, nuclear core protein was found 
only in UCp7con and UHCVcon 176 248, but not in UCcon (Figure 1B), UTHC 
(data not illustrated), and UTHCNS3 cells 246. 
 
 
Figure 1. Tetracycline-regulated cell lines.  
(A) Overview of the cell lines used in this study. The genetic organization and polyprotein 
processing of HCV are depicted at the top. Asterisks in the E1 and E2 region indicate 
glycosylation of the envelope proteins. Diamonds denote cleavages of the HCV polyprotein 
precursor by the endoplasmic reticulum signal peptidase and arrows indicate cleavages by 
HCV NS2-3 and NS3 proteases. UNS3-4A (Wölk et al., 2000) cell lines were derived from a 
prototype HCV H cDNA (genotype 1a) (Grakoui et al., 1993). UCcon (this work), UCp7con 
(this work), UNS4Acon (Moradpour et al., unpublished data), UNS4Bcon (Hügle et al., 2001), 
UNS5Acon (Brass et al., 2002), UNS5Bcon (Schmidt-Mende et al., 2001), UNS3-5Bcon (this 
work), and UHCVcon cell lines (Schmidt-Mende et al., 2001) were derived from a functional 
HCV H consensus cDNA (Kolykhalov et al., 1997). The cell lines UTHC (this work) and 
UTHCNS3 (Moradpour et al., 1998b) were derived from a genotype 1b cDNA, termed TH 
(Moradpour et al., 1998b; Wakita and Wands, 1994).  
(B) Expression of HCV core protein in UCcon and UCp7con cell lines. UCcon-39 and 
UCp7con-23 cells were cultured for 24 h in the presence (+ tet) or absence (- tet) of 
tetracycline and subsequently processed for indirect immunofluorescence analysis with the 
HCV core-specific mAb C7-50. Arrows indicate nucle(ol)ar localized core protein. 
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Expression of HCV structural proteins inhibits IFNα induced Jak-
STAT signaling  
To test for a possible interference of HCV proteins with IFN signal 
transduction, several independent clones of the inducible cell lines shown in 
Figure 1A were analyzed for IFNα induced SIF-A, -B, and -C as well as ISGF3 
formation after derepression of the HCV cDNA. Subconfluent cell monolayers 
were cultured for 24 h in the presence or absence of tetracycline. Cells then 
either were left untreated or were stimulated for 20 min with 500 U/ml IFNα. 
Nuclear extracts were prepared and tested for STAT DNA binding activity by 
electrophoretic mobility shift assay (EMSA) using the m67 or interferon-
stimulated response element (ISRE) oligonucleotide probes, respectively. 
Western blot analyses of UCcon-18, UCp7con-9, UNS3-5Bcon-27, UTHC-10, 
and UTHCNS3-43 cells cultured in the presence or absence of tetracycline 
revealed HCV protein expression only in derepressed cells, as shown in Figure 
2. As shown in Figure 2A and 2B, SIF-A, -B and -C as well as ISGF3 induction 
was inhibited in UCcon-18 and UCp7con-9 cells cultured in the absence of 
tetracycline. Figure 2 shows representative examples of experiments that were 
repeated 2-5 times with similar results (except for UCcon-18 IFN induced 
ISGF3, which was performed only once).  
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Figure 2. Expression of HCV structural proteins inhibits IFNα induced Jak-STAT 
signaling. UCcon-18, UCp7con-9, UNS3-5Bcon-27, UTHC-10, and UTHCNS3-43 cells were 
cultured in the presence (lanes indicated by tet +) or absence (lanes indicated by tet -) of 
tetracycline. Cells were then not treated (lanes indicated by IFN -) or stimulated for 20 min 
with 500 U/ml IFNα (lanes indicated by IFN +). Panels A, C and D demonstrate EMSAs with 
the m67 oligonucleotide probe. The positions of SIF-A, -B and -C are indicated by arrows. An 
example of an EMSA with the ISRE oligonucleotide probe is shown in panel B (using the same 
nuclear extracts as in panel A). Quantitation of EMSA signals was performed as described in 
the Materials and Methods section and arbitrary density values are depicted as bars. These 
values reflect the experiment shown in this figure and are included in the average ± S.D. 
values specified in the Results section. Light grey bars represent cells cultured in the presence 
of tetracycline, dark grey bars cells cultured in the absence of tetracycline. Panels A, C and D 
include Western blot analyses, depicted below the EMSAs, of cytoplasmic extracts 
corresponding to the nuclear extracts. Ten µg of protein was loaded per lane (except for 
UTHC-10 cells where 40 µg was loaded per lane). The positions of HCV proteins are indicated 
by arrows. Molecular weight markers in kDa are indicated on the left. (A) EMSA with nuclear 
extracts from UCp7con-9 and UCcon-18 cells and the m67 oligonucleotide probe. MAbs C7-50 
against core protein as well as A4 and A11 against E1 and E2, respectively, were used for 
Western blot. (B) EMSA with the nuclear extracts from panel A and an ISRE probe. (C) 
EMSA with nuclear extracts from UNS3-5Bcon-27 cells and the m67 oligonucleotide probe. 
MAb 11H was used for the detection of NS5A by Western blot. (D) EMSA with nuclear 
extracts from UTHCNS3-43 and UTHC-10 cells and the m67 oligonucleotide probe. MAbs C7-
50 against core as well as 384 and A11 against E1 and E2, respectively, were used for Western 
blot. 
 
 
Quantitative analyses of all experiments performed demonstrated a 30±11% 
(average ± S.D.) and 33±12% reduction of IFN induced SIF signals as well as a 
68±7% and 42% reduction of IFN induced ISGF3 signals in UCp7con-9 and 
UCcon-18 cells, respectively, when compared to cells cultured in the presence 
of tetracycline (Figures 2A and 2B). As shown previously 217, a low-level 
constitutive STAT3 activation was present even in unstimulated cells, whereas 
STAT1 was not detected in these control samples. In line with our previous 
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report 217, inhibition of STAT activation by HCV structural proteins appeared 
to be more complete for ISGF3 as compared to SIF-A, -B, and -C. This is likely 
a consequence of a higher threshold activation level for EMSAs using the ISRE 
as compared to the m67 oligonucleotide probe. Analogous results were 
obtained in UCp7con-10 and -23 as well as in UCcon-39 cells expressing 
different levels of HCV structural and core proteins (data not illustrated). 
By contrast, no inhibition of IFNα induced Jak-STAT signaling was observed 
in UNS3-5Bcon-27 cells which inducibly express the nonstructural region 
derived from the HCV H consensus cDNA clone (Figure 2C). Quantitative 
analyses actually demonstrated an 18±10% increase of the signal as compared 
to cells cultured in the presence of tetracycline. However, this slight increase 
was not uniformly reproducible in independent clones, namely UNS3-5Bcon-
33 and –35, expressing nonstructural proteins (data not illustrated). In 
addition, no inhibition of Jak-STAT signaling was observed in UNS3-4A-24, 
UNS4Acon-27, UNS4Bcon-4 and -52, UNS5Acon-26, -29, -37, and -46 as well 
as UNS5Bcon-8 cells. Thus, the HCV nonstructural proteins expressed in 
combination or alone did not interfere with IFNα induced signaling through 
the Jak-STAT pathway. 
To extend the findings obtained with genotype 1a-derived proteins, we 
investigated the effect of structural proteins derived from a HCV genotype 1b 
cDNA, designated TH 246 247, on IFNα induced Jak-STAT signaling. As shown 
in Figure 2D, a comparable inhibition of SIF-A, -B and -C induction was found 
in UTHCNS3-43 cells expressing the entire structural region and in UTHC-10 
cells which express the core protein alone. Quantitative analyses 
demonstrated a 32±10% reduction in UTHCNS3-43 cells and a 25±14% 
reduction in UTHC-10 cells expressing HCV structural and core proteins, 
respectively. Analogous results were obtained in UTHC-17 cells (data not 
illustrated). Thus, the inhibitory effect of HCV structural proteins was 
reproducible in two different viral isolates and was independent of nuclear 
localized core protein, because core was never found in the nucleus of 
UTHCNS3 cells.  
 
Inhibition of Jak-STAT signaling by HCV structural proteins occurs 
downstream of STAT tyrosine phosphorylation  
To determine the level at which inhibition of Jak-STAT signaling occurs we 
next examined IFNα induced STAT1 tyrosine phosphorylation in UCp7con-9, 
UCcon-18, and UNS3-5Bcon-27 cells. For this purpose, cells were cultured for 
24 h in the presence or absence of tetracycline, followed by stimulation for 20 
min with 500 U/ml IFNα. Cytosolic cell extracts were subsequently analyzed 
by Western blot with a polyclonal antiserum specific for Tyr701-
phosphorylated STAT1. As shown in Figure 3A, phospho-STAT1-specific 
signals showed the same intensity in repressed and derepressed cells, 
indicating that STAT1 phosphorylation was not affected by HCV proteins.  
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Figure 3. Inhibition of Jak-STAT signaling by HCV structural proteins occurs 
downstream of STAT tyrosine phosphorylation. UCp7con-9, UCcon-18, and UNS3-
5Bcon-27 cells were cultured for 24 h in the presence or absence of tetracycline (tet + or tet -) 
and were then either not treated or stimulated for 20 min with 500 U/ml IFNα (IFN - or IFN 
+). Cytosolic extracts corresponding to 10 µg protein per lane were analyzed by Western blot 
using (A) a polyclonal antiserum against Tyr701-phosphorylated STAT1 (P-STAT1) or (B) a 
mAb against STAT1. Quantitation of P-STAT1-specific Western blot signals was performed as 
described in the Materials and Methods section and arbitrary density values are depicted as 
bars. Light grey bars represent cells cultured in the presence of tetracycline, dark grey bars 
cells cultured in the absence of tetracycline. 
 
 
In addition, we could not detect any quantitative difference for total STAT1, 
indicating that viral protein expression did not diminish intracellular 
concentrations of STAT proteins by either enhanced protein degradation or 
impaired gene expression (Figure 3B). Analogous results were obtained in 
UCp7con-10 and -23, UCcon-39, UNS3-5Bcon-33 and -35 as well as 
UTHCNS3-43 cells. We concluded from these experiments, that activation of 
STATs through tyrosine phosphorylation at the receptor-kinase complex was 
not inhibited by HCV proteins. 
 
Inhibition of Jak-STAT signaling by HCV structural proteins 
results in impaired upregulation of IFNα target genes  
To examine the effect of HCV proteins on the expression of IFNα induced 
target genes, UCp7con-9, UCcon-18, and UNS3-5Bcon-27 cells were cultured 
for 24 h in the presence or absence of tetracycline, stimulated for 4 or 8 h with 
100 U/ml IFN-alpha, and subsequently examined for the expression of IRF-9.  
As shown in Figure 4, the inhibition of Jak-STAT signaling in UCp7con-9 and 
UCcon-18 cells resulted in reduced upregulation of IRF-9. This experiment 
was repeated twice. Quantitative analyses showed that the signal was reduced 
by 29±4% and 25±6% in UCp7con-9 cells after 4 h and 8 h, respectively, and 
by 44±4% after 4 h in UCcon-18 cells. In UCcon-18 cells the difference in 
upregulation of IRF-9 after 8 h was not significant. A similar inhibition was 
observed in the upregulation of the IFNα target gene STAT1 (data not shown). 
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By contrast, no decrease, or, in line with the EMSA data, even a slight increase 
was found in UNS3-5Bcon-27 cells. These observations indicate that the 
expression of HCV structural proteins affects not only IFN signaling but IFNα 
effector functions as well. Interestingly, the observed inhibition could be 
overcome by using a 5-fold increased concentration of IFNα (data not 
illustrated). 
 
 
 
 
 
Figure 4. Inhibition of Jak-STAT signaling by HCV structural proteins results in 
impaired upregulation of IFNα target genes. UCp7con-9, UCcon-18, and UNS3-5Bcon-
27 cells were cultured for 24 h in presence or absence of tetracycline (tet + or tet -) and were 
then either not treated (0 h) or stimulated for 4 h or 8 h with 100 U/ml IFNα (IFN). Whole 
cell extracts were analyzed by Western blot using a mAb against IRF-9.  The position of IRF-9 
is indicated by an arrow, a higher molecular weight nonspecific band can serve as an internal 
loading control. Quantitation of IRF-9-specific Western blot signals was performed as 
described in the Materials and Methods section and arbitrary density values normalized to the 
nonspecific bands are depicted as bars. These values reflect the experiment shown in this 
figure and are included in the average ± S.D. values specified in the Results section. Light grey 
bars represent cells cultured in the presence of tetracycline, dark grey bars cells cultured in 
the absence of tetracycline. 
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Discussion 
 
The mechanisms by which HCV evades the host immune response to cause 
persistent infection in the majority of patients are poorly understood. Various 
strategies of immune evasion have been proposed, including, among others, 
down-regulation of major histocompatibility complex gene expression, viral 
interference with antigen processing and presentation, inhibition of cellular 
signaling pathways, and the generation of viral humoral and cellular immune 
escape variants 211, 240, 254, 255. In this context, expression of HCV proteins was 
found not to interfere with major histocompatibility complex class I 
processing and presentation in vitro 256. 
We have shown previously that expression of the entire HCV polyprotein in U-
2 OS human osteosarcoma-derived tetracycline-regulated cell lines inhibits 
IFNα induced signaling through the Jak-STAT pathway. To identify the HCV 
gene product(s) responsible for the observed inhibition of Jak-STAT signaling 
we generated a comprehensive panel of well-characterized cell lines allowing 
the regulated expression of HCV structural proteins either individually or in 
different combinations. In addition to the previously described inducible cell 
lines (reviewed in 257), cell lines inducibly expressing the core protein derived 
from genotype 1a and 1b HCV cDNAs as well as the entire structural or 
nonstructural regions derived from a genotype 1a cDNA were generated for 
this study. 
 
Using this panel of cell lines, we demonstrate that expression of the HCV 
structural region - and to a somewhat lesser extent of core protein alone - 
interferes with IFNα induced signaling through the Jak-STAT pathway. The 
findings obtained with genotype 1a-derived proteins were confirmed in 
genotype 1b. As previously found in the context of the entire HCV polyprotein, 
in the cell lines 217 and in the HCV transgenic mice (Chapter 2) 129, inhibition 
occurred downstream of STAT tyrosine phosphorylation; i.e. the IFNα-
induced binding of STAT1 transcription factor complexes to their response 
elements in the promoters of ISGs is inhibited, and resulted in an impaired 
upregulation of IFN target genes. 
 
Duong et al. has recently showed in the HCV transgenic mouse, and in liver 
biopsies from HCV infected patients that this inhibition of IFNα-induced 
signaling might be the result of upregulation of the catalytic subunit of protein 
phosphatase 2A (PP2Ac). PP2Ac is overexpressed in liver extracts of HCV 
transgenic mice and expression of a constitutive active PP2A in Huh7 cells, 
resulted in inhibition of STAT1-DNA binding. This inhibition of STAT1-DNA 
binding was mediated by PP2Ac-induced hypomethylation of STAT1, which 
enhances its association with PIAS1 and prevents binding to DNA. So HCV 
viral protein expression can upregulate PP2Ac or can inhibit the PRMT1-
induced-methylation of STAT1. The specific PTP for STAT1, TC-PTP was 
neither upregulated in HCV transgenic animals nor in liver biopsies from 
infected patients. The results indicate that patients with high PP2Ac 
expression levels are less responsive to IFNα treatment ex vivo 130.  
Proof that inhibition of STAT1-DNA binding, resulting from HCV induced 
STAT1 hypomethylation and increased PIAS1-STAT1 association, is the cause 
for IFNα treatment resistancy and thus an important mechanism how HCV 
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induces inhibition of Jak-STAT signaling, was given through the generation of 
the PIAS1-deficient mice 92. The IFN antiviral activity, measured by 
expression of many IFN induced genes, was consistently enhanced in these 
mice. The PIAS1-deficient mice showed increased protection against 
pathogenic infection and an increased IFN-mediated antiviral response. 
 
The observed degree of inhibition of STAT-DNA binding seems not to 
correlate with the inhibition of upregulation of ISGs (IRF-9 in Figure4). A 
similar observation was made for upregulation of PKR and 2’-5’-OAS in the 
HCV transgenic mice. Only a slight inhibition of upregulation of these genes 
could be shown (Chapter 2, unpublished data).  
ISGs are upregulated in HCV infection, of which several have been analyzed 
for their ability to interfere with HCV replication. However the effector 
proteins that inhibit HCV replication have not yet been identified 258, 259.  
MxA, interferon inducible protein 44 (IFI-44) and IFI-56 were shown to be 
upregulated in HCV liver biopsies of patients compared to biopsies from non 
infected livers 260. Upregulation of 2’-5’-OAS was shown in chimpanzees, and 
was correlated with an increase in level of HCV particles 261. A DNA 
microarray study, in which hepatocytes from chimpanzee liver biopsies were 
probed for changes in gene expression during acute infection, revealed 
enormous fold upregulations of ISGs; p15/17, p27, IRF7,  MxA and 2’-5’-OAS. 
262. Another study in infected chimpanzees showed that 2’-5’-OAS, STAT1 and 
MxA were induced 263. PKR, MxA, 2’-5’-OAS and ISG15 were upregulated in 
liver biopsies from chronic HCV infected patients 264, 265. However, neither of 
these cases shows a positive correlation between the mentioned ISGs 
induction and viral clearance.  
This might be explained by the results obtained from a detailed gene 
activation analysis of 650 genes induced by IFNs in PIAS1-deficient 
macrophages. Only 9% of these interferon-inducible genes showed an 
induction. This suggests that PIAS1 specifically regulates a subset of 
interferon-induced genes 92. It could assumed that the ISGs found to be 
upregulated in the previous mentioned studies, are not regulated by PIAS1 
and therefore are not inhibited in their upregulation during HCV infection. A 
HCV effector protein might be an interferon-induced protein regulated by 
PIAS1.  Interferon-induced genes identified to be specifically regulated by 
PIAS1 are: GBP1 (guanylate binding protein), CXCL9 (CXC chemokine ligand 
9), CXCL10, IFI203 (interferon-inducible gene 203) and LY6E 92. 
 
A surprising side aspect of this study was the presence of a minor proportion 
of core protein in the nucleus of UCp7con, but not UCcon cells. In cell lines 
expressing genotype 1b TH cDNA-derived structural proteins, core protein 
was found only in the cytoplasm 222, 246. The reason for this discrepancy is not 
understood. Carboxyterminal truncation of the core protein results in nuclear 
translocation 222. However, no smaller size core protein products were seen by 
Western blot (data not illustrated). In addition, a nonspecific toxic effect of 
overexpressed HCV structural proteins seemed unlikely because nucle(ol)ar 
core protein was found also in UCp7con and UHCVcon cells expressing low 
levels of viral proteins (data not shown). 
 
Basu et al. recently presented data indicating an inhibitory effect of HCV core 
protein on ISGF3 formation 266. However, in contrast to our study this effect 
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seemed to be the result of reduced STAT1 expression in HeLa cells stably 
transfected with HCV cDNAs. In this context, the availability of tightly 
regulated cell lines inducibly expressing different HCV proteins allows to 
verify effects in the same cell in the presence or absence of HCV proteins. 
Keskinen et al. used the in this chapter described cell lines, to show that only 
the combined expression of all structural proteins, but not by only core 
expression, allowed viral replication (of VSV) despite IFNα treatment of the 
cells 267. With other words they show that the structural proteins impair IFNα 
antiviral activity.  
The HCV nonstructural protein 5A has been reported to interfere with the 
activity of the double-stranded RNA activated protein kinase (PKR) and, 
thereby, to inhibit the IFNα response 230, 268, 269. In this context, we found no 
inhibition of IFNα  induced Jak-STAT signaling by NS5A in 4 independent 
UNS5Acon cell clones analyzed. This is in accordance with recent data 
published by Polyak et al. 270. Interestingly, however, expression of the NS5A 
protein in cultured cells resulted in partial resistance to the antiviral effects of 
IFNα against IFN-sensitive viruses, such as vesicular stomatitis or 
encephalomyocarditis viruses 271, 272, 273, 274, 231, 275. In line with observations 
made earlier in the context of the entire HCV polyprotein 243, Podevin et al. 
recently found no effect of NS5A expression on PKR activity in HuH-7 cells 
constitutively expressing different NS5A sequences 274. Therefore, the 
inhibitory effect of NS5A may be mediated by PKR-independent mechanisms 
as well. Taken together, these observations indicate that HCV proteins may 
interfere with the IFN system by different mechanisms. 
Among other members of the Flaviviridae family, bovine viral diarrhea virus 
was found to interfere with the IFN system to establish persistent infection 276 
277. Therefore, interference with the IFN system may be a common mechanism 
of Flaviviridae family members leading to persistent infection. 
 
In conclusion, we show here that the HCV structural proteins interfere with 
IFNα induced signal transduction through the Jak-STAT pathway. Inhibition 
occurred downstream of STAT tyrosine phosphorylation and resulted in an 
impaired upregulation of IFNα target genes. A better understanding of the 
interactions between HCV and the IFN system may ultimately result in more 
effective therapies to inhibit HCV escape of the IFN-induced antiviral defense, 
and consequently to prevent establishment of chronic HCV infection. 
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Abstract 
 
The role of STATs in liver pathophysiology has been studied so far mainly with 
loss-of-function models (e.g. IL-6 KO mice, IFN-receptor KO mice, STAT1 and 
STAT5 KO mice, inducible STAT3 KO mice).  
To study the effects of enhanced activities of STATs, we generated fusion 
proteins between STAT1, STAT3 or STAT5a and the modified ligand-binding 
domain of the estrogen receptor. In addition, we generated several mutants of 
the fusion proteins to study the functionality of the fusion proteins and its 
ability to mimic activated STAT, when stimulated with 4-hydroxytamoxifen 
(4-HT).  
Fusion proteins between wild-type mSTAT1, mSTAT3 or mSTAT5a and the 
ligand binding domain of the estrogen receptor were generated. For each 
STAT three mutants were generated; a SH2-domain (R602→K, R609→K or 
R618→K), a tyrosine phosphorylation site (Y701→F or Y705→F) and a serine 
phosphorylation site (S727→A) mutant. STAT1-ER constructs were 
transfected in STAT1 ∆/∆ mouse embryonic fibroblasts (MEFs) and the 
STAT3-ER constructs in STAT3 ∆/∆ MEFs, and stable transfected clones were 
selected. 
STAT signaling was investigated after activation of cells with natural ligands 
(IFN, IL-6, LIF) and compared to effects generated by treatment of the cells 
with 4-hydroxytamoxifen (4-HT), a synthetic steroid drug that can dimerize 
and activate the STAT-ER proteins directly. The STAT1-ER fusion proteins 
appeared to be not functional. From the STAT3-ER fusion proteins only the 
wild type could be activated by 4-HT and was shown to mimic STAT3 
activation.  
STAT3wt-ER and STAT5aR618K-rER fusion protein construct are used to 
generate mice expressing the STAT-ER fusion proteins under the control of 
the albumin promoter.  
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Introduction 
 
The biological function of STAT proteins has been mainly studied with loss-of-
function models, i.e. dominant negative forms of STATs or STAT deficient 
mice. However, there are a number of diseases where constitutive active 
STATs have been found. We therefore wanted to generate conditionally active 
forms of STAT proteins that can be activated independently of their natural 
ligands. To that aim, we constructed fusion proteins between STAT1, STAT3 or 
STAT5a and the modified ligand binding domain (LBD) of the estrogen 
receptor (ER). Such fusion proteins can be dimerized by 4-HT (4-
hydroxytamoxifen). STAT1, 3 and 5a are chosen for the following reasons. 
STAT1 is central for IFN signaling and both Hepatitis B and C virus are 
treated with IFN. Enhanced STAT1 signaling could be a possible way to target 
HCV interference with IFNα induced Jak-STAT signaling. Furthermore has 
STAT1 been shown to induce apoptosis 103, 105 and to inhibit cell growth 278. 
Due to these properties is STAT1 described as tumor suppressor 5, 279 and it 
could be of importance during liver regeneration.  
STAT3 activation is one of the earliest events in the regenerating liver and 
prolonged activation is positively correlated with hepatocyte regeneration and 
survival. However IL-6 was shown to be not required for liver cell proliferation 
since some KO animals did regenerate normally without IL-6 substitution. 
STAT3 target genes cyclin D1 and c-Myc were not induced, and cell cycle 
progression was thought to take place with help of compensatory cyclin D3-
CDK6 activation. So it seemed that STAT3 activation is not required for cell 
cycle progression 199. With gain-of-function model for STAT3 we would be able 
clarify further the role of STAT3 in the process resulting in a restored liver. 
STAT3 is reported to act as an oncogene 150 and can upregulate antiapoptotic 
genes and genes involved in cell cycle, indicating its role in oncogenesis 149. 
STAT5a is, like STAT3 also a promoter of cell proliferation, cellular 
transformation and inhibitor of apoptosis 280. Especially because of its role in 
GH signaling in liver 123, it would be interesting to study STAT5a in a gain-of-
function model during liver regeneration or oncogenesis of e.g. hepatocellular 
carcinoma. A model for STAT5a would also be of use to examine whether 
STAT5a can protect hepatocytes against apoptosis in ischemia injuries during 
liver transplantation.  
Conditionally active STAT models that have been generated make it 
possible to analyze the function of the STAT proteins in their correct 
physiological context. Fusion proteins between the modified (G525R) ligand 
binding domain of the estrogen receptor (aa 281-599) and the full length 
mSTAT1, 3 or 5a protein (i.e. mSTAT-ER) have been created. The fusion 
protein can be activated by the synthetic steroid ligand 4-HT only; the 
mutation of the glycine at position 525 abolishes the ability of the receptor to 
bind 17β-estradiol 281. 4-HT binds to the modified ligand binding domain by 
forming two hydrogen bonds with E357 and R398, this result in the 
repositioning of ER’s ligand binding domain helix 12 over the NR box 
coactivator site, which prevents binding of the NR box protein and activation 
of the estrogen response element (ERE). Moreover, this mutant does not have 
transactivation activity 282. Upon binding with 4-HT, the ER ligand binding 
domain is phosphorylated on the tyrosine residue 541, which is thought to 
induce dimerization of the domains 283, and consequently of the STAT-ER 
fusion protein. It is then able to translocate to the nucleus where it can induce 
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STAT specific target gene transcription. Matsuda et al. showed in cells that the 
fusion protein between STAT3 and the modified ligand binding domain of the 
estrogen receptor (mSTAT3-ER) can mimic activated STAT3 in the presence 
of 4-HT without cytokine signaling. With this model proof was given that 
STAT3 activation is sufficient to maintain an undifferentiated state of mouse 
embryonic stem (ES) cells 284. In their hands, mSTAT3-ER could be tyrosine 
and serine phosphorylated by 4-HT or LIF, and it could bind to DNA when ES 
cells were stimulated. They also used this model to investigate the mechanism 
underlying the regulation of D-type cyclins during liver development. They 
showed that oncostatin M suppresses the expression of cyclins D1 and D2 in 
fetal hepatocytes in vitro and that this is mediated by STAT3 285. Other STAT-
ER fusion proteins have been published by Kamogawa et al. and Milocco et al. 
A STAT6-ER fusion protein could induce transcription of an IL-4-responsive 
promoter upon 4-HT stimulation. Additional IL-4 stimulation enhanced DNA 
binding 286. Fusion proteins between hSTAT1, STAT5a, STAT5b or STAT6 and 
the intact ligand binding domain of the estrogen receptor were reported to be 
activated upon estradiol, 4-HT and IFNγ stimulation, however not to be 
phosphorylated on Y701 (for STAT1ER) 287. 
 
For the cloning of the models we used the mSTAT3-ER and mSTAT5a-rER 
constructs generated by Matsuda 284. These constructs and mSTAT1 cDNA 
were used to clone the third construct; i.e. mSTAT1-ER.  
In the published studies there was no proof presented that tyrosine 
phosphorylation and/or a functional SH-2 domain are required to establish a 
stable STAT-ER dimer and induce STAT specific transcription. Due to the 
results with the STAT6-ER fusion protein, it was suggested that dimerization 
and activation of the STAT-ER fusion proteins occurs without phosphorylation 
of the C-terminal STAT tyrosine residue 286. It was also shown by all who 
published fusion proteins between STAT and the ligand binding domain of the 
ER, that the fusion protein could be activated, in addition to 4-HT, by 
cytokines. This would imply in an in vivo situation that the STAT-ER fusion 
proteins could be activated by any endogenous occurring ligand and activation 
responses would be difficult to control. If, as suggested, the dimerization of 
the fusion proteins is induced by the dimerization of its ER ligand binding 
domain upon 4-HT binding, then a mutation of the conserved arginine in the 
SH2 domain or of the tyrosine residue would not influence the functionality of 
the STAT-ER protein. As described, the conserved arginine in the SH2 domain 
is required for STAT recruitment to the receptor upon ligand binding and 
interactions between this arginine residue and the phosphorylated tyrosine 
residue is required for dimerization and activation of the STATs. Therefore, it 
is expected that these mutations would abolish the possibility that STAT-ER 
fusion proteins are activated by cytokines. To test this hypothesis and aiming 
to create a STAT-ER fusion proteins, which would be exclusively be activated 
by 4-HT, three mutants were designed for mSTAT1-ER, mSTAT3-ER and one 
for mSTAT5a-rER. A single amino acid mutation was introduced replacing 
arginine (R) 602 (mSTAT1), 609 (mSTAT3) or 618 (mSTAT5a) with a lysine 
(K), replacing tyrosine (Y) 701 (mSTAT1) or 705 (mSTAT3) with a 
phenylalanine (F) and serine (S) 727 with an alanine (A). The serine mutated 
fusion proteins will be used to test the functional significance of S727 
phosphorylation on transcriptional activity in the context of STAT-ER fusion 
proteins. 
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The wild-type and mutant constructs for mSTAT1-ER and mSTAT3-ER were 
expressed in mouse embryonic fibroblasts (MEFs) deficient for STAT1 and 
STAT3, respectively, to determine the most optimal inducible mSTAT-ER 
fusion protein variant to use in an in vivo model.  
Here we report our analysis of the activation of mSTAT1-ER and mSTAT3-ER 
fusion protein mutants compared to wild type, by either 4-HT, IFNγ or IL-6 in 
MEF cell lines. 
 
 
Materials and Methods 
 
Plasmid construction 
The wild type mouse STAT3-ER (mSTAT3wt-ER) and mSTAT5a-rER 
constructs ligated EcoRI-XhoI in the pCAGGS vector, were kindly provided by 
Dr. T. Yokota (Science University of Tokyo) (described in 284). The plasmids 
contain a puromycin acetyltransferase gene driven by the SV40 early 
promoter, expressing a fusion protein between full length mSTAT3 or 
mSTAT5a and modified ligand binding domain of the estrogen receptor (aa 
281-599) of mouse respectively rat (ER respectively rER). 
 
The SH2 domain mutation (R618→K) in pCAGGS-mSTAT5a-rER was 
introduced using the QuikChange XL Site-directed mutagenesis kit 
(Stratagene, The Netherlands) and mutagenic primers designed forward (5’-A 
CCTTCCTGCTGAAGTTCAGTGACTCGG-3’; mutation boldface) and reverse 
(5’-CCGAGTCACTGAACTTCAGCAGGAAGGT-3’; mutation boldface) 
complementary to opposite strands of pCAGGS-mSTAT5a-rER. With this 
method pfuTurbo DNA polymerase extends and incorporated the mutagenic 
primers during temperature cycling. Following temperature cycling, the 
product was treated with DpnI endonuclease, which is specific for methylated 
and hemimethylated DNA and was used to digest the parental DNA template 
and to select for mutation containing synthesized DNA. The vector DNA 
incorporating the desired mutation was then transformed into XL10-Gold 
ultracompetent bacterial cells.  
 
The mSTAT3wt-ER cDNA was amplified from pCAGGS using forwardHindIII 
(5’-GCCAGTCGGGCCTCAAGCTTGGAGACAGTCGAGACC-3’; HindIII site 
underlined) and reverseApaI/mutated stop codon (5’-AGATCCACTAGT 
AGGGGCCCTGAGATCGTGTTGG-3’; ApaI site underlined, mutated stop 
codon boldface) introducing primers. The PCR products were digested and 
cloned HindIII-ApaI into the pcDNA4/myc-His (frame A) vector 
(Invitrogen, Carlsbad, CA) in frame with the myc-His-stop tag, generating 
pcDNA4mSTAT3wt-ER-myc-His.  
Mutagenesis of pcDNA4mSTAT3wt-ER-myc-His, to introduce a SH2 domain 
(R609→K), a tyrosine phosphorylation site (Y705→F) or a serine 
phosphorylation site (S727→A) mutation, was performed according to the 
QuikChange XL Site-directed mutagenesis kit protocol and using the 
mutagenic primers designed forward (5’-CACCTTCCTACTGAAGTTCAGCGA 
GAGCAG-3’; R→K mutation boldface) and reverse (5’-CTGCTCTCGCTG 
AACTTCAGTAGGAAGGTG-3’; mutation boldface), forward (5’-TAGTGCTG 
CCCCGTTCCTGAAGACCAAG-3’; Y→F mutation boldface) and reverse (5’-
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CTTGGTCTTCAGGAACGGGGCAGCACTA-3’; mutation boldface), and 
forward (5’-GACCTGCCGATGGCCCCCCGCACTTTAG-3’; S→A mutation 
boldface) and reverse (5’-CTAAAGTGCGGGGGGCCATCGGCAGGTC-3’; 
mutation boldface), respectively, complementary to opposite strands of the 
plasmid. 
The mSTAT3wt-ER-myc-His, mSTAT3R609K-ER-myc-His, mSTAT3Y705F-ER-
myc-His and mSTAT3S727A-ER-myc-His cDNAs were amplified from 
pcDNA4/myc-His using forwardSpeI (5’-TATAGGGAGACCCAAGCTGACT 
AGTTAAGCTTGGAGACAG-3’; SpeI site underlined) and reverseNotI (5’-ATG 
GCTGGCAACTAGCGGCCGCAGTCGAGGCTGATC-3’; NotI site underlined) 
introducing primers. The PCR products were digested and cloned SpeI-NotI 
into the pEFzeo vector 288 (gift from Dr. T. Decker, Vienna Biocenter), 
generating pEFmSTAT3wt-ER-myc-His ect. 
 
The mSTAT1wt cDNA was amplified by PCR from pcDNA3 (XhoI-XhoI insert) 
(a gift from Dr. D.E. Levy, New York University school of medicine) using 
forwardKpnI (5’-GGGAACGGAAGCATTTGGTACCTCCAGGATGTCAC-‘3; 
KpnI site underlined) and reverse BamHI/mutated stopcodon (5’-
GTCGCCAGAGAGAAATTCGGATCCATACTGTGCTCATCATACTG-‘3; BamHI 
site underlined, mutated stop codon boldface) introducing primers. The PCR 
products were digested and cloned in a pcDNA3 vector (Invitrogen).  
To generate the mSTAT1wt-ER fusion construct, the modified ER ligand 
binding domain was amplified from the pCAGGS-mSTAT3wt-ER using 
forwardBamHI including/insertion (5’-GTGCTACCTCCCCCATGGATCCGGG 
CTCCGAGCCCGAATT-‘3; BamHI site underlined, insertion boldface) 
including and reverseNotI introducing/stop codon including (5’-GGGAGAT 
CCACTAGCGGCCGCTCTCAGATCGTG -‘3; NotI site underlined, stop codon 
boldface) primers. The mER BamHI-NotI PCR fragment was digested and 
ligated in frame at the C-terminal of mSTAT1 in pcDNA3. This fusion protein 
(STAT1wt-ER) contains 11 extra amino acids (WIRAPSPNSDP), which are not 
present in either mSTAT1 or ER ligand binding domain, at the fusion point. 
Mutagenesis of pcDNA3mSTAT1wt-ER, in order to introduce a SH2 domain 
(R602→K), a tyrosine phosphorylation site (Y701→F) or a serine 
phosphorylation site (S727→A) mutation, was performed according to the 
QuikChange XL Site-directed mutagenesis kit protocol and using the 
mutagenic primers designed forward (5’-AGGGACGTTCCTGCTTAAATTCAG 
TGAGAGCTCC-3’; R→K mutation boldface) and reverse (5’-GGAGCTCTCAC 
TGAATTTAAGCAGGAACGTCCCT-3’; mutation boldface), forward (5’-AAGC 
GAACTGGATTCATCAAGACTGAGTTG-3’; Y→F mutation boldface) and 
reverse (5’-CAACTCAGTCTTGATGAATCCAGTTCGCTT-3’; mutation 
boldface), and forward (5’-AACCTGCTTCCCATGGCTCCAGAGGAGTTTG-3’; 
S→A mutation boldface) and reverse (5’-CAAACTCCTCTGGAGCCATGGGAA 
GCAGGTT-3’; mutation boldface), respectively, complementary to opposite 
strands of the plasmid. 
The mSTAT1wt-ER, mSTAT1R602K-ER, mSTAT1Y701F-ER and mSTAT1S727A-
ER cDNAs were amplified from pcDNA3 using forwardSpeI introducing (5’-T 
AGGGAGACCCAAGCTTGGTAACTAGTGGATGTCACAGTGG-3’; SpeI site 
underlined) and reverseNotI including (5’-TCTAGATGCATGCTCGAGCGG 
CCGCTCTCAGATCG-3’; NotI site underlined) primers. The PCR products 
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were digested and cloned SpeI-NotI into the pEFzeo vector, generating 
pEFmSTAT1wt-ER ect. 
All sequences and mutations were confirmed using the DYEnamic Direct 
Cycle Sequencing system (Amersham Biosciences) or a ABI Prism™ DNA 
3730 sequencer (Perkin Elmer, MA, USA). 
 
Establishment of stable transfectants  
STAT1 deficient (∆/∆) MEFs 288 (gift from Dr. T. Decker, Vienna Biocenter) 
were transfected in 10 cm culture dishes, using 2 µg of pEFmSTAT1wt-ER, 
pEFmSTAT1R602K-ER, pEFmSTAT1Y701F-ER or pEFmSTAT1S727A-ER 
plasmid DNA and Effectene reagent according to the manufacturer’s 
instructions (Qiagen, Hilden, Germany).  Clones were selected with Zeocin 
(200 µg/ml, Invitrogen). Individual clones, isolated by limiting dilution were 
characterized for comparable STAT1-ER expression to STAT1 expression in 
STAT3 deficient MEFs by western blotting. 
STAT3 deficient (∆/∆) MEFS 289 (kind gift from Prof. V. Poli, DiPartimento di 
Genetica, Torino) were transfected in 10 cm culture dishes, using 2 µg of 
pEFmSTAT3wt-ER-myc-His, pEFmSTAT3R609K-ER-myc-His, 
pEFmSTAT3Y705F-ER-myc-His or pEFmSTAT3S727A-ER-myc-His plasmid 
DNA and Effectene reagent.  Clones were selected with Zeocin (400µg/ml). 
Individual clones, isolated by limiting dilution were characterized for 
comparable STAT3-ER expression to STAT3 expression in STAT1 ∆/∆ MEFs 
by western blotting. 
Cells were cultured in DMEM GlutaMAX™ supplemented with 5% fetal 
bovine serum, 50 U/ml penicillin and 50 µg/ml streptomycin (Gibco, 
Invitrogen AG, Switzerland).  
 
Reagents and antibodies  
4-Hydroxytamoxifen (4-HT) (H-7904) was purchased from Sigma (St. Louis, 
Mo.) and used at a concentration of 1µM (except where indicated differently), 
recombinant human IL-6 was produced as described 290 and used at a 
concentration of 200 ng/ml. Murine IFNγ (Gibco) was used at a concentration 
of 1000 U/ml and murine LIF (Sigma) at a concentration of 100 ng/ml. 
Antibodies against STAT1 (sc-346) and ERα (sc-542) were from Santa Cruz 
Biotechnology, and against STAT3 from Zymed Laboratories Inc. (13-7000; 
CA, USA). Polyclonal antiserums against Tyr705-phosphorylated STAT3 (07-
391) or Ser727-phosphorylated STAT3 (9134S) were obtained respectively, 
from Upstate Biotechnology (Lake Placid, N.Y.) and Cell Signaling 
Technologies (New Englands Biolabs, Beverly, MA).  The antibody against 
phosphorylated Jak1 (3331S) was from Cell Signaling Technologies, and 
against Jak1 (J24320) from Transduction Laboratories (Lexington, KY). 
 
EMSA 
After treatment with 4-HT, hIL-6, mLIF or mIFNγ, cells were lysed in low salt 
buffer (20 mM Hepes pH 7.9, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.2% 
NP-40, 10% glycerol, 0.1 mM Na3VO4, 1 mM PMSF, 1 mM dithiothreitol, 2 
µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin) at 4 °C for 10 min. 
After centrifugation for 30 s at 12,000 x g, supernatants (= cytoplasmic 
extracts) were immediately frozen on dry ice, and pellets were extracted with 
high salt buffer (same as low salt, except for 420 mM NaCl and 20% glycerol 
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and no NP-40) for 30 min at 4 °C. Samples were cleared by centrifugation at 
12,000 x g at 4 °C. Supernatants were aliquoted, frozen on dry ice and stored 
at –70 °C. For EMSA, nuclear extracts (2 µl) were incubated for 20 min at RT 
in 20 mM HEPES, pH 7.9, 4% Ficoll, 1 mM MgCl2, 40 mM KCl, 0.1 mM 
EGTA, 0.5 mM dithiothreitol, and 160 µg/ml poly[dI-dC]-poly[dI-dC] with 1 
ng of 32P-labeled oligonucleotides. Samples were separated on a 5% non-
denaturing polyacrylamide gel at 400 V for 5 h at 4 °C. Gels were then dried 
and exposed for 24 h to a storage phosphor screen. The following 
oligonucleotides corresponding to STAT response element sequences were 
used; SIE-m67 (mutated serum inducible element) = 5'-CATTTCCCGTAAAT 
CAT-3'.  
 
Protein extraction and Western blotting 
For the preparation of whole cell extracts, cells were lysed in a buffer 
containing 50 mM Tris-HCl, pH 8.0, 280 mM NaCl, 0.5% NP-40, 0.2 mM 
EDTA, 2 mM EGTA, 10% glycerol, 0.1 mM Na3VO4, 1 mM PMSF, 2 µg/ml 
aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin A. SDS-polyacrylamide gel 
electrophoresis and Western blot were performed according to standard 
protocols 253.  
 
Protein extraction and Immunoprecipitation 
For the preparation of IP whole cell extracts, cells were lysed in a buffer 
containing 50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM EDTA, 0.1% TX-
100, 10 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 2 µg/ml aprotinin, 1 µg/ml 
leupeptin, and 1 µg/ml pepstatin A. 50µg of total protein was incubated in a 
total volume of 300 µl with 3µl of anti-c-Myc (sc-42, Santa Cruz) antibody for 
overnight at 4 °C. Then protein A-Sepharose (Sigma) was added for 2.5 hours 
at 4 °C. After SDS-polyacrylamide gel electrophoresis and transfer onto 
nitrocellulose membrane, proteins were detected with the anti-c-Myc 
antibody. Blots were analyzed by densitometry using NIH image software. 
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Results and Discussions 
 
The pCAGGS-mSTAT3wt-ER and pCAGGS-mSTAT5awt-rER plasmids (a gift 
from Dr. Yokota) were used for cloning.  mSTAT1wt-ER was composed out of 
the entire coding region of mouse STAT1 put together with the modified ER 
ligand binding domain amplified from pCAGGS-mSTAT3-ER. The constructs 
were transferred to another murine expression vector to enable them to be 
expressed in MEFs under Zeocin selection. 
Three mutants of the mSTAT1wt-ER and mSTAT3wt-ER fusion protein 
constructs were generated; a SH2 domain mutant (R exchange for K); a 
tyrosine phosphorylation site mutant (Y to F); and a serine phosphorylation 
site mutant (S to A). Due to technical limitations of the mutagenesis 
procedure, it was possible to establish only the SH2 mutant of mSTAT5a-rER. 
The mSTAT5a-rER constructs were not expressed in cells, assuming that 
results for mSTAT1-ER and mSTAT3-ER would be as well valid for mSTAT5a-
rER. Domain structures of STAT1, STAT3 and STAT5 in relation to their 
conditional active form (i.e. STAT-ER) are shown in Figure 1. The locations of 
the introduced mutations indicated in red writing.  
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Figure 1. Schematical diagram showing the STAT1 (A), STAT3 (B) and STAT5a 
(C) domain structure in relation to their STAT-ER form. Domains are labeled as 
follows: N= N-terminal domain, C-C= coil-coil domain, DNA= DNA binding domain, LD= 
linker domain, SH2= SH2 domain, P= phosphorylated tail segment, T= transactivation 
domain, ER LBD= ligand binding domain of the estrogen receptor alpha. The whole fragment 
taken from ERα (including the LBD) to generate the fusion protein is shown in grey. The 
linker between the STAT and the ER is depicted as a black rectangle, showing on top the 
linkers’ aa residue composition. The three STAT mutation sites are indicated. In the ER LBD 
two residues are indicated that enable the binding to 4-HT. The mutation modifying the ER 
LBD is also indicated. The numbers of the aa that render the domain boundaries are shown. 
Between brackets, the original aa residue numbers from the complete mouse ERα protein 
sequence. 
 
 
mSTAT3-ER fusion proteins 
 
Cloning and mutagenesis procedures 
The mSTAT3wt-ER construct was amplified by PCR from the pCAGGS-
mSTAT3wt-ER plasmid and transferred to a pcDNA4-myc-His vector. The 
pCAGGS vector contained many GC-rich sequences which interfered with the 
mutagenesis procedure. Mutagenesis of pcDNA4mSTAT3wt-ER-myc-His was 
performed according to the QuikChange XL Site-directed mutagenesis kit 
protocol as described in the materials and methods section, using the 
mutagenic primers designed forward and reverse complementary to opposite 
strands of pcDNA4mSTAT3wt-ER-myc-His.  
Because of the incompatibility of the selection marker in pcDNA4-myc-His 
with the STAT3∆/∆ MEFs, mSTAT3-ER-myc-His wild-type and mutant 
constructs were amplified by PCR from the pcDNA4mSTAT3-ER-myc-His 
plasmids and transfered to the pEFzeo vector, which contains a Zeocin 
selection gene, designated pEFmSTAT3wt-ER-myc-His, pEFmSTAT3R609K-
ER-myc-His, pEFmSTAT3Y705F-ER-myc-His and pEFmSTAT3S727A-ER-myc-
His. These constructs were sequenced using forward and reverse primers at 
every 400 base pairs. In this way the sequencing results were confirmed by at 
least two primer readings. Sequencing results were compared to the NCBI 
GenBank. Some additional mutations have been discovered in the mutant 
fusion protein compared to the wild-type mSTAT3wt-ER-myc-His fusion 
protein. These are summarized in Table 1. K16E and T25S are described as 
variation in mSTAT3 by the GenBank.  
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 N C-C DNA LD SH2 P T ER LBD 
mSTAT3wt-ER K16E, 
T25S 
      M925T, 
G1025R 
mSTAT3R609K-
ER 
K16E, 
T25S, 
N82D 
 
 
G402D, L413P P496L G604D, 
R609K 
  G1025R 
mSTAT3Y705F-
ER 
K16E, 
T25S 
L207P N401S  M648V S691G, 
Y705F 
 G1025R 
mSTAT3S727A-
ER 
K16E, 
T25S 
     S727A N911I, 
G1025R 
 
Table 1. Summary of sequence analysis of the mSTAT3-ER-myc-His constructs. 
Amino acid substitutions revealed by sequencing of the pEFmSTAT3-ER-myc-His 
constructs. Confirmed aa mutations were summarized according to their location. Domains 
are labeled as in Figure 1. 
Presented in bold script are the intentionally introduced mutations, in grey the mutations 
already present in mSTAT3wt-ER-myc-His construct and in normal script, the mutations 
introduced due to the mutagenesis procedure. 
 
 
Expression of pEFmSTAT3-ER-myc-His constructs in STAT3-deficient MEFs 
The pEFmSTAT3-ER-myc-His wild-type and mutant plasmids were 
introduced into STAT3∆/∆ MEFs according to normal transfection procedures 
and stable transfectants were established. The expression level of the different 
mSTAT3-ER-myc-His clones in STAT3∆/∆ MEFs is shown in Figure 2. The 
calculated size of mSTAT3-ER-myc-His is 124.8 kDa. Clones with an 
expression level, when possible, comparable to STAT3 expression in 
STAT1∆/∆ MEFs, were chosen to use in functional assays; i.e. nr.10 for 
mSTAT3wt-ER, nr.71 for mSTAT3R609K-ER, nr.44 for mSTAT3Y705F-ER and 
nr.12 for mSTAT3S727A-ER. 
 
 
  
 
 
Figure 2. Expression of the different pEFmSTAT3-ER-myc-His clones in STAT3-
deficient MEFs.  Expression levels were analyzed by Western blotting using a monoclonal 
antibody against the STAT3 C-terminal. Whole cell lysates were prepared from untreated 
MEFs either transfected or left untransfected. Arrows indicate the positions of the STAT3 and 
STAT3-ER proteins. Lanes are labeled as follows: 1-/- = untransfected STAT1∆/∆ MEFS, 3-/- 
= untransfected STAT3∆/∆ MEFs, 3wt-ER= STAT3 ∆/∆ MEFS transfected with 
pEFmSTAT3wt-ER-myc-HIS ect. 
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Activation of mSTAT3-ER-myc-His fusion proteins   
The different cell lines expressing wild-type or mutant mSTAT3-ER-myc-His 
fusion proteins, were stimulated with 4-HT, hIL-6 or mLIF for 30 min or 1 
hour. Nuclear and cytoplasmic extracts were prepared. The cytoplasmic 
extracts at the 30 min timepoint were analyzed in Western blotting using 
antibodies against the tyrosine705 and serine727 phosphorylation site of 
STAT3 and against STAT3. We show in Figure 3 that both 4-HT and hIL-6 
stimulation did result in phosphorylation of tyrosine705 of mSTAT3wt-ER-
myc-His fusion protein. hIL-6 stimulation results in even a stronger signal 
then after 4-HT stimulation (Figure 3A). 4-HT stimulation, but not IL-6 or 
LIF stimulation (LIF stimulation data not shown) of the STAT3-ER expressing 
MEF cell lines, did result in serine727 phosphorylation of the mSTAT3wt-ER-
myc-His fusion protein (Figure 3B). Phosphorylation levels did not increase 
after 1 h of stimulation compared to the 30 min timepoint (data not shown). 
STAT3 expressed by STAT1-deficient MEFs could as well be tyrosine as serine 
phosphorylated by hIL-6, but not by 4-HT (4-HT stimulation not shown). 
Expression levels of STAT3 and STAT3-ER in the MEFs are shown in Figure 
3C. We were neither able to demonstrate tyrosine nor serine phosphorylation 
of the mutant forms of STAT3wt-ER fusion protein by either 4-HT, IL-6 or 
LIF.  
 
 
 
 
 
Figure 3. Activation of STAT3 and STAT3-ER after stimulation with 4-HT or IL-6 
in STAT1 ∆/∆, respectively STAT3 ∆/∆ MEFs. Tyrosine and serine phosphorylation of 
STAT3 and STAT3-ER. Cytoplasmic extracts were analyzed by Western blotting using 30 µg 
of lysate. The membrane was probed with anti-phosphoserine727-STAT3 antibody (B), 
stripped, reprobed with anti-phosphotyrosine705-STAT3 antibody (A), stripped and 
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reprobed for a third time with anti-STAT3 antibody (C). The positions of (phosphorylated) 
STAT3 proteins are indicated by arrows.  MEFS were either left untreated or treated for 30 
min or 1h with 1µM 4-HT or 200 ng/ml hIL-6.  
 
 
To determine whether the mSTAT3-ER-myc-His fusion proteins can function 
as DNA binding protein in response to 4-HT and cytokines, and to determine 
which or if one of the mutations mutation would diminish this function, the 
nuclear extracts prepared in the same experiment as the previous described 
cytoplasmic extracts were analyzed by EMSA. Figure 4 shows that the 
mSTAT3wt-ER-myc-His fusion protein is able to bind DNA upon already 30 
min of 4-HT stimulation, but not upon IL-6 stimulation.  
 
 
 
 
 
Figure 4. DNA binding assay of STAT3 and STAT3-ER stimulated with 4-HT or 
IL-6 in STAT1 ∆/∆, respectively STAT3 ∆/∆ MEFs. Nuclear extracts, corresponding to 
the cytoplasmic extracts used for Figure3, were analyzed by EMSA using the M67 
oligonucleotide. SIF-A (i.e. STAT3:STAT3 homodimer) shift is detected in STAT1-deficient 
MEFs only when stimulated with 200 ng/ml hIL-6, but not when stimulated with 1 µM 4-HT. 
STAT3wt-ER (=3wt-ER nr.10 in the Figure) could be activated by only 4-HT, but not by hIL-6. 
The position of the STAT3-ER: STAT3-ER dimer is indicated by an arrow. Samples of 4-HT-
stimulated mSTAT3wt-ER-myc-His fusion protein could be shifted by either 1 µl of polyclonal 
antibody against STAT3 (i.e. α-3, sc-482, Santa Cruz) or by 1 µl of an antibody against the 
LBD of ERα (sc-542). 
 
 
Although this wild-type STAT3 fusion protein can be tyrosine phosphorylated 
upon IL-6 stimulation, it obviously is not able to dimerize and bind DNA. 
Otherwise it might be possible that IL-6 induced binding of the activated 
fusion protein occurs below EMSA detection level. Only IL-6 stimulation 
resulted in DNA binding of STAT3.  We were not able to show DNA binding of 
the mutant forms of mSTAT3wt-ER fusion protein by either 4-HT, IL-6 or LIF 
(LIF activation data not shown). Several independent experiments confirmed 
these results. 
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Target gene induction by mSTAT3wt-ER-myc-His fusion protein  
To examine whether the mSTAT3wt-ER-myc-His fusion protein was able to 
induce transcription of STAT3 target genes, the upregulation of STAT3 target 
gene c-Myc 291 by 4-HT or IL-6 was analyzed. MEFs expressing the 
mSTAT3wt-ER-myc-His fusion protein were stimulated between 1 and 8 hours 
by either 4-HT or IL-6. As control normal 3T3 MEFs were stimulated with 4-
HT and IL-6. Whole cell extracts were prepared and precipitated with anti-c-
Myc antibody. Immunoprecipitates were separated on a Western blot and 
blotted against anti-c-Myc antibody. Figure 5A shows that 4-HT by activating 
mSTAT3wt-ER-myc-His can induce c-Myc protein expression in STAT3-
deficient MEFs. In contrast, IL-6 stimulation of the fusion protein did not 
result in c-Myc protein upregulation (Figure 5B). In 3T3 MEFs c-Myc 
expression was induced by only IL-6 (data not shown). These results suggest 
that 4-HT activates the STAT3 pathway in STAT3-deficient MEFs expressing 
mSTAT3wt-ER-myc-His.  
 
 
 
 
 
Figure 5. Function of mSTAT3wt-ER-myc-His. IP-Western blot analysis of STAT3∆/∆ 
MEFs transfected with pEFmSTAT3wt-ER-myc-His (clone nr.10). Cells were grown to 80% 
confluency and starved for 48 h. Subsequently the cells were stimulated with (A) 1 µM 4-HT 
or (B) 200 ng/ml hIL-6, for the timepoints indicated and IP whole cell extracts were 
prepared. 50 µg of total protein was precipitated with an antibody against c-Myc (sc-42). 
Precipitates were analyzed by Western blotting using the same anti-c-Myc Ab. The arrow 
indicates the position of c-Myc protein and the asterisk the IgG heavy chain. 
 
 
Discussion  
We did show that mSTAT3wt-ER fusion protein can be activated and mimic 
STAT3 signaling upon 4-HT stimulation. The mSTAT3wt-ER fusion protein 
can be tyrosine phosphorylated upon 4-HT, IL-6 or mLIF stimulation. This 
phosphorylation is concentration dependent in case of 4-HT (data not shown). 
Until up to 1h this signal does not increase or diminish. Despite tyrosine 
phosphorylation of the fusion protein by IL-6 or LIF no mSTAT3wt-ER DNA 
binding can be established upon cytokine stimulation, but only upon 4-HT 
stimulation. In a target gene induction assay we demonstrated that only 4-HT, 
but not IL-6 could induce c-Myc expression and not IL-6, in MEFs expressing 
mSTAT3wt-ER fusion protein. This might indicate that upon IL-6 stimulation 
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no stable fusion protein dimer and consequently DNA binding is established. 
Possible do the mSTAT3wt-ER fusion proteins dimerize as well upon cytokine 
stimulation, however lacking the 4-HT induced linking of the ER domains, are 
instable as dimer. We can not explain why Matsuda et al. can demonstrate LIF 
induced transcriptional activity of mSTAT3wt-ER, expressed in embryonic 
stem cells, in a luciferase assay and Northern blot analysis 284. In addition, it 
was not understood why we observed S727 phosphorylation of mSTAT3wt-ER 
upon 4-HT, but not upon IL-6 stimulation. We were able though to induce 
serine727 phosphorylation on endogenous STAT3 in STAT1-deficient MEFs by 
IL-6, but not upon 4-HT stimulation. It is not known how 4-HT stimulation 
result in phosphorylation of either the tyrosine or serine residue. 4-HT 
binding to the modified LBD of the ER, induces phosphorylation of Y541 in 
this domain, although is not clear by which mechanism 283. It might be that 
kinases responsible for this phosphorylation, are also able to phosphorylate 
tyrosine 705 and serine 727 of mSTAT3-ER. Therefore it might be that the 
serine phosphorylation in case of 4-HT stimulation is more a non-specific 
result than a regulated process.  
 
On a first glance, one could conclude that the mSTAT3-ER fusion proteins are 
only functional with intact SH2 and phosphotyrosine domains, because the 
corresponding mutated forms are not active. However the presence of the 
additional mutations shown in Table 1 could also explain the non-functionality 
of these mutant mSTAT3-ER fusion proteins. We could, however exclude 
another potential reason for the activation defect of these fusion proteins, e.g. 
that the expression of these mutant proteins is toxic for cells. When the 
transfected cells were treated with LIF, STAT1 dimers were easily detectable 
by EMSA. Therefore, the receptor-kinase complex is fully functional. We also 
demonstrated that Jak1 can be phosphorylated upon IL-6 and LIF stimulation 
in these mutant fusion protein expressing MEFs, which implies a normal IL-6 
and LIF induced signaling.  
It is possible that some of the additional introduced mutations, as described 
in Table 1, interfere with STAT dimerization, phosphorylation and/or DNA 
binding, although they are not described in literature as such. Residues and/or 
regions described in literature to be important for STAT3 phosphorylation, 
dimerization, nuclear translocation or DNA binding (see introduction), are not 
impaired in these mutant fusion proteins, except for the ones intentionally 
introduced. An exception is the L207P mutation in mSTAT3Y705F-ER. Since it 
is in the second α helix of the coiled-coil domain of mSTAT3, it could result in 
an inactive protein. Another proline mutation (L413P) in the DNA binding 
domain of mSTAT3R609K-ER could interfere with the DNA binding. The 
region of mSTAT3 aa 404-414 is described to be a nuclear export signaling 
element (NES) 80 and the point mutation of R414A did result in inhibition of 
DNA binding due to absence of nuclear translocation, although the STAT3 
could be Y705 phosphorylated as normal 42. In contrast, another point 
mutation in this region (L411A) did not have influence on nuclear 
translocation or DNA binding at all. Of course a lot of residues in the DNA 
binding domain interact with the DNA and although L413 is not described to 
be one of the essential residues in the process of DNA binding, the point 
mutation into a proline might lead to conformational change inhibiting other 
residues to bind DNA 28. However this does not explain why the SH2 domain 
mutant could not be tyrosine phosphorylated. Jak1 was phosphorylated by IL-
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6 stimulation, in MEFs expressing this mutant, so it might be that additional 
introduced mutations in the mSTAT3R609K-ER fusion protein, induce such a 
conformation of the protein that the tyrosine residue is not accessible 
anymore for kinases, induced by either IL-6 signaling or 4-HT. 
Moreover we can not explain why the mSTAT3S727A-ER fusion protein 
could not be Y705 phosphorylated. No additional point mutation was 
discovered in the STAT sequence. A mSTAT3S727A mutant was reported to be 
Y705 phosphorylated and able to bind DNA 85, 86, 292. Moreover it was shown to 
not have influence on DNA binding in both STAT1 and STAT3. It was 
suggested that the enhancement of transcription by the presence of the 
phosphorylated serine 727 residue occurs after DNA binding 86. 
 
New construction of the mutant fusion proteins or repair of these construct 
would be necessary to elucidate the mechanism behind the 4-HT-induced 
dimerization of mSTAT3-ER fusion proteins or/and the effect of the absence 
of serine phosphorylation. 
 
 
mSTAT1-ER fusion proteins 
 
Cloning and mutagenesis procedures 
The mSTAT1wt-ER construct was cloned by the ligation of full length mSTAT1 
cDNA with the modified ER LBD in a pcDNA3 vector, as described in the 
material and method section. Mutagenesis of pcDNA3mSTAT1wt-ER was 
performed according to the QuikChange XL Site-directed mutagenesis kit 
protocol as described in the materials and methods section, using the 
mutagenic primers designed forward and reverse complementary to opposite 
strands of pcDNA3mSTAT1wt-ER.  
Because of the incompatibility of the selection marker in pcDNA3 with the 
STAT1∆/∆ MEFs, mSTAT1-ER wild-type and mutant constructs were 
amplified by PCR from the pcDNA3mSTAT1-ER plasmids and transfered to 
the pEFzeo vector, which contains a Zeocin selection gene, designated 
pEFmSTAT1wt-ER, pEFmSTAT1R602K-ER, pEFmSTAT3Y701F-ER and 
pEFmSTAT1S727A-ER. These constructs were sequenced using forward and 
reverse primers at every 400 base pairs. In this way the sequencing results 
were confirmed by at least two primer readings. Sequencing results were 
compared to the NCBI GenBank. This revealed already many mutations in the 
STAT1 cDNA, which was used to clone mSTAT1-ER. In addition even more 
mutations have been introduced in the wild-type and mutant mSTAT1-ER 
fusion proteins compared to the original mSTAT1 cDNA, by the amplifying 
and mutagenesis procedures. These are summarized in Table 2.  
 
 
Table 2. Summary of sequence analysis of the mSTAT1 cDNA and mSTAT1-ER 
constructs. Amino acid substitutions revealed by sequencing of the pEFmSTAT1-ER 
constructs. Confirmed aa mutations were summarized according to their location. Domains 
are labeled as in Figure 1. Presented in bold script are the intentionally introduced mutations, 
in grey the mutations already present in mSTAT1 cDNA and in normal script, the mutations 
introduced due to the amplifying and mutagenesis procedures. 
Chapter 4 
  89
 
 N C-C DNA LD SH2 P T ER LBD 
mSTAT1  T261S S345L, S354L, 
L356Y 
L357N,T358L, 
C362V, 
H363S,L404F  
N567K,  
D568H 
K592N    
mSTAT1wt-ER T133I T261S S345L,  S354L, 
L356Y 
L357N, T358L, 
C362V, 
H363S, L404F 
L498P, 
N567K,  
D568H 
K592N   G1005R 
mSTAT1R602K-
ER 
T133I K240R,  
T261S 
S345L,  S354L, 
L356Y 
L357N, T358L, 
C362V, 
H363S, L404F 
L498P, 
N567K,  
D568H 
A589T, 
K592N, 
R602K 
  M810T, 
G1005R 
mSTAT1Y701F-
ER 
T133I T261S S345L,  S354L, 
L356Y 
L357N, T358L, 
C362V, 
H363S, L404F 
L498P, 
F506L, 
N567K,  
D568H 
K592N Y701F  G1005R 
mSTAT1S727A-
ER 
S69G, 
T133I 
T261S S345L,  S354L, 
L356Y 
L357N, T358L, 
C362V, 
H363S, L404F 
L498P, 
N567K,  
D568H 
K592N  S727A G1005R 
 
 
Expression of pEFmSTAT1-ER constructs in STAT1-deficient MEFs 
The pEFmSTAT1-ER wild-type and mutant plasmids were introduced into 
STAT1∆/∆ MEFs according to normal transfection procedures and stable 
transfectants were established. The expression level of the different 
pEFmSTAT1-ER wild type and mutant clones in STAT1-deficient MEFs is 
shown in Figure 6. The calculated size of mSTAT1-ER is 119.8 kDa. Clones 
with an expression level comparable to STAT1 expression in STAT3∆/∆ MEFs 
were chosen to use in functional assays; i.e. nr.13 for mSTAT1wt-ER, nr.3 for 
mSTAT1R602K-ER, nr.5 for mSTAT1Y701F-ER and nr.32 for mSTAT1S727A-ER. 
 
 
 
 
Figure 6. Expression of the different pEFmSTAT1-ER clones in STAT1-deficient 
MEFs.  Expression levels were analyzed by Western blotting using a polyclonal antibody 
binding to the STAT1 C-terminal. Whole cell lysates were prepared from untreated MEFs 
either transfected or left untransfected. Arrows indicate the positions of the STAT1 and 
STAT1-ER proteins. Lanes are labeled as follows: 1-/- = untransfected STAT1∆/∆ MEFS, 3-/- 
= untransfected STAT3∆/∆ MEFs, 1wt-ER= STAT3 ∆/∆ MEFS transfected with 
pEFmSTAT1wt-ER ect. 
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mSTAT1wt-ER and mutant fusion proteins could not be activated  
In contrast to the results obtained with the mSTAT3wt-ER fusion protein, we 
could not activate the mSTAT1-ER wild-type by either 4-HT, mIFNα or 
mIFNγ.  As well the mutant mSTAT1-ER fusion proteins could not be activated 
upon stimulation. Also after longer periods of stimulation (up to 4 hours) 
and/or with higher concentrations of 4-HT (up to 10 µM) tyrosine/serine 
phosphorylation and DNA binding of the fusion proteins could not be shown.  
 
Discussion 
The mSTAT1-ER constructs, even the wild-type, have been proven to be 
inactive, when expressed in STAT1-deficient MEFs. The sequence analysis 
data showed that already the mSTAT1 cDNA, received from Dr. Levy, did 
contain many additional mutations, when compared to the Genbank 
sequence. To exclude that the starting material was already infunctional due 
to the many mutations, we transient transfected the pcDNA3-mSTAT1 
plasmid, containing the full length mSTAT1 cDNA, in STAT1-deficient MEFs. 
Cells were stimulated with mIFNγ, nuclear extracts were analyzed by EMSA 
and corresponding cytoplasmic extracts by Western blot. Figure 7 shows that 
transfectionally expressed STAT1 is activated by mIFNγ and can bind to DNA. 
The cytoplasmic extracts demonstrate the expression of mSTAT1 compared to 
non-transfected cells and STAT1 expressed by STAT3-deficient MEFs. Figure 7 
summarizes results from two independent transfection experiments. 
 
 
 
 
Figure 7. Transient transfection of pcDNA3-mSTAT1 in STAT1 ∆/∆ MEFs. STAT1 
∆/∆ MEFs were transfected (TX) with 2 µg of plasmid DNA.  After 24 hours the cells were 
either left untreated or stimulated for 25 min with 1000 U/ml mIFNγ. Nuclear and 
cytoplasmic extracts were prepared and analyzed in respectively EMSA, using the M67 
oligonucleotide and Western blotting using a polyclonal antibody against STAT1 (sc-346).  
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The position of SIF-C (i.e. STAT1:STAT1 homodimer) is indicated. Samples of IFNγ-
stimulated mSTAT1 could be shifted by either 1 µl of polyclonal antibody against STAT1 (sc-
592). 
 
 
So the mutations in pcDNA3-mSTAT1 do not seem to interfere with the 
activation and DNA binding of the STAT1 protein. It is likely, that the 
infunctionality of the mSTAT1wt-ER fusion protein is caused by the T133I or 
L498P substitutions introduced during amplification of the mSTAT1 sequence 
by PCR, from the pcDNA3-mSTAT1 plasmid. Especially the L to P mutation 
could induce conformational changes (see discussion mSTAT3-ER) which 
might interfere with DNA binding. It might be that the combination of the 
mutations in the starting cDNA together with new mutations in the wild-type 
fusion protein results in conformational changes incompatible with STAT 
phosphorylation and DNA binding. Other possibility is the fusion of the 
modified ER LBD to the C-terminal of STAT1 is interfering with STAT 
activation. Second structure analyses of the mSTAT1wt-ER sequence did 
reveal a different structural organization in the region between 
phosphorylation domain and ER domain compared to the same region in the 
mSTAT3wt-ER fusion protein. However these predictions are difficult to 
interpret and moreover, a functional conditional active mSTAT1wt-ER fusion 
protein has been reported by Milocco et al. although they used an unmodified 
ligand binding domain of the ER 287. 
New mSTAT1-ER fusion proteins would have to be constructed to continue 
studies that could lead to the generation of a STAT1 gain-of-function model. 
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Abstract 
 
To obtain conditional and liver-specific gain-of-function models for STAT3 
and STAT5a signaling, we generated transgenic mice that express the 
mSTAT3wt-ER and mSTAT5aR618K-rER fusion proteins under control of the 
liver-specific albumin promoter. In order to circumvent interference with the 
genomic organization of the mouse albumin gene, and acquire stable 
transgene expression patterns, the mSTAT3wt-ER and mSTAT5aR618K-rER 
coding sequences were inserted in the first exon of the albumin gene. Here, we 
describe the multistep cloning approach, involving site-specific homologous 
recombination with a P1-derived artificial chromosome (PAC), to prepare the 
fusion protein constructs for mouse oocyte injection. The PAC contained 185 
kb of mouse chromosome 5 including the entire albumin gene.  
The transgene animals, designated albmSTAT3wt-ER and albmSTAT5aR618K-
rER, appeared to be healthy and show a normal phenotype. Several transgenic 
founders have been identified, as well as a transgenic F1 off spring. Presently 
the transgenic mice are being characterized and transgenic lines are being 
established. In the future we plan to use these transgenic mice to investigate 
involvement of STAT3 and STAT5a signaling in liver pathogenesis and repair. 
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Introduction 
 
We generated conditional gain-of-function mouse models to analyze the role 
of STAT3 and STAT5a signaling in liver. To obtain inducible activated STAT3 
and STAT5a proteins, a wild-type fusion protein has been used between full 
length mSTAT3 and the modified ligand binding domain (LBD) of the 
estrogen receptor (ER) (i.e. mSTAT3wt-ER), and a SH2 domain mutant fusion 
protein of full length mSTAT5a and the modified LBD of the ER (i.e. 
mSTAT5aR618K-rER), to be expressed in mice. Activity of the fusion proteins 
can be regulated by administration of the synthetic steroid 4-
Hydroxytamoxifen (4-HT), a metabolite of tamoxifen. The effects and 
pharmacology of 4-Hydroxytamoxifen have been well characterized through 
its use in animal and human trials and its not likely that its inhibiting effects 
on breast cell 293 and endometrium proliferation, lipid peroxidation 294 and 
formation of tumor promoted-induced hydrogen peroxide in human 
neutrophils 295, will influence the experiments in the liver, especially because 
the concentration used in the described experiments is much lower then the 
concentrations required to give rise to 4-HT’s other biological effects 282. 
 
Until now the only transgenic mouse expressing ubiquitously a fusion protein 
between a STAT protein and the ER LBD has been generated by Matsuda et 
al.. However, for unknown reasons, activation of their mSTAT3-ER fusion 
protein in an adult animal has not yet been shown 284, 285. There are several 
other transgenic mice that expressing fusions of other proteins than STATs 
with the modified LBD of the ER. In these mice, the fusion proteins could be 
activated in vivo by 4-HT at doses that had no apparent toxicity. In a 
transgenic mouse expressing a Myc-ER fusion protein under control of the 
CD2 locus control region, Myc dimerization could be induced in thymocytes 
by 4-HT administration, causing myc mediate proliferation of thymocytes 296.  
Another mouse, expressing a fusion protein between Cre and the ER (Cre-ER), 
allowed 4-HT inducible Cre-mediated recombination in diverse tissues of the 
mouse at embryonic and adult stages 297. Leone et al. generated functional 
tamoxifen-inducible glia-specific Cre mice 298.  
 
To allow liver-specific expressing, the mSTAT3/5a-ER fusion proteins were 
expressed in mice under a liver specific promoter. Expression systems that 
have been used in the past to generate liver-specific expression in vivo include 
cosmids containing the human α1-antitrypsin gene 220, 299, 300, expression 
vectors containing transthyretin (TTR) regulatory sequences and part of the 
coding sequence as well as additional poly A sequences 301 and expression 
vectors containing albumin enhancer/promoter fragments 302, 303 or albumin 
enhancer/promoter fragments in combination with alpha-fetoprotein 
enhancers 304. The disadvantage of most of these approaches is that due to the 
disrupted genomic organisation/unnatural configuration of the albumin 
promoter, the transgene expression pattern can be highly variable 305.  
To circumvent this problem, we chose to embed the transgene in the first exon 
of the albumin 1 gene. Serum albumin is accounting for more then 10% of total 
protein synthesis by the liver 306. The albumin gene is located upstream from 
the alpha-fetoprotein (AFP) gene and its expression is controlled by the AFP 
enhancers located between both genes as well as by other distant enhancer 
located 10 kb upstream of the albumin promoter 307, 308. Extensive studies of 
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this region have suggested that interactions between enhancer and enhancer, 
as well as between promoter and enhancer are part of this regions 
organization. An important part of these interactions is mediate through the 
nuclear factor Y site in the albumin promoter 309. So the genomic organization 
of the albumin-AFP locus is very complex. Therefore we decided to use an 
approach in which we cloned a continuous DNA stretch of approximately 185 
kb from mouse chromosome 5, harbouring the entire albumin 1 gene, AFP 
gene, afamin gene, a gene coding a protein showing similarities to a 
hypothetical zink finger protein and a gene coding a protein showing 
similarities to AFP. This will allow us to express the transgenes in a natural 
context of native promoters, enhancers and introns that can affect expression 
and regulation. We used a P1 derived artificial chromosome (PAC), which is a 
cloning vector that can carry large inserts. 
 
PACs are vectors that combine the features of two other vectors that can carry 
large DNA inserts, i.e. the bacteriophage P1 system and the F-factor based 
bacterial artificial chromosomes (BACs). The bacteriophage P1 system makes 
use of a vector which contains a P1 packaging site to package vector and 
cloned DNA into phage particles, two P1 loxP recombination sites to cyclize 
the packaged DNA once it has been injected into E.coli containing the P1 Cre 
recombinase, as well as a selection gene and a P1 plasmid replicon. It can hold 
DNA fragments up to only 100 kb and the use of a two-step in vitro 
bacteriophage T4 packaging reaction makes it more difficult to work with 310, 
311. BACs are bacterial artificial chromosomes, derived from the F-factor 
plasmid, a natural occurring plasmid of E.coli. The F plasmid in E.coli carries 
genes that give rise to male E.coli, its replication is strictly controlled and is 
maintained in low copy numbers. The F-factor not only codes for genes that 
are essential to regulate its own replication but also its copy number. The 
regulatory genes include oriS, repE, parA and parB. The oriS and repE genes 
mediate the unidirectional replication of the F-factor while parA and parB 
maintain copy number at a level of one or two per E.coli genome. The BAC 
incorporates these genes as well as a resistancy selection marker and a cloning 
segment. The BACs are introduced in bacteria by electroporation and exist as 
supercoiled circular plasmids in bacteria, which permit easy isolation 312. BACs 
allow cloning of DNA fragments up to 350 kb (average insert 120kb), while 
PACs inserts are typical between 130 and 200 kb.  
PAC vectors are derived from the bacteriophage P1, but can like BACs, be 
introduced to bacteria using electroporation. Like the bacteriophage P1, PACs 
are maintained in low copy number (one or two per cell) because of the 
integrated P1 phage based replicon, thus reducing the potential for at random 
recombination between DNA fragments carried by the plasmids 313.  
 
For the functional studies we have planned, it was necessary to insert the 
mSTAT3wt-ER and mSTAT5aR618K-rER transgenes in the albumin gene 
precisely at the desired site, i.e. in frame with the ATG of the albumin gene. 
Conventional cloning methods that rely on the occurrence of suitable 
restriction sites are impractical for this purpose because of the size of the PAC 
plus inserted mouse chromosomal DNA 314, 315. Therefore, the transgenes were 
inserted in the albumin gene with a strategy allowing site specific or 
homologous recombination in E.coli. Homologous recombination allows 
exchange of genetic information between two DNA molecules in a precise, 
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specific and faithful manner. It occurs through homology regions, which are 
stretches of DNA shared by the two molecules that recombine genes 316, 317. In 
our approach, albumin homologous arms of 150-200 bp were cloned to flank 
the target constructs. The used recombination strategy is mediate through the 
recombination genes exo, beta and gam from the defective λ prophage in 
E.coli 318. The recombination genes are under the control of a temperature-
sensitive λ repressor, which can be switched off at 42 °C and is switched on at 
32 °C. When the recombination genes are switch on (at 42 °C) the cells 
become more recombinogenic and take up linear DNA without destruction. 
Gam inhibits the E.coli RecBCD exonuclease from attacking linear DNA, and 
exo and beta generate recombination activity for the in the cells introduced 
DNA 318. The prophage system modified for the use in BAC/PAC 
recombinogenic engineering was developed by Lee et al. The system was 
transferred to DH10B E.coli cells, a BAC host strain, generating the strain 
EL250 among others 319. 
This system has several advantages over earlier published recET cloning 
system, in which redα, redβ (=recombinases) and gam genes are expressed 
under an arabinose dependent promoter 316. Most important, plasmid 
expression systems can be leaky. Uncontrolled presence of gam causes a 
RecBCD exonuclease defect, resulting in plasmid instability and loss of cell 
viability. Gam and reds can also cause BAC/PAC instability 319. 
 
Homologous  recombination in this strategy is performed with the linearized 
target gene constructs  flanked by homology arms, including as well a 
selectable marker gene (AmpR gene) in between site specific recombination 
target sites (FRT sites). Selection is necessary to identify the cells that carry 
the recombinant, because homologous recombination is a rare event. After 
recombination and selection, the recombined construct is exposed to EL250 
integrated arabinose dependent expressed Flpe recombinases which delete the 
selectable cassette at the FRT sites, leaving behind a single FRT 314, 316, 317 319. 
 
We describe here the method that enabled us to generate two transgenic mice, 
albmSTAT3wt-ER and albmSTAT5aR618K-rER. 
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Methods and Materials 
 
Cloning of the fusion protein constructs suited for homologous 
recombination   
mSTAT3wt-ER and mSTAT5aR618K-rER constructs were cloned between 
flanking albumin homologous regions (albHR) to allow site specific  
recombination with the first exon of the albumin gene. The 5’albHR is an 
approximately 200 bp long sequence derived from the 3’end of the albumin 
promoter up to the ATG. The 5’albHR sequence correspond to nt 14478427 – 
14478584 of C57Bl6 mouse chromosome 5 (NCBI MGI:87991 /NT:039307.1) 
The 3’albHR is an approximately 150 bp long sequence derived from first 
coding albumin exon plus connected intron  and correspond to nt 14478603 – 
14478751 of C57Bl6 mouse chromosome 5 (NCBI MGI:87991 /NT:039307.1).  
 
I. Cloning of mSTAT3wt-ER construct to allow homologous recombination 
A schematic overview of the cloning procedure for mSTAT3wt-ER is depicted 
in Figure 1. The 5’albHR was fused in front of the mSTAT3wt-ER sequence by 
3 overlapping PCR reactions in order to replace the ATG of the albumin gene 
for the ATG of mSTAT3wt-ER.   
1) The 5’albHR was amplified and at the 3’ end elongated with 24bp of 5’ end 
mSTAT3wt-ER sequence by PCR using as template p5’albHR (gift from Dr. 
Emilio Casanova, DKFZ, Heidelberg, Germany) and forwardEcoRV-NheI 
introducing (primer 3A) (5’-TTTTTTCGATATCCAAAGATGCTAGCATTTT 
GTAATGGGGTAGG-3’; EcoRV and NheI sites underlined) and 
reversemSTAT3wt-ER overlapping (primer 3B) (5’-CTGCAGCTGGTTCCA 
CTGAGCCATTTTGCCAGAGGCTAGTGGGGT-3’; ATG boldface, STAT3wt-ER 
sequence underlined) primers.  
2) A 5’ mSTAT3wt-ER fragment of 986 bp up to a SphI restriction site was 
amplified and at the 5’end elongated with 21 bp of 3’ end 5’albHR sequence by 
PCR using as template pCAGGS-mSTAT3wt-ER 284 and forward5’albHR 
overlapping (primer 3C) (5’-ACCCCACTAGCCTCTGGCAAAATGGCTCAGT 
GGAACCAGCTGCAG-3’; ATG boldface, 5’HRalbumin sequence underlined) 
and reverseSphI including  (primer 3D) (5’-GGGCCGGTCCGGGTGCATG 
GGCATGCAGGGCTGCCGCTCCACC-3’; SphI site underlined) primers.  
3) The products of these two reactions were mixed to serve as template, from 
which an overlapping 5’albHR-mSTAT3wt-ER-SphI product was amplified by 
PCR using forward primer 3A and reverse primer 3D.  
 
The overlapping 5’albHR-mSTAT3wt-ER-SphI PCR product was digested 
EcoRV-SphI and ligated SphI-EcoRV in pSL1180 (Pharmacia, Amersham 
Biosciences Europe, CH), generating pSL5’albHR-mSTAT3wt-ER-SphI. 
The remaining part of mSTAT3wt-ER was digested SphI-SacI from pCAGGS-
mSTAT3-ER and ligated SacI-SphI in frame with the 5’albHR-mSTAT3wt-ER-
SphI fragment in pSL5’albHR-mSTAT3wt-ER-SphI, generating pSL5’albHR-
mSTAT3wt-ER. Thus, the 5’albHR-mSTAT3wt-ER sequence is inserted reverse 
and complement in pSL1180. 
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Figure 1. Schematic overview of the cloning procedure for mSTAT3wt-ER. 
Overlapping PCR (reaction 1-3 indicated in boldface script in the text) was performed using 
pCAGGS-mSTAT3wt-ER and p5’albHR as templates, and primers 3A-3D designed specific for 
mSTAT3wt-ER as described in boldface script in the text. The cloning procedure of the 
constructs into pSL1180 and into the pECE plasmid is described in the text. 
 
 
The 5’albHR-mSTAT3wt-ER construct was amplified from pSL5’albHR-
mSTAT3wt-ER using forwardSpeI (5’-ACGGCCCACGTGGCCACTAGTACTT 
CTCGAG-3’; SpeI site underlined) and reverseApaI (5’-TGAGGTAATTATAA 
CCCGGGCCCTATATATGG-3’; ApaI site underlined) including primers. SpeI 
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and ApaI restriction sites were present upstream and downstream, 
respectively, of the construct inserted in pSL1180. This PCR product was 
digested and ligated ApaI-SpeI in the plasmid called: pECE-intron-polyA-
frtampfrtnoIres, generating pECE5’albHR-mSTAT3wt-ER-frtampfrt.  
The 3’albHR sequence was excised PacI-BstZ17I from pGFP3’albHR (gift from 
Dr. E. Casanova) and ligated in pECE5’albHR-mSTAT3wt-ER-frtampfrt, 
creating pECE5’albHR-mSTAT3wt-ER-frtampfrt-3’albHR. 
 
II. Cloning of mSTAT5aR618K-rER construct to allow homologous 
recombination 
A schematic overview of the cloning procedure for mSTAT5aR618K-rER is 
depicted in Figure 2. The 5’albHR was fused in front of the mSTAT5aR618K-
rER sequence by 3 overlapping PCR reactions in order to replace the ATG of 
the albumin gene for the ATG of mSTAT5aR618K-rER. 
1) The 5’albHR was amplified and at the 3’ end elongated with 24bp of 5’ end 
mSTAT5aR618K-rER sequence by PCR using as template p5’albHR and 
forwardApaI-NheI introducing (primer 5A) (5’-TTTTTTGGGCCCGCAAAGA 
TGCTAGCATTTTGTAATGGGGTAGG-3’; ApaI and NheI sites underlined) and 
reversemSTAT5aR618K-rER overlapping (primer 5B) (5’-CTGGGCCTGAAT 
CCAGCCCGCCATTTTGCCAGAGGCTAGTGGGGT-3’; ATG boldface, 
mSTAT5aR618K-rER sequence underlined) primers.  
2) A 5’ mSTAT5aR618K-rER fragment of 545 bp up to a BamHI restriction site 
was amplified and at the 5’end elongated with 21 bp of 3’ end 5’albHR 
sequence by PCR using as template pCAGGS-mSTAT5aR618K-rER 
(construction is described in materials and method section of Chapter 4) and 
forward5’albHR overlapping (primer 5C) (5’-ACCCCACTAGCCTCTG 
GCAAAATGGCGGGCTGGATTCAGGCCCAG-3’; ATG boldface, 5’albHR 
sequence underlined) and reverseBamHI including  (primer 5D) (5’-GGGC 
AAACTGAGCTTGGATCCGCAGGCTCTCCTGGT-3’; BamHI site underlined) 
primers.  
3) The products of these two reactions were mixed to serve as template, from 
which overlapping 5’albHR-mSTAT5aR618K-rER-BamHI product was 
amplified by PCR using forward primer 5A and reverse primer 5D.  
 
The overlapping 5’albHR-mSTAT5aR618K-rER-BamHI PCR product was 
digested and ligated ApaI-BamHI in pECE-intron-polyA-frtampfrtnoIres.  
The remaining part of mSTAT5aR618K-rER was amplified from its plasmid 
pCAGGS using forwardBamHI including (5’-ACCAGGAGAGCCTGCGGA 
TCCAAGCTCAGTTTGCCC-3’, BamHI site underlined) and reverseSpeI 
introducing (5’-AGGGATTCGCAGAAACTAGTGGGGAGCCTGGGAGT-3’, SpeI 
site underlined) primers. The PCR product was digested and cloned BamHI-
SpeI downstream of 5’albHR-mSTAT5aR618K-rER-BamHI in pECE-intron-
polyA-frtampfrtnoIres, generating pECE5’albHR-mSTAT5aR618K-rER-
frtampfrt.  
The 3’albHR sequence was excised PacI-BstZ17I from pGFP3’albHR and 
ligated in pECE5’albHR-mSTAT5aR618K-rER-frtampfrt, creating 
pECE5’albHR-mSTAT5aR618K-rER-frtampfrt -3’albHR.  
 
All sequences were confirmed using the DYEnamic Direct Cycle Sequencing 
system (Amersham Biosciences) or a ABI Prism™ DNA 3730 sequencer 
(Perkin Elmer, MA, USA). 
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Figure 2. Schematic overview of the cloning procedure for mSTAT5aR618K-rER. 
Overlapping PCR (reaction 1-3 indicated in boldface script in the text) was performed using 
pCAGGS-mSTAT5aR618K-rER and p5’albHR as templates, and primers 5A-5D designed 
specific for mSTAT5aR618K-rER as described in boldface script in the text. The cloning 
procedure of the constructs into the pECE plasmid is described in the text. 
 
 
Homologous recombination procedure 
An on scale overview of the integration of the 5’albHR-mSTAT-ER-3’albHR 
constructs into the first exon of the albumin gene is depicted in Figure 3. 
A PAC (designated pPAC4, kanamycin resistant) harbouring 185 kb of the 
mouse chromosome 5 including the albumin gene (pPAC4-albumin), was 
isolated from the RPCI-21 mouse genomic library (RZPD library nr. 711, 
Germany. MM strain 129/SvevTACfBr 320). pPAC4-albumin was grown in 
DH10B bacterial cells, extracted and electroporated into EL250 (genotype 
DH10B [λcl857 (cro-bioA) substituted with araC-PBADflpe] 319 E.coli, which 
contain the machinery to allow homologous recombination. 
 
The pECE5’albHR-mSTAT3wt-ER-frtampfrt-3’albHR and pECE5’albHR-
mSTAT5aR618K-rER-frtampfrt-3’albHR constructs were excised from their 
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plasmids at the NheI restriction sites, which were introduced at the 5’albHR 
and present at the 3’end of the 3’albHR. 
A 50 ml culture of EL250 pPAC4-albumin containing E.coli was grown at 32 
°C until OD600=0.5-0.7. The culture was divided in 5 portions of 10 ml and 
grown at 42 °C for 15 min to induce the recombination machinery, i.e. induce 
exo, beta and gam expression. Each 10 ml culture of induced bacteria was 
centrifuged at 7000 rpm for 8 min at 1°C. The pellet was resuspended in 1 ml 
of ice cold water and transferred to an eppendorf tube. Subsequently the cells 
were washed three times in 1 ml of ice-cold water (2 min 7000 rpm 1 °C). The 
final pellet was resuspended in 100 µl of ice-cold water. 50µl of these 
electrocompetent prepared EL25o pPAC4-albumin containing E.coli, were 
electroporated with 150 or 300 ng of linearized construct. Electroporation was 
performed with a Biorad Gene Pulser at 1.8 kV and 25 µF. The cells were 
grown for an additional 2 hours at 32 °C, collected and plated. Recombinant 
pPAC4-albumin-mSTAT3wt-ER-frtamp-frt or pPAC4-albumin-
mSTAT5aR618K-rER-frtamp-frt colonies were identified by double selection 
for ampicillin (50 µg/ml) and kanamycin (25 µg/ml). Positive colonies were 
identified by restriction site analysis /pulsed-field gel electrophoresis (PFGE) 
(CHEF DR-II system, BioRad Laboratories) and Southern blot. For the 
Southern blot analysis, probes were generated by PCR, designed to hybridize 
to the albumin promoter region (probe 1), to the mSTAT3wt-ER (probe 2-3ER) 
or mSTAT5aR618K-ER (probe 2-5aER) sequence or to a region containing part 
of intron 2, exon3 and intron 3 of the albumin gene (probes are indicated in 
purple in Figure 3). Probes were labeled by random-priming with α-32PdCTP. 
Restriction enzymes were purchased from either Promega, Catalys AG, CH or 
New England Biolabs, Bioconcept, CH. 
 
To remove the ampicillin cassette, overnight recombinant cultures from single 
kan/ampR colonies were diluted 50-fold and grown at 32 °C till OD600=0.5. 
Transiently expression of Flpe recombinase from the EL250 E.coli was 
induced by incubating the cultures with 0.1% final concentration of L(+) 
arabinose for 1 h. Induced cultures were 10-fold, grown for another hour at 32 
°C, collected and plated. Colonies growing with kanamycin but not with 
ampicillin, were selected, these bacteria contain pPAC4-albumin-mSTAT3wt-
ER-frt or pPAC4-albumin-mSTAT5aR618K-rER-frt recombinants. The 
isolation of the correct ampicillin lacking recombinants was confirmed by 
restriction digest and by PCR.  
 
 
Figure 3. Integration of 5’albHR-mSTAT3wt-ER-3’albHR and 5’albHR-
mSTAT5aR618K-rER-3’albHR transgenes, by site specific recombination into 
exon 1 of the albumin gene, present in the pPAC4.  Scheme of the DNA constructs 
used for transgenesis. Total length of the recombined pPAC4 inserts is 190 kb. The 
recombined pPAC4-albumin has approximately 34kb of genomic sequence upstream of the 
ATG and 156 kb of downstream sequence, included the mSTAT-ER fusion protein. The 
relative position of other genes present in the PAC, exons 1-5 of the albumin gene and 
Southern blot probes (* 1, 2, 3) are presented on scale.  
Location of the Southern blot probes are indicated in purple. The probe 1 (0.99 kb) hybridizes 
to a fragment of the albumin promoter, probe 3 (0.9 kb) to intron2-exon3-intron3 of the 
albumin gene. Probe 2-3ER (1.4 kb) hybridizes to a fragment including the c-terminal of 
STAT3 to the half-way down the ER domain in the mSTAT3wt-ER,  Probe 2-5aER (1.47 kb) 
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hybridizes to a fragment including the c-terminal of STAT5a to the half-way down the ER 
domain in the mSTAT5aR618K-rER. 
 
 
 
 
Generation of the albmSTAT-ER mice 
The pPAC4-albumin-mSTAT-ERfrt recombinants were isolated from EL250 
E.coli by standard alkaline/SDS lysis procedure. Due to the fact that PACs 
replicate at low copy number in E.coli (one or two copies), the yield of DNA is 
limited and therefore large culture volumes are required to obtain sufficient 
PAC DNA (200ml≅ 2 ng/µl DNA). Prior to lysis, the cells were once washed 
with 0.5 M NaCl to remove polysaccharides. The PAC DNA is not purified over 
columns, since this reduced the yield enormously. The DNA is filtered from 
the bacterial cell debris and precipitated with isopropanol. The DNA pellet was 
washed several times with 70% ethanol to remove salts and dissolved in 200 µl 
5mM Tris. 40 µl of the prep DNA was digested overnight in a total volume of 
100 µl with 100 U of NotI at 37 °C, to release the inserts of 190 kb (185 kb 
chromosome 5 + 5 kb fusion protein sequence) from the 16.7 kb pPAC4. The 
digested fractions of the modified pPAC4-albumin separated through a 5 ml 
Sepharose 4B-CL (Pharmacia) column (methods according to 321) in 
microinjection buffer (5 mM Tris pH 7.5, 0.1 mM EDTA pH 8.0, 100mM 
NaCl). Fractions of 0.5 ml were collected, from which 20 µl was analyzed by 
PFGE. A typical PFGE gel showing the fractionated DNA in the collected 
fractions is shown in Figure 4.  
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Figure 4. NotI digested pPAC4-albumin-mSTAT-ERfrt fractions. pPAC4-albumin-
mSTAT-ERfrt recombinants were digested with NotI, applied to a Sepharose 4B-CL column 
and 0.5 ml fractions were collected. Fractions 3 to 10 were analyzed by PFGE. The fractions 7-
9 contain the 190 kb pPAC4 recombinant insert and are devoid of vector, which is present in 
fraction 5 and 6. 
 
 
Fractions containing the approx. 190 kb fragment were selected, and 
concentrated to 10ng/µl and purified in ultra clean microinjection buffer 
through Microcons® (YM-100, Amicon, Millipore AG, Switzerland). The DNA 
was throughout the whole procedure neither exposed to phenol, ethidium 
bromide or UV light, nor was it frozen, as well was it handled with extreme 
care to avoid shearing of the linearized constructs, or induce toxicity to the 
oocytes or unintentional mutagenesis in the mouse. 
 
The linearized 190 kb inserts were microinjected at a concentration of 3 µg/ml 
into the pronucleus of approx. 300 fertilized oocytes/per construct of 
B6D2/F1Crl mice, isolated from crosses between C57Bl6 females and DBA2 
males using standard methods 322. Approximately 86% of the oocytes survived 
the injection and were reimplanted in pseudopregnant mice. Microinjection 
was performed at the Transgene laboratory of the Zentrum für Molekulare 
Biologie of the University of Heidelberg (ZMBH), Germany. Mice were bred in 
a specific pathogen free environment under standard conditions. 
 
Genotyping of the transgenic offspring 
DNA was prepared from mouse tail by overnight lysis at 56 °C in 200 µl of tail 
buffer (10 mM EDTA pH8, 100 mM Tris pH8, 100 mM NaCl, 0.2% SDS and 
0.25 mg/ml proteinase K). The next day the proteinase K was inactivated for 
30 min at 70 °C and 700 µl of autoclaved water was added. From this solution 
was 1 µl used to identify the presence of the transgene by PCR. A mixture of 
three primers was used to obtain product amplified from the endogenous 
albumin gene, to serve as internal control and in case of a transgenic animal, a 
product amplified from the transgene. Primer1forward; 5’-TGCTCTGGCTT 
CTTCTCAGTTCAC-3’, primer2reverse; 5’-ACTCTTACGTGCTTCTCGGCG-3’, 
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mSTAT3wt-ER specific primer reverse; 5’-CTCCACCACCTTCATTTTC-3’, and 
mSTAT5aR618K-rER specific primer reverse; 5’-GGGCAAACTGAGCTT 
GGATCCGCAGGCTCTCCTGGT-3’. The PCR strategy is schematically depicted 
in figure 8A.  
 
 
Results 
 
The pCAGGS-mSTAT3wt-ER and pCAGGS-mSTAT5awt-rER plasmids, as 
described in Chapter 4 were used for the cloning of two transgenic mice 
expressing mSTAT3wt-ER or mSTAT5aR618K-rER fusion proteins under the 
control of the liver specific albumin promoter in a natural genomic 
configuration. 
 
albmSTAT3wt-ER mice 
A part of mSTAT3wt-ER construct was amplified from pCAGGS-mSTAT3wt-
ER plasmid and fused to the 5’albHR by overlapping PCR. Together with the 
remaining part of the mSTAT3wt-ER sequence, the 5’albHR-mSTAT3wt-ER 
fragment was inserted into pSL1180. The 5’albHR-mSTAT3wt-ER fragment 
was subcloned in pSL1180 due to lack of suitable restriction sites in the pECE-
intron-polyA-frtampfrtnoIres plasmid containing other expression enhancing 
elements and a selection (ampicillin) marker gene flanked by FRT sites. The 
extra intron and polyA were included to be assured of a stable mRNA product.  
Suitable restriction sites present in the multiple cloning site upstream and 
downstream of the inserted 5’albHR-mSTAT3wt-ER fragment, were used to 
excise and ligate the fragment into the pECE-intron-polyA-frtampfrtnoIres 
plasmid. The 3’albHR was excised from its vector and ligate downstream of 
the frtampfrt in pECE5’albHR-mSTAT3wt-ER-frtampfrt, creating 
pECE5’albHR-mSTAT3wt-ER-frtampfrt-3’albHR.  
 
The fusion protein-intron-polyA-frtampfr construct flanked by the albHRs 
was excised from its plasmid and electroporated into EL250 containing the 
pPAC4-albumin E.coli, induced to allow homologous recombination of the 
construct at the ATG into the first exon of the albumin gene. Colonies were 
analysed for the desired recombination event and the orientation of the 
modified pPAC4-albumin by restriction enzyme analysis (NotI, SalI, EagI, and 
RsrII) and by Southern blot analysis. Restriction patterns were compared with 
unrecombined pPAC4-albumin by PFGE. An example is shown in Figure 5. 
Seven out of 18 analyzed colonies gave the expected pattern of recombination. 
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For the Southern blot analysis, recombinants for pPAC4-albumin-mSTAT3wt-
ER-frtampfrt were digested with BamHI and hybridized to probe1, 2-3ER or 3 
(probes are indicated in Figure 3). An example is shown in Figure 6.  
 
 
 
 
 
 
Figure 6. Southern blot analysis of BamHI digested modified pPAC4-albumin. 
BamHI cuts upstream from the probe 1 hybridization site (see Figure 3), in the probe 2-3ER 
hybridization site (so in the fusion protein sequence) and downstream of the hybridization 
site of probe 3. This results in the binding of probe 1 to a 17.2 kb fragment in the 
unrecombined pPAC4-albumin (U in the figure) and a fragment of 7.9 kb in the recombined 
pPAC4-albumin. Probe 2-3ER can not bind the unrecombined, but binds two fragments of 7.9 
and 15.1 kb obtained from recombinant colonies. Probe 3 binds a fragment of 17.2 kb 
(unrecombined) or 15.1 kb (recombinant DNA). 
 
 
After removal of the ampicillin selection cassette, recombinants sensitive to 
ampicillin were confirmed by restriction digest with SalI, which cuts in the 
ampicillin cassette, and should be lost after Flpe recombination. The cassette 
was removed in all of the analyzed colonies. An example of the comparison of 
restriction digest patterns before and after removal of the ampicillin cassette is 
shown in Figure 7. 
Figure 5. Representative 
PFGE gel results of SalI 
digested PAC DNA from 
colonies obtained after 
homologous recombination 
of fusion protein-intron-
polyA-frtampfr into pPAC4-
albumin. Lanes marked with 
(+) represent recombinant 
colonies, showing two SalI 
fragments of 88 and 51 kb 
instead of the one of 139 kb 
shown for the unrecombined 
pPAC4-albumin. 
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The injection of the linearized 190 kb chromosomal-mSTAT3wt-ER transgene 
integrated DNA into fertilized oocytes gave rise a total of 6 (out of 63 living 
analyzed animals) female pups carrying the albmSTAT3wt-ER transgene. The 
transgenic offspring was identified by PCR amplification of tail DNA using 
three primers in one reaction, amplifying a fragment of transgene and an 
endogenous albumin fragment, to serve as internal control. Schematic 
overview (A) and results (B) of the genotyping of the founders is shown in 
Figure 8.  
 
 
A 
 
 
 
 
Figure 7. Restoration of the 
SalI-digested restriction 
pattern of the modified 
pPAC4-albumin. PFGE gel 
comparison of the restriction 
digest patterns of the modified 
pPAC4-albumin before and after 
the removal of the ampicillin 
selection cassette by Flpe 
recombination. 
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B 
 
 
Figure 8.  Genotyping of mSTAT3wt-ER fusion protein expressing transgenic 
founder animals. A) A PCR strategy was developed to amplify in one PCR reaction a 
fragment of endogenous albumin and when transgenic, a fragment of the fusion protein 
sequence. In case of the presence of the transgene is the product amplified by primer1for and 
primer2rev not amplified from the transgene sequence due to the size of the product. Instead 
is a product amplified by the primer1for and the mSTAT3wt-ER specific primer rev. B) 
Agarose gel electrophoresis of PCR products amplified from tail DNA of the founders animals, 
born from oocytes injected with the albmSTAT3wt-ER transgene. Animals expressing the 
transgene are indicated by a (+).  
 
 
F1 transgenic offspring was identified using the same PCR strategy. Figure 9 
shows the results of the F1, proving that the albmSTAT3wt-ER transgene is 
integrated in germline DNA. The transgenic mice appeared to have a normal 
phenotype and are healthy. 
 
 
 
 
 
Figure 9. Germline transmission of the albmSTAT3wt-ER transgene. Agarose gel 
electrophoresis of PCR products amplified from tail DNA of the F1 generation, born from 
founder animals carrying the albmSTAT3wt-ER transgene crossed to C57Bl6 mice. Animals 
expressing the transgene are indicated by a (+).  
 
 
albmSTAT5aR618K-rER mice 
Although we did not know whether a SH2 domain mutant of a STAT-ER 
fusion protein could be activated by 4-HT, we decided out of time saving 
motives, to take the risk and use the construct to generate a transgenic mouse. 
A part of mSTAT5aR618K-rER construct was amplified from pCAGGS-
mSTAT5aR618K-rER plasmid and fused to the 5’albHR by overlapping PCR. 
Together with the remaining part of the mSTAT5aR618K-rER sequence, the 
5’albHR-mSTAT5aR618K-rER fragment was inserted into the pECE-intron-
polyA-frtampfrtnoIres plasmid. The 3’albHR sequence was also inserted in 
this plasmid, creating pECE5’albHR-mSTAT5aR618K-rER-frtampfrt-3’albHR.  
 
The fusion protein-intron-polyA-frtampfr construct flanked by the albHRs 
was excised from its plasmid and electroporated into EL250 containing the 
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pPAC4-albumin E.coli, induced to allow homologous recombination of the 
construct in the first exon of the albumin gene. Colonies were analysed for the 
desired recombination event and the orientation of the modified pPAC4-
albumin by restriction enzyme analysis (NotI, SalI, SacII, EagI, and RsrII) and 
by Southern blot analysis. Restriction patterns were compared with 
unrecombined pPAC4-albumin by pulsed-field gel electrophoresis. 16 out of 17 
analyzed colonies gave the expected pattern of recombination (Figure 10).  
 
 
 
 
 
For the Southern blot analysis, recombinants for pPAC4-albumin-
mSTAT5aR618K-rER-frtampfrt were digested with BsaBI, PmlI or EcoRI and 
hybridized to probe1, 2-5aER or 3 (probes are indicated in Figure 3). An 
example is shown in Figure 11.  
 
 
 
 
 
 
Figure 11. Southern blot analysis of BsaBI digested modified pPAC4-albumin. 
BsaBI cuts upstream from the probe 1 hybridization site (see Figure 3), in the probe 2-5aER 
hybridization site (so in the fusion protein sequence) and downstream of the hybridization 
site of probe 3. This results in the binding of probe 1 to a 13.9 kb fragment in the 
unrecombined pPAC4-albumin (U in the figure) and a fragment of 13.2 kb in the recombined 
pPAC4-albumin. Probe 2-5aER can not bind the unrecombined, but binds two fragments of 
Figure 10. Representative PFGE gel 
results of SacII digested PAC DNA 
from colonies obtained after 
homologous recombination of 
fusion protein-intron-polyA-
frtampfr into pPAC4-albumin. Lanes 
marked with (+) represent recombinant 
colonies, showing two SalI fragments of 
110 and 30 kb instead of the one of 140 kb 
shown for the unrecombined pPAC4-
albumin 
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13.2 and 6.5 kb obtained from recombinant colonies. Probe 3 binds a fragment of 13.9 kb 
(unrecombined) or 6.5 kb (recombinant DNA). 
 
 
After removal of the ampicillin selection cassette, recombinants sensitive to 
ampicillin were confirmed by restriction digest with SalI. The cassette was 
removed in 100% of the analyzed colonies, like for the mSTAT3wt-ER 
modified pPAC4-albumin.  
 
The injection of the linearized 190 kb chromosomal-mSTAT5aR618K-rER 
transgene integrated DNA into fertilized oocytes gave rise a total of 9 (out of 
79 living analyzed animals) pups (8 female and 1 male) carrying the 
albmSTAT5aR618K-rER transgene. The transgenic offspring was identified by 
PCR amplification of tail DNA as described for albmSTAT3wt-ER transgene. 
The result of the PCR analysis of the founders is shown in Figure 12.  
 
 
 
 
 
Figure 12. Genotyping of mSTAT5aR618K-rER fusion protein expressing 
transgenic founder animals. Agarose gel electrophoresis of PCR products amplified from 
tail DNA of the founders animals, born from oocytes injected with the albmSTAT5aR618K-rER 
transgene. Animals expressing the transgene are indicated by a (+). PCR approach is as 
described under Figure 8A, instead of mSTAT3wt-ER specific primer rev, the mSTAT5aR618-
rER specific primer rev was used. 
 
 
F1 transgenic offspring was identified using the same PCR strategy. Figure 13 
shows the results of the F1, proving that the albmSTAT5aR618K-rER transgene 
is integrated in germline DNA. The transgenic mice appeared to have a normal 
phenotype and are healthy. 
 
 
 
 
 
Figure 13. Germline transmission of the albmSTAT5aR618K-rER transgene. 
Agarose gel electrophoresis of PCR products amplified from tail DNA of the F1 generation, 
born from crossed founder animals carrying the albmSTAT5aR618K-rER transgene. Animals 
expressing the transgene are indicated by a (+). 
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Ongoing work to characterize the transgenic mice 
 
We have established a new approach to generate inducible and liver-specific 
STAT3 and STAT5a gain-of-function mouse models. We have showed 
germline transmission of the described transgenes. The transgenic mice will 
be tested on copy number of the integrated transgenes in the genome and on 
expression patterns of the fusion proteins in liver. Transgene copy number 
will be determined by Southern blot analysis and/or RT-PCR. Expression and 
levels of expression of the fusion protein will be investigated by Western blot 
using antibodies against STAT3, STAT5a or the ERα. Furthermore could 
expression levels of the mSTAT3wt-ER and mSTAT5aR618K-rER fusion 
proteins be compared to respectively endogenous STAT3 or STAT5a and 
examine whether the protein expression levels are dependent on copy number 
of the transgene. Also could the total integration of the transgene (190 kb 
pPAC4 insert) in the genome of the founder, F1 and F2 mice be examined by 
PAC end PCR amplification.   
Parallel to the ongoing work on the characterization of the mice, the activation 
of the fusion protein induced by i.p. and p.o. administration of different 
amounts of 4-HT. Liver samples will be analyzed by phospho-STAT Western 
blots, EMSAs and upregulation of STAT3 or STAT5a target genes (cell cycle 
mediators c-myc, junB, c-fos, cyclins D1, D2, D3 and A, SOCS3, coagulation 
factor/acute phase proteins fibrinogen, haptoglobin and SAP and proteinase 
inhibitor α2-macroglobulin) using Western blotting and RNase protection 
assays. 
Possible applications and future plans for the use of the mice will be discussed 
in chapter 6. 
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The inducible liver-specific gain-of-function mouse models for STAT3 and 
STAT5a, as described in Chapter 4 and 5, will be a powerful tool to analyze 
involvement of STAT3 and STAT5a signaling in many different physiological 
and pathophysiological conditions in liver. Future possible applications of 
transgenic mice will be discussed here.  
 
The albmSTAT3wt-ER transgenic mouse to study effects of STAT3 
signaling  
We plan to perform partial hepatectomy in these mice to examine liver cell 
regeneration in presence and absence of mSTAT3wt-ER activation by 4-HT. 
We hope to elucidate the importance of STAT3 signaling in liver cell 
regeneration. Is liver cell regeneration hampered by the lack of SHP2/MAPK 
signaling? Would continuous activation of mSTAT3wt-ER for a certain period 
induce the liver cells to regenerate faster after two-third hepatectomy? Could 
continuous STAT3 signaling disturb the process that stops hepatocytes 
proliferating once the original size of the liver has been restored?  
In our experiments with STAT3-deficient MEFs stably transfected with 
mSTAT3wt-ER we found that only 4-HT but not IL-6 stimulation resulted in 
the upregulation of STAT3 target genes. In vivo the results might be different. 
If the mSTAT3wt-ER fusion protein can indeed be activated by IL-6 in vivo, 
we plan to cross the albmSTAT3wt-ER transgenic mice with IL-6 KO mice. In 
this model, the role of STAT3 signaling in liver regeneration could be 
investigated independent from other intracellular signals generated by IL-6 
stimulation of liver cells.  
 
Due to the importance of STAT3 signaling in promoting mitogenesis and 
inhibiting apoptosis, the transgenic mice could be well used in studying 
STAT3 mediated cellular transformation.  
STAT3 was shown to be upregulated (together with SOCS3 and cyclin D1) in 
HCC compared to normal liver tissue 323. Also in chemically induced rat HCC a 
high activity of STAT3 was observed using EMSA. Dexamethasone treatment 
resulted in downregulation of the STAT3 activation and reduction of cell 
proliferation in the tumors, thus STAT activity might be required for HCC 
growth 324. Furthermore, it has been shown that a constitutive active form of 
STAT3 can be an oncogene 150. STAT3 seems to promote cell cycle G1 to S 
phase transition by upregulating cyclins D1, 2, 3 and A, cdc25A and 
downregulating p21 and p27 325. A recent study showed that constitutive active 
STAT3 induced cellular transformation of fibroblasts through upregulation of 
c-fos expression 326. Through the upregulation of Bcl-XL and Mcl-1, STAT3 
protects against apoptosis 151. STAT3 is also involved in tumorgenesis through 
the activation of VEGF to promote angiogenesis 155.  
Long-term administration of 4-HT would constitutive activate STAT3 
signaling through mSTAT3wt-ER fusion protein. Periodic examination of the 
livers on development of tumors and analysis of induction of STAT3 target 
genes, like the ones described here, could contribute to clarify the role of 
STAT3 in oncogenesis. It could also be examined whether chemically induced 
carcinogenesis could be accelerated by activated mSTAT3wt-ER. 
  
In addition, the use of the albmSTAT3wt-ER transgenic could be interesting in 
some other liver pathology research areas, which involve STAT3 signaling. 
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Absence of STAT3 leads to an impaired acute phase response, which is 
commonly induced by bacterial infection. This was shown in LPS-induced 
acute phase response in mice displaying an interferon-induced deletion of 
STAT3. These mice were generated by crossing of a conditional Cre-mediated 
STAT3 deficient mice to a Mx-Cre transgenic mouse, in which the expression 
of Cre recombinase can be induced by IFN type I 25, 72. AlbmSTAT3wt-ER mice 
could be used to investigate the function of STAT3 in the protection or defense 
against bacterial infection. AlbmSTAT3wt-ER mice could be challenged with a 
bacterial infection, and the effect of 4-HT induced mSTAT3wt-ER activation 
could be analyzed.  
Otherwise it might be worthwhile to examine the function of STAT3 in 
regulation of hepatic gluconeogenic genes and carbohydrate metabolism in 
the context of diabetes mellitus. Mice with a liver specific deficiency in STAT3 
are insulin resistant, probably caused by an increased expression of G6PC and 
PCK-1. Restoration of hepatic STAT3 expression normalized insulin levels and 
expression of gluconeogenic genes. Overexpression of STAT3 reduced 
expression of these genes, as well as blood glucose and plasma insulin levels in 
leptin receptor KO diabetic mice 111. Inducing diabetes in our albmSTAT3wt-
ER mice could provide a model to reveal STAT3 function further and examine 
STAT3 down stream targets involved. This could provide insights for 
development of new therapeutic targets for diabetes mellitus. 
 
 
The albmSTAT5aR618K-rER transgenic mouse to study effects of 
STAT5a signaling  
STAT5a is a promoter of cell proliferation, cellular transformation and 
inhibitor of apoptosis. Activated STAT5a is critical in GH, prolactin, GM-CSF 
and IL-2 signaling. STAT5a KO mice showed normal body growth or serum 
IGF-1 (mediator of the somatic effects of GH) levels 122. Still, in liver STAT5a 
and 5b are the most prominent mediators activated by GH 123. The 
albmSTAT5aR618K-rER transgenic mouse could be used to examine STAT5a 
contribution to liver growth or liver cell proliferation during liver regeneration 
after partial hepatectomy. 
 
Constitutively activated mutants of STAT5 have been found to transform 
Ba/F3 cells 327 and STAT5a was found to be constitutively activated in several 
leukemias 5, 328, showing STAT5a involvement in oncogenesis. Constitutive 
activation of STAT5a/b was shown to deregulate the cyclin complexes 
D/CDK4-6, which controls progression from the G1 to the S-phase of the cell 
cycle, deregulate c-Myc dependent cell growth, and activate antiapoptotic 
signals and therefore induce cell survival 149, 151.  
The antiapoptotic properties of STAT5a could be investigated in the context of 
ischemia injuries induced by partial hepatectomy and its consequences for the 
progress of liver regeneration. The protection of hepatocytes against apoptosis 
could be examined in albmSTAT5aR618K-rER transgenic mouse during liver 
regeneration after partial hepatectomy or in sham surgery induced apoptosis, 
in presence and absence of activated mSTAT5aR618K-ER by 4-HT.  
Furthermore one could, like for the albmSTAT3wt-ER transgenics, activate 
mSTAT5aR618K-rER over longer periods by 4-HT and check for development 
of hyperplasia or tumors, and involvement of specific STAT5a target genes in 
the process of oncogenesis. Another possibility would be to cross both 
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transgenic mice and activate both fusion proteins over a longer period of time 
by 4-HT. It might be that in parallel activated STAT3 and STAT5a signaling 
enhances each others cell transformational and antiapoptotic effects. This 
would be interesting in the context of many tumors in which both STAT3 and 
STAT5a are constitutively activated. Maybe regulatory mechanisms from one 
signaling pathway to the other could be revealed when oncogenesis would be 
studied in double fusion protein expressing transgenic mice compared to the 
single fusion protein expressing transgenic mice. 
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